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Résumé 
Malgré le progrès technologique et nos connaissances pharmaceutiques et médicales 
croissantes, le développement du médicament demeure un processus difficile, dispendieux, 
long et très risqué.   Ce processus mérite d'être amélioré pour faciliter le développement de 
nouveaux traitements.  À cette fin, cette thèse vise à démontrer l’utilité de principes 
avancés et d’outils élaborés en pharmacocinétique (PK), actuels et nouveaux.  Ces outils 
serviront à répondre efficacement à des questions importantes lors du développement d’un 
médicament, sauvant ainsi du temps et des coûts. 
Le premier volet de la thèse porte sur l’utilisation de la modélisation et des 
simulations et la création d’un nouveau modèle afin d’établir la bioéquivalence entre deux 
formulations de complexe de gluconate ferrique de sodium en solution de sucrose pour 
injection.  Comparé  aux méthodes courantes, cette nouvelle approche proposée se libère de 
plusieurs présuppositions, et requiert moins de données.  Cette technique bénéficie d’une 
robustesse scientifique tout en étant associée à des économies de temps et de coûts.   Donc, 
même si développé pour produits génériques, elle pourra également s’avérer utile dans le 
développement de molécules innovatrices et « biosimilaires ». 
Le deuxième volet décrit l’emploi de la modélisation pour mieux comprendre et 
quantifier les facteurs influençant la PK et la pharmacodynamie (PD) d’une nouvelle 
protéine thérapeutique, la pegloticase.  L’analyse a démontré qu’aucun ajustement 
posologique n’était nécessaire et ces résultats sont inclus dans la monographie officielle du 
produit.  Grâce à la modélisation, on pouvait répondre à des questions importantes 
concernant le dosage d’un médicament sans passer par des nouvelles études ni 
d'évaluations supplémentaires sur les patients.  Donc, l’utilisation de cet outil a permis de 
réduire les dépenses sans prolonger le processus de développement.  Le modèle développé 
dans le cadre de cette analyse pourrait servir à mieux comprendre d’autres protéines 
thérapeutiques, incluant leurs propriétés immunogènes. 
Le dernier volet démontre l’utilité de la modélisation et des simulations dans le 
choix des régimes posologiques d’un antibiotique (TP-434) pour une étude de Phase 2.  Des 
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données provenant d’études de Phase 1 ont été modélisées au fur et à mesure qu’elles 
devenaient disponibles, afin de construire un modèle décrivant le profil pharmacocinétique 
du TP-434.  Ce processus de modélisation exemplifiait les cycles exploratoires et 
confirmatoires décrits par Sheiner.  Ainsi, en se basant sur des relations PK/PD d’un 
antibiotique de classe identique, des simulations ont été effectuées avec le modèle PK final, 
afin de proposer de nouveaux régimes posologiques susceptibles d’être efficace chez les 
patients avant même d'effectuer des études.  Cette démarche rationnelle a mené à 
l’utilisation de régimes posologiques avec une possibilité accrue d’efficacité, sans le dosage 
inutile des patients.  Ainsi, on s’est dispensé d’études ou de cohortes supplémentaires 
coûteuses qui auraient prolongé le processus de développement.  Enfin, cette analyse est la 
première à démontrer l’application de ces techniques dans le choix des doses d’antibiotique 
pour une étude de Phase 2. 
En conclusion, cette recherche démontre que des outils de PK avancés comme la 
modélisation et les simulations ainsi que le développement de nouveaux modèles peuvent 
répondre efficacement et souvent de manière plus robuste à des questions essentielles lors 
du processus de développement du médicament, tout en réduisant les coûts et en épargnant 
du temps. 
 
Mots-clés : modélisation de population, pharmacocinétique, pharmacodynamie, 
développement du médicament 
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Abstract 
Despite the scientific and technological breakthroughs that have graced the last 
century, the path to bringing a drug to the market is fraught with risk and remains an 
expensive and time-consuming process.  Significant improvements to this process are 
needed if patients are to continue to benefit from new therapies.  The objective of this thesis 
is to demonstrate the use of modeling and simulations in this regard.  It will show how 
advanced pharmacokinetic (PK) techniques can be used to answer critical questions that 
arise during the drug development process, and that their use can lead to cost and time 
savings. 
The first part of this thesis shows how modeling and simulations, including the 
development of an innovative model, can be used for the relative bioequivalence 
assessment of a new sodium ferric gluconate complex intravenous formulation.  Compared 
to traditional methods, this approach did not make inaccurate assumptions about drug 
characteristics, nor did it necessitate the enrollment of hundreds of subjects.  Thus, this 
scientifically robust approach was associated with significant financial savings and 
economy of time.  Although this research was conducted within the generic drug 
development, it could also be applied to innovator or biosimilar drug development. 
The second section illustrates the use of modeling and simulations in the 
development of an innovative biological therapeutic agent, pegloticase.  This approach 
allowed us to answer important questions pertaining to the factors influencing pegloticase’s 
PK and pharmacodynamics (PD), confirming that no special dosing adjustments were 
required, thus contributing to the official product labeling.  These questions were answered 
without conducting additional trials or performing supplementary assessments on patients, 
which resulted in significant cost and time savings.  In the future, such PK/PD models 
could be used to better understand other biological agents, including their immunogenicity 
profiles which remain a concern for clinicians. 
The third part of this thesis focuses on the use of modeling and simulations to select 
optimal dosing regimens for the Phase 2 study of the novel antibiotic TP-434.  A PK model 
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for TP-434 was developed with Phase 1 data.  This model was continuously updated and 
confirmed as new Phase 1 data became available, similar to the approach advocated by 
Sheiner’s learn and confirm paradigm.  Based on simulations performed with this model, 
and knowledge of PK/PD relationships for another compound, Phase 2 dosing regimens 
were recommended that were likely to show efficacy in the patient population.  This 
rational approach to dose selection ensured that patients were not needlessly exposed to the 
drug, and that efficacy would likely be demonstrated in Phase 2.  Consequently, it was 
unnecessary to dose additional cohorts or conduct additional trials, which would have 
lengthened the process and been expensive.  Moreover, this was the first published account 
of Phase 2 dose regimen selection based solely on simulated Phase 1 data for an 
antimicrobial drug.   
In summary, the research presented in this thesis illustrates how advanced 
pharmacokinetic techniques like modeling and simulations, including the creation of 
innovative models, can efficiently answer key drug development questions, leading to 
significant cost and time savings.  
 
Keywords : population modeling, pharmacokinetics, pharmacodynamics, drug 
development 
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Preface 
In spite of the scientific and technical advances made by our society in the last 
century, drug development today remains a gruelling process.  Not only is it expensive, 
time consuming, and a highly risky endeavour, but it is associated with a very low 
probability of success.  This thesis will demonstrate how modeling and simulations, 
including the creation of innovative PK models, can help answer key questions within the 
drug development process (DDP), thereby improving its efficiency and decreasing some of 
the inherent risk. 
To better illustrate the relevance and significance of the research presented in this 
thesis, it is necessary to first review some basic principles of drug action and describe the 
types of analyses typically conducted to better understand drug effects.  It is also important 
to understand the drug development process, appreciate its strengths and more importantly 
underline some of its weaknesses. 
After describing the context in which the research presented herein has evolved, the 
following articles will be presented individually: 
1) Novel Population Pharmacokinetic Methods Compared to the Standard 
Noncompartmental Approach to Assess Bioequivalence of Iron Gluconate 
Formulations 
2) Population pharmacokinetic and pharmacodynamic analysis of pegloticase 
administered by intravenous infusion in two dose regimens to subjects with 
chronic gout 
3) Optimizing Drug Development of TP-434, a Novel Fluorocycline, with 
Adaptive Learn & Confirm Cycles of Modeling & Simulation Using Single 
Ascending Dose Data 
  2 
4) Population Pharmacokinetic Modeling of TP-434 Following Multiple Dose 
Administration 
   3 
 
Chapter 1 – Introduction 
1.  The Drug 
The word “drug” evokes different associations in people, ranging from therapeutic 
aid to illicit activities.  The Canadian government defines a drug as “any substance or 
mixture of substances manufactured, sold or represented for use in (a) the diagnosis, 
treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its 
symptoms, in human beings or animals, (b) restoring, correcting or modifying organic 
functions in human beings or animals, or (c) disinfection in premises in which food is 
manufactured, prepared or kept” (1).  A similar definition is employed by the American 
“Food, Drug and Cosmetic Act”, which defines a drug as: “(A) articles recognized in the 
official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United 
States, or official National Formulary, or any supplement to any of them; (B) articles 
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in 
man or other animals (C) articles (other than food) intended to affect the structure or any 
function of the body of man or other animals (D) articles intended for use as a component 
of any article specified in clause (A), (B), or (C)” (2).  
It is clear that drugs can be used to fulfill different therapeutic roles, ranging from 
the diagnosis to the treatment of disease.  Although most clinicians are taught to favor non-
medical treatments whenever possible (such as adopting lifestyle changes), the benefits of 
appropriate drug therapy are undeniable.  Patients themselves recognize the importance of 
drug therapy.  In a survey of 1000 patients in the United States, over 85% indicated that 
prescription medication was very or extremely valuable to their health and well-being (3).    
While not solely attributable to drug therapy, in the span of the last 60 years, 
modern medicine has contributed to increasing our lifespan from 30 years  up to 78 years in 
developed countries, which is a remarkable feat (4, 5).  In the first half of the last century, 
medical advances such as vaccinations and antibiotics caused a significant decline in 
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infection-related mortality, which leveled off in the second half of the century (5).   Drug 
and medical interventions also contributed to decreasing mortality rates in the second half 
of the century, especially those related to cardiovascular events (5).  Clearly, the use of 
drug therapy has revolutionized modern medicine by providing viable treatment options 
when they did not exist before.   
The poster child for drug therapy is without a doubt penicillin, which, even in its 
early commercial form was able to treat infections ranging from pneumonia to syphilis, 
including those that proved to be resistant to sulphonamide antibiotics.  Although it was not 
the first antibiotic used to treat bacterial infections, more than 70 years after its discovery 
by Fleming, penicillin remains part of our modern therapeutic arsenal (6, 7).  Its use, which 
began in World War II, serves as a reminder that while drug therapy as we know it is 
relatively new, it is a cornerstone of modern medicine. 
As the benefits of drug therapy throughout the years have greatly evolved, so have 
our methods for discovering and developing new drugs.  In the early days of drug 
discovery, fortuitous findings related to plants and other natural products were the key to 
developing new medicines (8).  Some classic examples include the discovery that digitalis 
extracted from the foxglove plant had certain cardiac properties (9) and that extracts from 
moldy sweet clover hay could produce dicoumarol, a powerful anticoagulant compound 
(10).  Since then, drug discovery has come a long way.  Advances in disciplines such as 
analytical chemistry, biochemistry, microbiology, and more recently molecular biology and 
genomics have helped shape the process to its current state (11).  Our improved 
understanding of chemistry, disease and pharmacology has allowed us to move away from 
reliance on serendipity to a more targeted approach to drug discovery.    
Despite the contributions of drug therapy to the improvement of healthcare and the 
progression of drug discovery, unmet needs still remain.   Although our lifespan has more 
than tripled in comparison with that of our cave-dwelling ancestors (5), there is still much 
for us to learn about the human condition.  Mortality caused by infection or cardiovascular 
events have declined in the previous century, but they still remain among the top 15 causes 
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of death in North America (12, 13) and are among the ten leading causes of death in 
Canada (14).  Added to this list are diseases such as cancer and Alzheimer’s disease (12, 
13), which were closer to the bottom of the list at the turn of the 20th century in the United 
States (15).  Thus, with an increasingly aging population, we are faced with additional 
medical challenges that call for new uses for products already on the market, or for 
innovative new products.     
It is important to remind ourselves that the ultimate goal of drug therapy will always 
be to improve lifespan as well as quality of life, and the aim of the drug development 
process is to create products that will help achieve these goals.  In addition to developing 
products that are novel in their mechanisms of action (exemplified by pegloticase in 
Research Project #2), the drug development process can also produce therapies that are not 
necessarily different in terms of mechanism of action but that offer clinical advantages with 
respect to what is already on the market (such as developing anti-infective agents that are 
associated with less bacterial resistance, exemplified by TP-434 in Research Projects #3 
and #4).  Another important aspect of the drug development process is the development of 
generic drugs, which allow medication to be more accessible in terms of costs (as 
illustrated by sodium ferric gluconate complex in glucose in Research Project #1).      
Before embarking upon an overview of the drug development process, the following 
section will describe some fundamental aspects of drug pharmacology that play a key role 
in the process.  More details on the general pharmacology of the drugs  and/or therapeutic 
classes of the drugs studied within this thesis can be found in Appendix 1.  
   6 
 
2.  Pharmacokinetic and Pharmacodynamic Principles 
In order to better appreciate why drug products have had, and continue to have, such 
an important impact on health and mortality, it is necessary to have a global understanding 
of “what the body does to the drug”, otherwise known as pharmacokinetics (PK), and “what 
the drug does to the body”, defined by the term pharmacodynamics (PD) (16).   
2.1 Pharmacokinetics 
For all drugs, pharmacokinetics encompasses different phenomena, which will each be 
discussed separately.  These include liberation, absorption, distribution, metabolism and 
excretion, and are often referred to collectively as “LADME”.  Whether or not a drug’s PK 
includes all of these steps depends on its route of administration.  Drugs that are 
administered by the enteral route (i.e., they enter the gastrointestinal (GI) tract after being 
given orally) generally involve more processes than those that are administered by 
parenteral routes, such as intravenously (IV) administered products.  An overview of all of 
the processes is depicted in Figure 1 and presented in more detail hereafter, with special 
attention being paid to intravenous drug products. 
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Figure 1. Illustration of Typical Pharmacokinetic Processes 
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2.1.1 Liberation 
The liberation of a drug from its pharmaceutical form is a critical first step in a 
drug’s disposition pathway.  This process is inherently tied to drug formulation.  For 
instance, an active ingredient that is administered as a solid form (tablet, capsule, etc.) must 
be dissolved into a solution before any of the other PK processes can occur (17).  This also 
implies that the product must first disintegrate (break up into smaller particles) and 
disperse.  Conversely, a drug that is administered as a solution (for either oral or injectable 
administration) does not require this dissolution step.  Because the drugs studied in the 
context of this thesis were all administered intravenously (IV), liberation will not be 
described any further in this chapter.   
2.1.2 Absorption 
Once the drug has been solubilized, it is ready to be absorbed by the body and enter 
the bloodstream.  Drugs administered intravenously bypass this step, since they are injected 
directly into the bloodstream, but most drugs that are given via other routes must 
necessarily undergo this process.  Although the topic of drug absorption is beyond the 
scope of this thesis, it should be mentioned that it is a complex process that is governed in 
part by physicochemical drug properties (such as lipophilicity and molecule size), the 
presence of membrane transporters (both influx and efflux), and physiological states (such 
as intestinal transit time or food intake).    
2.1.3 Distribution 
Once the drug has entered the bloodstream (either directly or via passage through 
various membranes), it has the opportunity to enter different tissue or organs throughout the 
body.  If the human body can be compared to a large city made up of dynamic components 
(people, animals, vehicles, etc.), and the drug is a person trying to reach a particular 
destination, then the bloodstream is analogous to the city streets that allow that person to 
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navigate through the city until the target building (representative of a tissue or organ) is 
attained.  Depending on various factors (size, use of a vehicle, mobility), people are able to 
access multiple buildings or only certain ones, much like drugs whose distribution is 
controlled by different factors.  
Protein binding plays a critical role in drug distribution, since generally only free 
(unbound) drug is able to cross membranes and reach specific tissues.  In the cityscape 
analogy, plasma proteins are analogous to vehicles such as automobiles or buses which 
transport people (the drugs) to various locations.  However, in order to enter buildings 
(reach target tissue), occupants must disembark from their vehicles.  In human plasma, the 
most important transport proteins include albumin, 1-acid glycoprotein (AAG) and 
lipoproteins (18, 19).  Albumin is the most important plasma protein (accounting for 
roughly 60% of plasma protein (20)) and exhibits low affinity, high capacity binding. 
Conversely, AAG is less present in the plasma but is considered to have a high affinity, low 
capacity binding site (19).  Most drugs that are acid or neutral bind to albumin while AAG 
is a major binding protein for basic drugs.  Variations in albumin or AAG levels due to 
pathophysiological conditions can thus affect the concentrations of free (unbound) drug that 
are available to distribute to organs or tissue.       
In order to reach target receptors in organs or tissues, drugs must cross membrane 
barriers.  As with drug absorption, different types of transport mechanisms across 
membranes exist, such as paracellular transfer (passage between cells), passive diffusion 
(passage through cell lipid bilayers dependent upon a concentration gradient that follows 
Fick’s law) (21), simple diffusion (drug transfer through aqueous pores of the cell that 
follows the concentration gradient), facilitated transport (drug transfer along the 
concentration gradient using a transporter protein) and active transport (drug transfer 
against the concentration gradient using a transporter protein and requiring energy 
expenditure).  Therefore, many of the factors governing the membrane permeability during 
drug absorption will also influence drug distribution.  For example, drug distribution is 
influenced by the size of the compound and its lipophilicity.  Larger molecules (≥ 15-30 
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kDa) such as biologicals tend to remain in the plasma compartment and/or extracellular 
space (22).  More lipophilic molecules cross the membrane barrier by passive diffusion 
more readily than hydrophilic, charged molecules.        
2.1.4 Metabolism 
The human body is remarkably endowed with protective mechanisms, and the 
metabolic processes surrounding drugs generally aim to transform them into compounds 
that are more easily eliminated or excreted.  Due to its size and the high content of 
metabolizing enzymes, one of the major organs involved in metabolism is the liver (23), 
which oversees two general types of chemical reactions that are known as Phase I and 
Phase II type reactions.  Phase I reactions involve (but are not limited to) the oxydation, 
reduction and hydrolysis of compounds while some Phase II reactions include 
glucuronidation, sulfation and methylation, whereby groups (glucuronide, sulfate or 
methyl, for instance) are conjugated to the drug to facilitate its excretion (21, 24).  
Metabolites resulting from Phase I or Phase II reactions can either be active or inactive 
compounds.  Some drugs, termed “pro-drugs”, are specially formulated as inactive 
compounds which must be transformed into metabolites which possess the desired 
pharmacological activity. 
Many enzymes are responsible for Phase I and II reactions. Some examples of 
Phase I enzymes include (but are not limited to) catalases, peroxidases, reductases, 
cholinesterases, dehydrogenases, while examples of Phase II enzymes are N-
acetyltransferase, glucuronosyltransferases, glutathione-S-transferase, and sulfotransferases 
(25). However, one type of enzyme formerly known as cytochrome P450 (now referred to 
as CYP) is responsible for the metabolism of approximately 90% of all drugs (26).  These 
enzymes are divided into different families (such as CYP1, CYP2, CYP3, etc.) which have 
amino acid sequences that are < 36% similar to each other.  Each family is further divided 
into sub-families (such as CYP2A, CYP2B, etc.) where each member has an amino acid 
sequence that exhibits greater than 68% similarity to other members.  Individual enzymes 
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are identified by a number following the letter, such as CYP2C9 or CYP2C19.  The 
families CYP1, CYP2 and CYP3 are those which are mainly involved in drug metabolism 
while other CYPs are associated with the biosynthesis and catabolism of endogenous 
substances (27). Enzymes belonging to the CYP3A sub-family, especially CYP3A4, 
account for approximately 30% of all hepatic cytochromes (27) while they make up the 
majority of all intestinal CYP (21, 28).  This family of cytochromes is responsible for most 
of the body’s hepatic and intestinal metabolism (23), and is involved in the metabolism of 
approximately 50% of all drugs (26).  
Although a comprehensive review of the topic is beyond the scope of this 
introduction, enzyme polymorphisms deserve a brief mention.  Countless research has been 
devoted to better understand the genetic variations in metabolizing enzymes that frequently 
translate into starkly different drug responses between individuals.  A classic example of 
polymorphisms that influence drug effect involves CYP2D6.  Approximately 5 to 10% of 
Caucasians exhibit a poor metabolizer phenotype for CYP2D6, which can be attributed to a 
number of alleles.  Compared to extensive metabolizers, these individuals have a limited 
capacity to inactivate drugs such as fluoxetine, and therefore have a greater risk of suffering 
from adverse events due to supratherapeutic levels of active drug.  Conversely, drugs such 
as codeine, which must be metabolized into an active metabolite by CYP2D6, are mostly 
ineffective in such populations compared to extensive metabolizers (27).           
Many drugs are subject to hepatic metabolism, but this is not true of all drugs.  
Compounds that are proteins undergo catabolic processes that allow the body to recycle the 
amino acids found in such proteins (22).  In other words, proteins are degraded into their 
amino acid subunits through proteolytic processes, such as those in the ubiquitin-
proteasome pathway (29).  Polyethylene glycol (PEG)-modified recombinant mammalian 
urate oxidase (pegloticase) is an example of a biological product that is not metabolized 
(30).  In addition, for many drug products, only a portion of the administered drug is 
metabolized while another remains unchanged. 
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As previously discussed, metabolism can occur in other organs, such as the 
intestine, where both Phase I and Phase II reactions take place (21).  Other sites of drug 
metabolism include the kidneys, the lungs, skin and brain (27).  The presence of 
hydrolyzing enzymes, such as cholinesterases, in the plasma compartment even allows 
metabolism to occur within the vascular space (31).       
Metabolism of an orally administered drug can occur after systemic absorption, but 
it can also occur before a drug reaches systemic circulation.  This pre-systemic metabolism 
is often called “first pass metabolism”, and includes metabolism that may occur at the 
intestinal and hepatic levels (21).  The fraction of a drug that is metabolized during its 
initial transit through an organ is referred to as the extraction  ratio, which is also known as 
“first pass” or “pre-systemic” elimination.  Examples of drugs that are subject to significant 
first pass metabolism in the intestine include cyclosporine (32), midazolam, nifedipine, 
quinidine, saquinavir and terfenadine (21).  
2.1.5 Excretion 
Drugs and their metabolites can be excreted via different organs such as the skin or 
lungs, but the main eliminating organs remain the kidney and the liver.  Hepatic excretion 
involves biliary elimination of drugs and metabolites in fecal matter.  ABCB1 transporters 
located on the canalicular membrane of hepatocytes are often involved in expulsing drugs 
into the bile (23). Renal excretion of unchanged drugs and/or their metabolites can involve 
glomerular filtration, tubular secretion, and reabsorption (23).  
A key element of renal excretion involves the filtration of unbound (free) drug 
through the glomerulus. Another process that contributes to renal elimination is secretion to 
the proximal tubule, which is an active process involving transporters such as the organic 
anion transporter (OATP) and organic cation transporter (OCT).  ABCB1 transporters 
located on the luminal brush-border membrane of renal cells also play a role in drug 
excretion by expulsing drugs into the urine (23).  Finally, tubular reabsorption is a 
component of renal excretion that involves the reuptake of drugs by passive diffusion, 
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sometimes with the aid of endocytosis.  Thus, the extent to which a drug is eliminated by 
the kidney depends on the relative importance of each of the processes involved.   
Exceptionally, some compounds are not eliminated at all from the human body, 
such as iron.  This mineral plays a vital role in many bodily functions, most notably 
involving the heme protein and oxygen transport (33, 34).  Although the average human 
body contains 3 to 4 g of iron, only about 1 mg is lost daily (33, 35-37), which represents 
negligible elimination.  Similarly, biotechnology derived proteins (biologicals) often 
undergo catabolism which generates amino acids that are re-used by the organism (22).  
This is the case for the biological product pegloticase. 
2.1.6 Bioavailability 
Extravascular routes of drug administration, in particular the oral route,  are the 
generally preferred route of administration (38), which explains in part why over 60% of 
currently marketed products are for oral administration (39, 40).  Although this route of 
administration is favoured, absorption and metabolism can be huge impediments to its use, 
since both phenomena can contribute to a decreased bioavailability (F). 
Bioavailability is a contraction of the terms “biological availability” (41) and it is 
defined as “the rate and extent to which the active drug ingredient or therapeutic moiety is 
absorbed from a drug product and becomes available at the site of drug action” (42).  In 
other words, bioavailability indicates the proportion of an administered drug dose that 
attains the site of action, after accounting for the fraction that is not absorbed as well as the 
fraction that undergoes metabolism in the gut or liver (21, 43).   
The European Agency for the Evaluation of Medicinal Products (EMEA), 
Committee for Proprietary Medicinal Products, has also defined F in a similar manner, but 
has nuanced its description by replacing “site of drug action” by the phrase “general 
circulation” (44).  The latter definition reflects the difficulties faced with measuring drug 
levels at the site of action, which can be highly impractical and extremely invasive.  
Instead, it is often assumed, as in this definition, that drug concentrations in the general 
  14 
 
 
circulation (for instance as characterized by venous plasma concentrations) are indicative of 
drug levels at the site of action. 
The use of plasma (or urinary) concentrations to calculate metrics for rate and extent 
of drug exposure is widely accepted as a surrogate for concentrations at the site of action, 
for drugs that reach the systemic circulation before or at the same time as they reach their 
site(s) of activity. Maximal observed serum or plasma concentration (Cmax) is associated 
with the rate of exposure, or how quickly drug concentrations attain their peak level, while 
area under the plasma/serum concentration time curve (AUC) is a measure of the overall 
extent of drug exposure.  In Phase 1 studies, both parameters are calculated using 
noncompartmental PK analysis (45), which, is a robust approach when many plasma 
samples are available. This method of analysis is described in more detail in Section 3.1.   
2.2 Pharmacodynamics 
The drug development process is ultimately concerned with bringing a product to 
the market that will exert a desired effect or elicit a particular response.  Such drug 
responses, otherwise known as pharmacodynamics, are intrinsically linked to PK and will 
be briefly described in this section.  For a more detailed overview of the subject, the reader 
is referred to a book chapter previously published by our laboratory (46).  A review of PK-
PD modeling in a historical context (covering the 1960’s until 2004) has also been 
published by Csajka and Verotta (47).       
2.2.1 Classification of Effects 
The pharmacological activity of a drug comprises both beneficial and harmful 
effects, the former generally being the reason for which the drug is administered.  Although 
a drug may be administered with a specific purpose in mind, such as eradicating bacteria to 
treat an infection, other unwanted effects can occur, such as diarrhea.  One of the 
challenges of drug therapy is finding the right balance between these pharmacodynamic 
effects, to help patients while avoiding undesirable effects as much as possible. 
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Pharmacological responses can be categorized broadly as quantal or continuous 
variables.  Quantal responses are discrete categorical responses that do not belong to a 
continuum of responses.  Such responses include dichotomous responses (awake/asleep) or 
polychotomous responses (grades of hematological toxicity) (48).  Continuous responses 
can include laboratory values such as triglyceride levels or other clinical results such as 
heart rate. 
PD responses can range from easily measured short-term responses (such as 
decrease in plasma glucose level or decrease in pain), to long-term outcomes (for instance 
increased survival or decrease of the risk of irreversible morbidity).  A PD response can be 
considered to be a “clinical endpoint”, which is defined as a characteristic or variable that 
reflects how a patient feels, functions or survives (49-51). When clinical endpoints are 
difficult to assess, surrogate endpoints that are a substitute for clinical endpoints provide an 
alluring alternative especially when there are severe time constraints.  For instance, the 
desired clinical outcome of a drug may be a decrease in mortality and it may be difficult to 
wait for information on patient mortality. Therefore, it would be more practical to associate 
drug levels with a biomarker that is easily and quickly detectable (52, 53).  By definition, a 
biomarker is “a characteristic that is objectively measured as an indicator of normal or 
pathologic, biologic or pathogenic processes, or pharmacological responses to a therapeutic 
indication” (49, 51).  Biomarkers can server diagnostic purposes (for prognostic purposes 
or to guide therapeutic choices), they can measure disease activity, they can assess drug 
effect, or they can server as markers of drug kinetics (e.g., polymorphisms transporter 
proteins or in metabolizing enzymes) (50, 51).  Biomarkers that are intended substitutes for 
clinical endpoints and that are expected to “predict clinical benefit (or harm or lack of 
benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific 
evidence” are considered “surrogate endpoints” (49-51). 
Cases have been reported where the use of a biomarker proved to be successful as a 
predictor of clinical outcome (e.g. HMG-CoA reductase inhibitors (54)) and could be used 
as a surrogate endpoint, while in other cases (e.g. antiarrhythmic agents (55, 56)), the 
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biomarker proved to be inadequate.  However, caution must be employed with the use of 
surrogate endpoints because there is always the danger that they might fail to predict rare, 
negative side effects that can lead to overall negative clinical outcomes (54).  
2.2.2 Types of PK-PD Relationships 
A fundamental principle of clinical pharmacology is the link between the PK of the 
drug and its PD.  Although this relationship may not be easily discernible, it is always 
present.  This fundamental relationship is depicted in Figure 2. 
Figure 2. Relationship between Drug Pharmacokinetics and Pharmacodynamics 
 
Drugs can exert their effects in a direct or indirect manner.  For instance, the drug 
bivalidurin (57) acts directly on thrombin to produce an anticoagulant effect, while a drug 
such as warfarin exerts an indirect anticoagulant effect on blood clotting by inhibiting the 
formation of clotting factors (58).  In addition, effects can be reversible or irreversible, or in 
other terms, the effect will either dissipate or remain well after the drug is no longer present 
in the system.  An example of a reversible drug effect is the bronchodilation caused by 
theophylline, while irreversible tumour cell death caused by an anticancer drug exemplifies 
irreversible effects (46). 
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Direct response models can be used to relate a drug’s PK to its PD using linear 
models (with a slope and intercept), Emax models or sigmoidal Emax models.  The 
ordinary Emax model and sigmoidal Emax model are intuitively appealing because they 
indicate that there is no effect when drug levels are equal to zero and that, above a certain 
concentration threshold, increases in concentration cause no further increment in effect 
(59).  Although the ordinary or sigmoidal Emax models are hyperbolic in nature, it must be 
pointed out that, within certain concentration ranges, the relationship between the 
concentration and response is linear.  For the sigmoidal Emax model, there is a log-linear 
relationship between concentration and response between 20 to 80% of the maximal effect 
while below 20% or above 80% of the maximal response, the relationship is non-linear 
even on a log scale.  
In many cases, there is a delay between the change in plasma drug concentrations 
and the associated drug response and/or the same drug concentration can be associated with 
different responses.  To account for these time-dependent effects, many response models 
have been developed from the now classic effect compartment (or link) model to the more 
recent indirect modeling approach.  The link model includes an artificial delay 
compartment where concentrations are in equilibrium with those in the biophase, which 
results from “collapsing” of the hysteresis curve. The link model attributes the delay in 
drug response to a process whereby the drug must attain the biophase from systemic 
circulation (47, 48, 60).  As previously described, this process is influenced by many 
pharmacokinetic factors.  Therefore, the observed delay between the pharmacological 
response and drug concentration levels are related to the time necessary for equilibration of 
concentrations in the plasma and the effect compartments (61).  The drug concentrations in 
the effect compartment can then be related to the PD marker using direct models such as 
the Emax model or sigmoidal Emax model.  
A major advance was made in our ability to relate the PK to the PD of drugs with 
the indirect modeling technique proposed by Jusko (60, 62). As the name suggests, indirect 
models relate drug concentrations to their pharmacological effect by an indirect 
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mechanism.  In this approach, concentrations of drugs inhibit or induce the formation or the 
elimination of an effect.  The basic indirect or turnover model includes Kin (the zero-order 
constant for production of the response) and Kout (which represents the first-order rate 
constant for loss of the response).  An increase in response can be achieved by either 
stimulation of the response production (Kin) or by inhibition of the loss of response (Kout).  
Conversely, a decreased response can be attributed to an inhibition of Kin or a stimulation 
of Kout.  These four situations, illustrated in Figure 3, correspond to the four basic indirect 
models (62, 63).  Of course, response can be described by a combination of these four basic 
models.  As with the link model and indirect model, drug effect on Kin or Kout can be 
described by an Emax or sigmoidal Emax function. 
Figure 3. Indirect PD Models 
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3.  Quantification of Pharmacokinetic and Pharmacodynamic 
Properties 
The characterization of a drug’s pharmacokinetic and pharmacodynamic behaviour 
is an essential component of the drug development process.  The quantification of these 
properties allows researchers and drug developers to make informed decisions concerning 
doses, dosing regimens and clinical benefits, among other things.  Improved understanding 
of a drug’s PK and PD gained from post-marketing studies can also help clinicians use the 
drug in a more judicious manner. 
Essentially, two approaches exist for quantifying the PK and PD of drugs: 
noncompartmental analysis and compartmental analysis.  These analyses can be performed 
with data obtained from animals or humans, although only the latter will be discussed here.  
Both methods will be briefly outlined and contrasted in the following sections.   
3.1 Noncompartmental Analysis 
Noncompartmental analysis stems from statistical moment theory, where parameters 
describing PK or PD can be easily derived from concentration-time data (45).  The rate of 
drug absorption or exposure is often characterized by the parameters Cmax and Tmax, 
which represent the maximal observed concentration (in a biological matrix such as blood, 
plasma or serum) over the time period studied, and time at which this concentration is 
observed, respectively.  For PD parameters, maximal observed effect is often denoted as 
Emax, while TEmax corresponds to the time associated with this maximal effect. 
Following the administration of a single dose of a drug, exposure can be assessed by 
determining the area-under-the-concentration-time curve (AUC) using linear trapezoidal, 
log-linear trapezoidal or a combination of both linear and log-linear trapezoidal methods.     
Using the linear trapezoidal method, the AUC from time zero to time “t” (AUC0-t) is 
calculated using Equation 1 while the AUC from time zero to infinity (AUC0-inf) is 
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calculated using the formula in Equation 2.  In both equations, a total of n concentrations 
are available, with the last detectable concentration (Cn) being associated with time tn (45). 
Equation 1 
   
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
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The second term in Equation 2 represents the extrapolated AUC from time t to 
infinity, and it requires the determination of Kel, or the terminal elimination rate constant.  
This parameter is calculated by ln-transforming the terminal portion of the concentration-
time profile and estimating the slope of this transformed data using linear regression.  In 
turn, this parameter can be used to calculate the terminal half-life (T1/2), using Equation 3.  
T1/2 represents the time necessary for the amount of drug in the organism to decrease by 
50%.  It should be noted that for PD analyses, the term AUC is replaced by the term AUEC 
to denote “area-under-the-effect-curve”.  
Equation 3 Kel
T
)2ln(
2/1     
The area-under-the-first-moment-curve (AUMC) also requires the determination of 
Kel.  Equation 4 and Equation 5 can be used to calculate AUMC from time zero to time t 
(AUMC0-t) and AUMC from time zero to infinity (AUMC0-inf), respectively. 
Equation 4 
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Other pharmacokinetic parameters can be calculated using the ones described 
above.  Following the administration of a drug by the IV route, the mean residence time 
(MRT) can be calculated by dividing AUMC0-inf by AUC0-inf and subtracting half of the 
duration of infusion.  MRT represents the average time spent by a molecule in the body, or 
the time necessary for 63.2% of an intravenously administered drug to be eliminated from 
the organism if the drug’s PK is well described by a 1-compartment model  (45). 
The body’s capacity to eliminate a drug is often characterized by clearance (CL).  
Clearance is often expressed as a volume per time unit (such as L/h), representing the 
volume of blood or plasma that is cleared of the drug per unit of time.  For a drug 
administered intravenously, clearance is calculated as dose divided by AUC0-inf.  For an 
orally administered drug, the formula is similar except that it is an apparent clearance 
(CL/F) that is calculated, since the dose in the numerator is actually the bioavailable dose 
(dose x F), which is not necessarily the total dose.  The total volume of distribution (Vss/F 
for a parenteral dose), which does not necessarily correspond to a true physiological 
volume, can also be determined by noncompartmental methods.  This parameter should be 
viewed as a constant that relates the amount of drug in the body to the measured 
concentration at pseudo equilibrium, and it can be calculated as CL x MRT following 
single-dose intravenous administration of a drug.  Should the drug be administered by an 
extra-vascular route, the volume of distribution can then be approximated in the terminal 
phase and is denoted by Varea/F or Vz/F. Generally, Vss/F is a much more meaningful 
parameter than Varea/F, but it should be noted that both parameters are equivalent if the PK 
of the drug follows a one-compartment model. 
If concentration data obtained following IV and oral administration of a drug are 
available, it is possible to calculate the absolute bioavailability (F) of the orally 
administered product using noncompartmental analysis, as demonstrated by Equation 6.  
Similarly, the relative bioavailability (Frel) of two products can also be determined with 
AUCs using Equation 7.     
  22 
 
 
Equation 6 
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In order to perform noncompartmental analyses in a robust manner, it is necessary 
to include an important number of concentration values sampled at appropriate times.  The 
trapezoidal method of calculating AUC actually provides an approximation of the true 
AUC (which could be determined by integrating the function describing the concentration 
as a function of time over the desired time interval), therefore more samples leads to a 
better approximation (45).  In addition to requiring an important number of concentration 
values (biological samples), noncompartmental analyses should only be applied when 
certain assumptions hold true.  The first assumption is that the drug in question displays 
linear pharmacokinetics (45, 64).  In other words, exposure increases in proportion with 
increasing dose and PK parameters are stable through time.   A second important 
assumption is that the drug is eliminated from the body strictly from the pool in which it is 
being measured, the plasma, for example (64, 65).  Finally, this approach assumes that all 
sources of the drug are direct and unique to the measured pool (64).  Examples of drugs 
which may not be candidates for noncompartmental analyses because they do not fulfill 
these criteria include iron supplements and thyroid hormones (66). 
3.2 Compartmental Analysis 
The essence of compartmental analysis is to create a model defined by integrated, 
matrix, or partial differential equations (equations that have derivatives with respect to 
more than one variable) that describe the PK or PD behaviour of a drug.  Although this 
approach may not explain the true mechanisms underlying PK or PD behaviour, important 
correlations between covariates and parameters may point the way to further studies or 
provide deeper mechanistic understanding (67).  Among other advantages of this method 
are its use in special populations (such as pediatric or hepatic impairment patients) and its 
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potential partitioning of variability into inter-individual, intra-individual, inter-occasion and 
residual sources (68). 
Various types of compartmental analyses exist, ranging from individual analysis to 
population PK modeling including the naïve pooled data approach, the standard two stage 
approach, and non-linear mixed effect modeling that includes among others the iterative 
two stage, the First Order Conditional Estimation (FOCE) and the MLEM (Maximum 
likelihood Expectation Maximization) approaches (67, 69, 70).  In these last approaches, all 
data is modeled simultaneously while retaining individual information, in order to obtain 
estimates of population mean and variance as well as quantify sources of variability (68, 
71). 
At the core of compartmental analyses is non-linear regression.  In contrast with 
linear regression, where data is being fitted with a straight line defined by a slope and 
intercept, non-linear regression depends on equations whose partial derivatives (with 
respect to each of the parameters) involve other model parameters (72).  Another important 
difference between the two types of regressions is that linear regressions have analytical 
solutions, such that the functions can be manipulated to obtain a specific equation for the 
solution, while only numerical solutions exist for non-linear regressions.  For non-linear 
equations, approximate solutions to the equations can only be obtained through iterative 
processes that are described in further detail below.  Since most biological processes are 
described by non-linear equations, linear regressions will not be examined any further. 
3.2.1 Individual Analysis 
As its name implies, individual analysis involves the development of a model using 
data from one source (such as one human or one animal).  Because of the error that is 
always inherent in data, whether it be related to the collection procedures themselves or to 
analytical assays, a model can never perfectly predict the observed data.  The relationship 
between observed and predicted concentration values must therefore account for this error, 
as defined in Equation 8.  In this equation, Xi represents a vector of known values (such as 
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dose and sampling times), Ci represents the vector of observed concentrations, i represents 
the measurement errors, j represents the vector of model parameters (in other words the 
pharmacokinetic parameters) and ƒi is the function that relates Ci to j and Xi.  The 
subscript i represents the total number of observations or values.  
Equation 8   iijii XfC   ,   
The successful creation of a model might give rise to a semi-log concentration-time 
profile similar to the one in Figure 4. 
 
Figure 4. Example of a Concentration Time Profile from Individual Compartmental 
Analysis 
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3.2.1.1 Numerical Approaches for Individual Analyses 
The aim of PK compartmental analysis is to develop a model that is associated with 
predicted concentration values (or whatever observation is being studied) that are as close 
as possible to the observed values.  In other words, the goal is to minimize the difference 
between the predicted and observed values (represented by i in Equation 8), and generally 
the least-squares and maximum likelihood approaches are used to quantify these 
differences (73).   
Various least-squares metrics (often termed “residual sum of squares”) can be used 
to quantify these differences, and they are outlined in Table 1 below (72, 73). 
Table 1. Comparison of Least-Squares Methods  
Method Objective Function Formula Characteristics 
Ordinary least 
squares (OLS) 



n
1i
2
iiOLS )CˆC(O  
No weighting 
Weighted least 
squares (WLS) 



n
1i
2
iiiWLS )CˆC(WO  
Model and parameters 
must be defined and stated 
empirically 
Extended least 
squares (ELS) or 
Maximum 
Likelihood (ML) 
 


n
1i
i
2
iiiELS ))Cˆln(var()CˆC(WO  
Models can be defined, but 
parameters of the models 
are fitted within the 
procedure, e.g., 
)Cˆvar(1W ii   
Ĉi = predicted i
th concentration value, Ci = observed i
th concentration value, Wi = weighting factor,  
n = number of observations, var = variance 
  
Although it is a simple formula, OOLS is inherently biased because it tends to favour 
model estimates that provide better predictions for larger observations compared to smaller 
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ones.  The WLS and ML/ELS approaches are an improvement over the OLS method since 
they account for the magnitude of observations (and their relative variability) by 
incorporating a weighting factor into their formulas. The ML/ELS approaches differ from 
the least-squares approach, because they deal with the probability of observing the actual 
data given the model and its parameter estimates.  In these methods, the function that is 
being minimized is the log-likelihood (LL), or the probability of observing the actual 
concentration values given a set of model parameter estimates.  The function for LL is 
presented in Equation 9. It should be noted that the only difference between ELS and ML is 
in the assumptions about the distribution of the variance parameters. In the ML approach, 
the distribution is assumed to be normal, while the ELS approach makes no such 
assumption (74). 
Equation 9     2222
2
n
n
CC
Ln
n
Ln
n
CLL
ii

























  
Because it is easier to minimize a positive number rather than a negative one, the 
LL is often multiplied by -2 to obtain a positive number called the “-2LogLikelihood” (-
2LL).  
3.2.1.2 Algorithms for Numerical Problem Solving 
Since many combinations of parameter estimates must be evaluated in order to find 
the parameters that minimize one of the objective functions described previously, many 
algorithms have been developed to systematically do so.  Some algorithms apply 
linearization techniques to approximate the model using linear equations.  Cauchy’s method 
employs a first-order Taylor series expansion, Newton or Newton-Raphson based methods 
utilize a second-order Taylor series expansion while the Gauss-Newton method iteratively 
uses multiple linear regressions via first-order Taylor series expansion.  The Levenberg-
Marquardt method is another algorithm which includes a modification of the Gauss-
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Newton method. Finally, in contrast with the algorithms previously described, the Nelder-
Mead simplex approach does not involve linearization procedures.  This technique involves 
the examination of the response surface (in order to find the lowest point) using a series of 
moving and contracting or expanding polyhedra (three dimensional objects composed of 
flat polygonal faces joined by vertices) (73).  
3.2.2 Population Analysis 
Population analysis can be viewed as an extension of individual analysis, since it attempts 
to develop a model that predicts concentration data associated with different individuals or 
animals.  The general concept is similar to that embraced by individual analysis, except that 
the model must also take into consideration inter-individual variability.  The resulting 
model is therefore able to predict concentration values for each individual within the 
population, but it also provides an “overall” (mean or population) set of predictions.  In 
other words, the model describes the behaviour of the whole population as well as the 
behaviour of each individual within this population.  This concept is illustrated by Figure 5, 
where the coloured circles represent observed concentrations from different individuals, 
and the dotted lines of the same colour represent the predicted concentrations for that 
specific individual.  The solid orange line passing through the middle of the figure 
represents the population predicted values. 
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Figure 5. Example of Concentration Time Profiles from Population Compartmental 
Analysis 
 
Observed concentrations must therefore be ascribed to specific subjects, as defined 
in Equation 10 which is analogous to Equation 8.  In this equation, Xij represents a vector 
of known values (represented by i) for the j
th
 subject, Cij represents the vector of observed 
concentrations for the j
th
 subject, ij represents the measurement errors for the j
th
 subject, j 
represents the vector of model parameters for the j
th
 subject and ƒij is the function that 
relates Cij to j and Xij. 
Equation 10   ijijjijij XfC   ,   
Each individual has a distinct set of PK model parameters (j) that will provide the 
best predicted values for that individual’s observed data.  However, as previously 
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mentioned, there is also a typical profile of “population predictions” that is associated with 
population PK model parameters () that can be regarded as mean values.  The relationship 
between the mean PK parameters and individual PK parameters is described by   Equation 
11, where g is a known function that relates j to  using the individual’s characteristics 
such as height or weight, denoted by zj.  The last term, j, represents random (unexplained 
or uncontrollable) variability that also causes j to deviate from . 
  Equation 11   jjj zg   ,  
3.2.2.1 Numerical Approaches for Population Analyses 
The numerical approaches described for individual compartmental analysis are also 
used in population compartmental analyses.  In population compartmental analyses, the 
goal is also to minimize some sort of objective function. 
3.2.2.2 Various Approaches to Population Compartmental Analyses  
The most basic type of population compartmental analysis is the “naïve-average 
data” method, where the average concentration value at given time points are computed 
from the entire dataset, and then a model is developed using these average values.  A 
similar method is the “naïve-pooled data” approach, where data from different individuals 
are treated as though they were obtained from a single individual, and then analyzed using 
the individual approach. 
The two-stage approach to population compartmental analyses offers some 
improvement over the previous ones.  In essence, data from each subject is first fitted 
individually (in other words using the individual approach), and in the second step, 
population parameter estimates are obtained.  Different types of two-stage approaches exist, 
such as the standard two-stage (STS) approach, the global two-stage (GTS) approach, and 
finally a mixed effect modeling approach known as the iterative two-stage approach (IT2S 
or ITS).  In the STS approach, the population parameters estimates (for mean and variance) 
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are determined by calculating the mean and variance of the individual PK parameters, while 
the GTS approach actually estimates expectations for the mean and variance through an 
iterative process.  The ITS method is a non-linear mixed effect modeling technique that 
uses a more refined iterative approach utilizing a mixture of ML and MAP (Maximum a 
posteriori probability) techniques. Within each population iteration, prior values are used to 
estimate individual PK parameters in the first step, while individual values are then used in 
the second step to recalculate a newer, more probable set of population parameters.  Steps 
one and two are subsequently repeated until there is little to no difference between the new 
and old prior distributions (e.g., until the algorithm “converges”). 
In contrast with the iterative two-stage approach, other types of non-linear mixed 
effect modeling techniques proceed by first fitting the data in a reverse manner so they 
obtain population mean estimates followed in a second step with individual data estimates 
(therefore called “post-hocs”). The fixed effects (variables that can be controlled, such as 
dose or pharmacokinetic parameters) and random effects (uncontrollable factors like inter-
occasion variability) are fitted simultaneously as it regards to population mean and 
variability estimates as well as the residual variability.  
3.2.2.3 Algorithms for Numerical Problem Solving 
Some of the algorithms used in the context of population compartmental analyses 
include the first order (FO) method, first order conditional estimation (FOCE) approach, 
and the maximum likelihood expectation maximization (MLEM) method.  In both the FO 
and FOCE algorithms, the minimum objective function is sought out by linearization of the 
model through a series of first order Taylor series expansions of the error model.  The 
difference between the FO and FOCE algorithms is that in the former, inter-individual 
variability for PK parameters is estimated using estimates of the population mean and 
variance in a post hoc step, while in the latter, inter-individual variability is estimated 
simultaneously with the population mean and variance (75).  In other words, the FO 
algorithm uses a linearization technique that first assumes  = 0, contrary to the FOCE 
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algorithm which uses the posterior mode of  (that relies on conditional estimates) (73).  
Furthermore, the FO method assumes that inter-individual variability follows a constant 
coefficient of variation model, even if it is coded for a log-normal model.  This is due to the 
Taylor expansion, whose first term is the same for the log normal model and the constant 
coefficient of variation model.  A modification of the FOCE algorithm, known as the 
Laplacian FOCE method, exists whereby a second order Taylor series is performed instead 
of the first order expansion (75).  
The MLEM algorithm is different from the previous methods because it does not 
rely on any linearization techniques (76).  This algorithm involves maximizing a likelihood 
function through an iterative series of two steps which are repeated until convergence.  In 
the first step, termed the expectation step or “E-Step”, the conditional mean and covariance 
for each individual’s data are computed and the expected likelihood function associated 
with these parameters is obtained.  In the second step, the maximization step or “M-step”, 
the population mean, covariance and error variance parameters are updated to maximize the 
likelihood from the previous step (73, 76). 
3.2.3 Software Available for Compartmental Analyses 
Although many computer programs are available to perform both individual and 
population pharmacokinetic analyses, only the two that were used in the context of this 
thesis (NONMEM
® 
and ADAPT 5
®
) will be described briefly.  One of the first software 
developed for this purpose was NONMEM
®
, which was created by Sheiner and Beal in the 
early 1980’s for mainframes and personal computers (77-79), and many consider it to be 
the gold standard even today.  Many versions of NONMEM
®
 have been developed over the 
years, incorporating various types of algorithms, including FO, FOCE, FOCE Laplacian 
and most recently, ITS and MLEM.  The second software is ADAPT 5
®
, the fifth version of 
the ADAPT-II® software developed by D’Argenio and Schumitzky in 1982 (76).  Different 
algorithms are also available in ADAPT 5
®
, such as STS, ITS and MLEM. 
  32 
 
 
3.3 Differences Between Noncompartmental and Compartmental 
Approaches 
Noncompartmental and compartmental analyses are both excellent methods that can 
be used to characterize the PK and/or PD of a drug, when used in their appropriate context.  
The disadvantages of each method highlight the advantages of the other method, but when 
utilized correctly, each approach has its own merits.  Table 2 summarizes the key 
advantages and disadvantages of each approach (68, 80). 
Table 2. Advantages and Disadvantages of Noncompartmental and Compartmental 
Population Analyses 
 
 Advantages Disadvantages 
N
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m
p
a
rt
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en
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l 
A
n
a
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s 
- Easy and quick to perform 
- No special software is needed 
- Robust and easily reproducible 
- Requires rich sampling 
- Makes assumptions regarding 
linearity  
C
o
m
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m
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l 
P
o
p
u
la
ti
o
n
 A
n
a
ly
si
s - Can be performed with rich or 
sparse data 
- Can be performed using data from 
heterogeneous sources or special 
populations 
- Quantifies inter-subject variability 
- Can perform covariate analyses 
- Can deal with both linearity and 
nonlinearity 
- Requires experienced analyst 
- Time-consuming and labour intensive 
- Software is not user-friendly 
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4. The Drug Development Process 
Now that we have examined some of the pharmacokinetic and pharmacodynamic 
principles that underlie drug development, we can turn our attention to the process itself, in 
order to better introduce the benefits of modeling and simulations within this process that 
will be demonstrated throughout this thesis. 
Although each phase of the drug development process is important, in the context of 
this thesis, more emphasis will be placed on the clinical pre-marketing phases (Phases 1 to 
3) of the process.  Generally the process is viewed as a series of sequential (and sometimes 
overlapping) phases, as illustrated in Figure 6 (81).  The whole process can take anywhere 
from 10 to 20 years to complete (82, 83).   
Figure 6. Phases of the Drug Development Process 
  
The subsections below present an overview of each of the phases of the DDP.  
Additionally, a description of the drug development process for generic products is also 
provided. 
Pre-clinical (including discovery)
Phase 1
Phase 2
Phase 3
Submission 
to Launch
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4.1 Pre-clinical 
Once promising drug compounds are identified and a suitable formulation is 
developed, pre-clinical tests are performed.  At this stage, compounds are screened for 
efficacy and safety through in vitro and animal studies, to make sure that they will be 
potentially effective and reasonably safe to administer to humans (84).  Four general types 
of studies are conducted during this phase.  The first type of studies (often called the 
“pharmacological screen”) aim to detect drug effects that are not the intended ones.  The 
second series of tests are performed to characterize the PK of the compound in relevant 
animal species, while the third type of test includes toxicology assessments in the same 
species, to evaluate the effects of single-dose and repeated administration of the drug in 
target animals.  Toxicology tests in animals are actually pursued throughout clinical 
development, in order to assess potential long term toxicity (85). Tests are also conducted 
to assess the compound’s teratogenicity (in vivo) and mutagenicity (in vitro) (86).   
During this phase, the maximal tolerated dose and no-observed-adverse-event-level 
(lower dose level where no adverse events are observed) will be determined in at least two 
different species (85).  Using this information, a safe dose that can be administered to 
humans for the first time is then selected. 
4.2 Clinical 
4.2.1 Phase 1 
The studies undertaken during Phase 1 aim to assess the safety and tolerability of 
the drug in humans, and they offer the first opportunity to characterize the PK/PD of the 
compound in humans (82, 87).  Phase 1 studies are generally conducted in a small group of 
healthy volunteers, with the exception of some drugs (such as oncology drugs) which are 
administered to patients instead (82).  A small number of healthy volunteers, ranging from 
20 to 100 (85, 88), are normally included in these studies.  
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The types of studies encountered in Phase 1 are generally randomized, placebo-
controlled studies which may include a single, ascending dose administration study and a 
multiple (repeated administration), ascending dose  study.  Ultimately, these studies should 
help determine a range of doses that are safe and tolerated in humans (85).  In addition to 
the ascending dose studies, Phase 1 studies may also include drug-drug interaction studies, 
studies to assess the effect of food on PK, special population studies such as in renally or 
hepatically impaired subjects, a thorough QTc study, and others  (82).  
4.2.2 Phase 2 
In Phase 2 studies, the goal is to obtain preliminary evidence of efficacy and safety 
by administering the drug to patients who suffer from the targeted disease or condition (85).  
A relatively small number of patients are included in these studies, often numbering in the 
hundreds (85, 88).  In addition to providing insight into the drug’s efficacy, these studies 
can also indicate what type of short term adverse events may occur in this population.  
Phase 2 studies are normally randomized, placebo-controlled trials.  They are 
sometimes divided into two parts, Phase 2a and Phase 2b, but occasionally the two trials are 
combined into a larger trial.  In Phase 2a, a range of doses of the compound is administered 
to a small group of patients (twelve to one hundred) to prove the drug’s short term efficacy 
(and safety) (85).  This is what is known as “Proof-of-concept” (POC).  POC has also been 
described as “the earliest point in the drug development process at which the weight of 
evidence suggests that it is ‘reasonably likely’ that the key attributes for success are present 
and the key causes of failure are absent” (89), and therefore POC studies can also be 
performed within Phase 1.  POC might require demonstrating proof of mechanism, 
identifying novel endpoints, confirming PK-PD behaviour or assessing safety. 
The subsequent Phase 2b trial administers a range of doses to patients for a longer 
period of time, starting from doses deemed to be sub-therapeutic to maximally tolerated 
ones, in order to establish a dose-response relationship.  This is done to find the minimal 
effective dose or dosing regimen that will be used in subsequent stages of the DDP (82). 
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In addition to determining the minimal effective dose to be further investigated in 
Phase 3, Phase 2 is often a period during which other issues must be taken into 
consideration before proceeding any further.  As always, the safety and tolerability of the 
dose in question remains a concern.  In addition, the efficacy of the product with respect to 
competitor compounds must also be addressed, as well as the probability of technical and 
regulatory success, and potential market share (82).   
4.2.3 Phase 3 
This phase of the DDP involves even more patients from the target population than 
in Phase 2.  The number of patients recruited for these trials can range from several 
hundred to several thousand (82, 85, 88).  Though they vary in design, they are frequently 
conducted as multi-center trials. They aim to confirm the efficacy and safety that was 
demonstrated in Phase 2 and to uncover side effects that may be infrequent (87).  In 
addition, they serve to confirm the dose and dosing regimen selected based on the Phase 2 
results. 
The drug product that is tested at this stage is generally the one that the company is 
planning to market in terms of composition, formulation and strength (85). 
Generally, two successful, pivotal Phase 3 trials are required by regulatory 
authorities.  A placebo arm is generally included in these studies, but it is not uncommon to 
include treatment arms where other treatments (currently on the market) are administered, 
especially if a “gold-standard” is available or if a placebo arm is not ethical.  In this way, 
the efficacy of the new compound can be compared to that of the current treatment(s), with 
the hopes of demonstrating non-inferiority or superiority.  Non-inferiority could be targeted 
when the drug being studied possesses other attributes (such as a superior safety profile or 
simplified dosing regimen) that make it an appealing therapeutic alternative to what is 
already on the market.  At a minimum, the drug’s efficacy and safety must be compared to 
that of the placebo (82, 85) if it is ethical to administer one. 
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4.2.4 Phase 4 
Once a drug is on the market, it is still the object of investigations often called 
“post-marketing studies” or “pharmacovigilance”.  The overall objective of these studies is 
to continue to monitor the drug’s efficacy but especially its safety and tolerability (85).  
Now that the drug has found its way to the market, it is being exposed to a broader 
audience than the population tested in Phase 3 studies, therefore Phase 4 studies may reveal 
the presence of rare but dangerous adverse events that were not previously noted.  Phase 4 
studies may also have pharmacoeconomic objectives, or may seek to study additional 
indications (85). 
4.3 Generic Product Development 
Although the development of generic drug products must adhere to stringent rules 
and regulations, bringing a generic product to market is generally a shorter, less risky and 
easier process than bringing an innovator product to market (90).  Unlike the DDP for 
innovator products, companies that develop generics are not usually required to submit 
clinical data that establishes their product’s safety and efficacy.  This is because regulatory 
authorities rely on the already-approved safety and efficacy profile of the innovator 
reference product (88).  Furthermore, no pre-clinical data are normally submitted for review 
(91). 
A key concept in generic drug product development is termed bioequivalence (BE), 
where the relative bioavailability of two drug products are judged to be equivalent, with the 
underlying assumption that drug levels in systemic circulation reflect levels, or will 
eventually be linked to levels, at the site of action.  The U.S. FDA, Health Canada, and 
European Agency describe products as being bioequivalent if administration of the same 
molar dose of the active ingredient or moiety under identical conditions leads to similar 
bioavailability, or bioavailability that is not significantly different. 
BE can be assessed by various means, such as PK studies, PD studies, clinical 
studies and in vitro studies, although European, Canadian and U.S. regulatory authorities 
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favour PK studies in general (91, 92).  PK studies typically involve conducting in vivo trials 
in healthy volunteers.  Specific BE guidelines outlining the ideal in vivo study design and 
statistical approaches that are preferred have been emitted by various regulatory 
(government) agencies (93-96), but for most drug products, BE is generally assessed by 
comparing the average relative bioavailability parameters (Cmax and AUC) of two 
products (91).  Study designs tend to be two-way, two-treatment, two-sequence crossovers 
conducted in healthy volunteers, to minimize variability by administering the test and 
reference products to the same subjects (91).  Using the ln-transformed PK parameters 
calculated for each subject, analyses of variance (ANOVA) are then performed and least 
square mean (LSM) ratios of test to reference PK parameters are obtained.  Pre-defined 
confidence interval (CIs) limits, which can be viewed as target goalposts, are then used to 
determine BE by assessing whether or not LSM ratios and CIs fall within the targeted 
range.  
Pharmacodynamic methods can be employed when it is not possible to measure 
systemic concentrations, such as in the case of locally-acting products like bronchodilators 
or topical creams, which have limited systemic absorption.  This approach can also be 
adopted when systemic concentrations are not reflective of concentrations at the purported 
site of action.  For such products, bioequivalence may be evaluated using an appropriate PD 
endpoint instead of PK parameters (91).  When PD endpoints are employed instead of PK 
parameters in what is referred to as a Therapeutic Equivalence (TE) study, it is normally 
necessary to establish a dose response curve (depicted by the black line in Figure 7), by 
administering a placebo, a low dose of both test and references treatments and a high dose 
of the reference product (illustrated by the green circles in Figure 7).  (The inclusion of a 
high dose test product is not necessary, and it is only included in the figure to illustrate the 
importance of selecting the right dose, as described in more details below.) The approach of 
projecting the PD effect on the dose scale in order to construct a ratio and a 90% CI is 
known as the dose-scale approach (97).  The inclusion of a placebo will confirm that the 
low dose of the test or reference product is more efficacious than a placebo, and the 
administration of the high dose of the reference product will demonstrate that the 
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comparison between products at the low dose is truly discriminatory. In other words, by 
establishing a complete dose-response curve, it can be shown that the test and reference 
product meet BE criteria because they are truly BE and not because their responses are both 
at the upper end (plateau) of the dose-response curve or at the bottom end where no 
difference with placebo is seen. In the example depicted in Figure 7, the red squares depict 
test doses that are more than 2 times greater than the corresponding references doses (green 
circles).  At a low dose, the difference in percentage PD response (45% vs. 61%) is more 
apparent and reflects the true difference in doses (300 mg vs. 620 mg).  However, at higher 
doses which are located on the plateau portion of the dose-response curve, the similarity in 
percentage PD response (82% vs. 86%) masks the true difference in doses (3000 mg vs. 
6100 mg).  This highlights the importance of selecting appropriate doses when undertaking 
this type of study.  
Figure 7. Example of a Dose-Response Curve in a Therapeutic Equivalence Study 
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In some cases, PK or PD studies can be replaced by adequate and well-controlled 
clinical trials (91).  Furthermore, there are situations where the conduct of in vivo BE 
studies for immediate-release products can be waived entirely, based on the principles set 
forth by the “biopharmaceutic drug classification” system (BCS).  In the mid 1990’s, 
Amidon and coworkers published a seminal paper on the BCS that categorized drugs 
according to their solubility and permeability (98).  Drugs belonged to one of four classes, 
more specifically I: high solubility and high permeability drugs, II: low solubility and high 
permeability drugs, III: high solubility and low permeability drugs or IV: low solubility and 
low permeability drugs, as depicted in Figure 8.  It was suggested that in vivo 
bioavailability of products could be predicted from this classification system.  Based on this 
premise, the FDA adopted the BCS in their 2000 guidance entitled “Waiver of In Vivo 
Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage 
Forms Based on a Biopharmaceutics Classification System” (99).  According to this 
document, in vivo bioavailability and bioequivalence studies may be waived for immediate-
release formulations of drugs belonging to Class I.  Health Canada has also adopted a 
similar guidance, but their guidance includes drugs belonging to Class I and Class III (100). 
Figure 8. Biopharmaceutics Classification System 
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It should be noted that BE studies do not only fall within the domain of generic drug 
development, but that innovator products require the conduct of BE equivalence studies to 
bridge the different formulations that they have used during their clinical trials.  For 
instance, formulations typically evolve and change during the development process or after 
approval by regulatory authorities has been granted. BE studies must be performed to 
ensure that the changes that were made do not impact the drug’s PK properties and call into 
question the associated efficacy and safety (91).  In other words, BE studies can be 
performed to bridge results obtained with different drug formulations at various stages of 
the DDP. 
A description of the generic  drug product development would not be complete 
without mentioning “supergenerics”, although a detailed description of the topic is beyond 
the scope of this thesis.  These products differ from traditional generics because rather than 
being pure copies of the innovator drug, they offer an improvement over the latter, with 
regards to drug delivery system or formulation, among other possibilities (90).  Some 
“added value” that could be provided by a supergeneric drug include modification of a 
dosing form to improve patient compliance or improvement of a compound’s safety 
margins (90). 
5.  Current Use of Modeling and Simulations in the DDP 
The utility of PK/PD modeling and simulations throughout the drug development 
process has been the focus of many reports and discussions (53, 80, 84, 101-111).  
Although it is not being used to its full potential, some of its current applications in the 
development of both innovator and generic drug products are described herein. 
5.1 Innovator Drugs 
Performing PK/PD modeling using animal (pre-clinical) data can provide some 
insight into the nature of the exposure-response shape as well as estimates of potency 
(EC50) or maximal effect (Emax) (108).  Information on PK properties (absorption, 
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distribution, metabolism, elimination) that could impact pharmacological response can also 
be obtained at this stage.  Modeling can also make use of existing clinical data on similar 
compounds.  Despite its utility in screening potential drug candidates, one of the main uses 
of PK/PD modeling at the nonclinical stage remains the selection of doses for first-time 
human administration (102).  Different modeling approaches can be used for dose range 
projection including population PK/PD analyses of sparse nonclinical data, allometric 
scaling to predict human PK and efficacy scaling, or physiological-based PK modeling 
(105). 
The PK/PD model developed at the pre-clinical stage can be further refined using 
data obtained from Phase 1 studies conducted in small numbers of healthy volunteers.  A 
model can actually be developed to link animal and human data.  In this first phase of 
clinical development, a PK/PD model can describe complex exposure-response 
relationships, such as those which involve non-linearity, as well as make use of scarce data 
(related to sparse sampling or assay limitations) (112).  PK/PD modeling can make use of 
data available from all Phase 1 studies in order to get robust parameter estimates.  Modeling 
can also reveal if there are any deviations from dose-proportionality, and can describe 
possible time-related phenomena such as tolerance or sensitization.   
Phase 2 studies are conducted in a larger number of subjects and information can 
therefore be obtained to better understand inter-subject variability.  Another important 
application of PK/PD modeling at this stage is that it can support proof-of-concept (POC) 
claims by demonstrating that the drug acts on its targeted mechanism, thereby leading to 
the desired short-term outcome.  PK/PD models can, in fact, be used to support claims of 
efficacy throughout drug development (101).  As in Phase 1 studies, PK/PD modeling can 
be used for further evidence of POC as well as in the selection of dosing regimens, 
sampling schedules and study design.  Information gleaned from Phase 2 studies can be 
also used to optimize the design of future trials, as well as further enrich the understanding 
of a compound’s attributes that will distinguish it from competitor drugs (105).  For 
example, based on a developed PK/PD model, several dosing schemes can be simulated in 
  43 
 
 
order to select the range of doses or types of regimens that could provide optimal response 
(113). 
In later stages of clinical development, PK/PD models can be used to understand the 
impact of covariates on drug response.  Since Phase 3 studies are conducted in larger 
numbers of patients from the target population compared to Phase 2 trials, they provide key 
information regarding the effect of patient characteristics and different pathological states 
on drug response.   
Models developed during Phase 3 can further confirm the dose-exposure-response 
relationship in the target population.  In some cases, when surrogate markers are available, 
the use of exposure-response information coupled with a single pivotal clinical trial can be 
sufficient evidence of effectiveness (101).  This demonstrates how a thorough 
understanding of the exposure-response relationship can even obviate the need for 
additional studies.  In addition to developing PK-PD models, disease-drug models can be 
developed at this stage. 
Modeling and simulations are not only being used and further developed by the 
pharmaceutical industry or academia, but from a regulatory perspective, they have also 
been used to enhance decision-making and contribute to product labeling (pertaining to 
dosage and administration, safety or clinical pharmacology) (114).  In some submissions to 
the FDA, drug companies benefitted from modeling and simulations performed by 
reviewers, who were able to extract information from the data that had not otherwise been 
presented (114, 115).  Over an eight year period studied (2000 to 2008), modeling and 
simulations contributed to the approval of 64% of products while it influenced the labeling 
of 67% of products (116).  However, although modeling and simulations are being used 
more frequently by regulatory reviewers as an aid to decision-making, this tool remains 
under-utilized by drug developers and the research presented in this thesis will demonstrate 
other ways in which it can be applied or further developed.  
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5.2 Generic Drugs 
While the use of modeling and simulations in the development of innovator drugs is 
gaining greater acceptance, its use in the world of generic drug development is still in its 
infancy.  Indeed, the generic drug industry still relies heavily on simple noncompartmental 
methods to assess PK and PD.   
One exception to this is when BE or TE studies require Emax calculations such as 
those for topical corticosteroids (117) or certain locally acting products (118, 119) for the 
U.S. FDA. Many times equivalence can be calculated with the dose-scale approach where a 
dose-response relationship is developed for the drug under study, and modeling (i.e., data 
fitting) is often relied upon to establish this relationship.  An example of an equation that 
could be used to describe the dose-response relationship is provided in Equation 12. 
Equation 12 
50
max
Response
EDFDose
FDoseE
rel
rel



 
By fitting the overall response data to this equation, it is then possible to obtain 
mean estimates for the parameters Emax (maximal response), Frel (relative bioavailability) 
and ED50 (the dose associated with half of the maximal response).   But, as previously 
mentioned, modeling and simulation is still in its infancy for generic drugs because even 
though this equation would be better solved using mixed-effect modeling, at this time U.S. 
regulators are still recommending the use of a naive pooled data approach to sponsors. 
Once parameter estimates are found, a non-parametric bootstrap can then be performed to 
establish a bias-corrected and accelerated 90% confidence interval (120) around the 
estimated Frel.     
6. Challenges in the Drug Development Process 
While there are undeniable benefits to drug therapy, the process of discovering a 
new chemical entity (NCE) and bringing it to market, whether it be a small or large 
molecule, is marred by several obstacles.  Indeed, two major issues faced by drug 
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developers are the staggering costs associated with the DDP and the extremely low rate of 
success.  In the following subsections, each of these problems will be addressed in more 
detail.  Finally, some reflections on how the DDP can be improved with the use of 
modeling and simulations are presented in the last sub-section. 
6.1 High Costs 
Bringing a drug to the market is far from being inexpensive, and costs associated with the 
DDP have risen dramatically within the last 40-year period.  Over the years, researchers 
have attempted to calculate the cost associated with drug development, using various 
methodologies.  The findings of some of the more prominent studies are illustrated in 
Figure 9 (81, 87, 121-123).  In this figure, the year associated with each cost represents the 
mid-point of the range of years studied by the researchers.  These estimates represent the 
cumulative costs of all stages of the DDP.  They take into consideration the revenues that 
are invested (and ultimately wasted) on compounds that never made it to the market, and 
they also account for the time involved in the DDP by increasing the cost by a certain 
percentage that represents the potential return if the funds had been invested elsewhere 
(hence the term capitalized estimate). 
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Figure 9. Capitalized Estimates (in 2009 Million US Dollars) of Drug Development Costs 
Over Time 
 
This figure shows that despite differences in methodologies, data sources and 
studied timeframes, there is a trend towards increase costs associated with the entire DDP.  
This trend is confirmed when comparing the results of studies conducted at different times 
but by the same research group (121).  The increase may actually even be exponential in 
nature, as suggested by others (124, 125).        
The rising cost of drug development can be attributed to many factors, but one of 
the important ones is the increase in the number and magnitude of clinical trials in response 
to increased regulatory requirements (83).  Indeed, although the cost of pre-clinical research 
has also increased over the years, the overall increases can mostly be attributed to costs 
associated with increased human trials rather than pre-clinical efforts (87).   
An increase in the number and size of clinical trials also adds to the development 
time, which also impacts the DDP costs (83).  Over the past decade, the time required for 
research and development has increased by 12 to 15 months (126).  The old adage “time is 
money” also holds true in the pharmaceutical industry, where it has been estimated that a 
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delay of six months to launch a product translates to a loss of 100$ million in net present 
value (126). 
Although the majority of drug development costs (approximately 63%) are 
associated with clinical phases (Phases 1 to 3) (81), these costs are not evenly divided 
between the different phases, and they increase with each phase.  According to one study, 
mean costs associated with pre-clinical, Phase 1, Phase 2, and Phase 3 studies were 5.2, 
15.2, 23.5, and 86.3 millions (dollars in the year 2000), respectively (87).  These figures 
were even higher in 2012, with mean costs rising to 35.7, 34.3, 82.1 and 245.1 millions for  
pre-clinical, Phase 1, Phase 2, and Phase 3 studies , respectively (127).  The elevated cost 
associated with Phase 3 studies is not surprising, as these studies can include thousands of 
patients from different sites, and can span many years. 
6.2 High Attrition Rates 
What makes drug development such a high-stakes venture is that in addition to the 
staggering costs associated with the process, the chances of success are very slim.  
Estimates of the probability of successfully bringing a drug to the market (starting from 
pre-clinical stages) have ranged from 11.7% to 30.2% (81, 87, 121-123).  Even with the 
most optimistic of these probabilities, it is clear that the likelihood of success is marginal.   
These numbers can also be viewed from the perspective of the number of tested candidates 
that eventually make it to the market.  Some analyses suggest that for every new molecular 
entity that makes it to the market, 8 others will have been pursued but eventually discarded 
(81).  Similarly, other authors have reported that only 1 in 9 or 10 drugs that are tested in 
clinical trials will make it to the market (82, 128). 
In the past, a drug’s inability to make it to market was mostly related to 
pharmacokinetic causes (poor characterization of pharmacokinetic properties or low 
bioavailability) (128).  However, improvements in our understanding of pharmacokinetics 
and in the quality of the tools used for pharmacokinetic analyses have led to less 
pharmacokinetic-related failure. Now, at the beginning of the twenty-first century, attrition 
rates remain high, but rather than being attributable to pharmacokinetics, failure is often 
  48 
 
 
related to safety and efficacy outcomes revealed at the end of the drug development process 
(Phase 3).  What is striking is that Phase 3 attrition rates remain high and have not 
decreased since the last decade despite advances in technology and our increasing 
knowledge (124). 
Failure of drugs in Phases 1 or 2 of the DDP can be broadly categorized as being 
due to poor drug characteristics (either PK or PD) or due to poor choices made by 
researchers.  In the former, the drug may not act on its target as anticipated, or it may cause 
unacceptable adverse events.  In the latter, Phase 2 attrition may be caused, among other 
reasons, by the selection of the wrong patient population, the administration of an 
inappropriate dose or by the inadequacy of the measured endpoint to detect the desired 
effect (89).  One analysis of Phase 2 failures occurring between 2008 and 2010 suggests 
that 51% of all Phase 2 failures could be attributed to a lack of efficacy while 19% were 
due to safety or toxicology concerns (129).  Despite technological advances and increased 
medical knowledge, the attrition rate for drugs entering Phase 2 of the drug development 
process can be as high as 62% (128).  Nevertheless, if a drug is destined to fail, it would be 
better to do so in Phase 2 than during or after costlier Phase 3. 
In two analyses conducted in 1991 and 2003, DiMasi and colleagues used similar 
methodologies to estimate the failure rates of drug compounds in different phases of drug 
development.  Interestingly, there was an increased failure rate in Phase 1 studies (from 
32.5% to 37%) and a decreased failure rate in Phase 3 (17.1% to 12.6%), while rates for 
Phase 2 studies remained stable.  This shows that companies today may be more proficient 
at weeding out less promising compounds earlier in the drug development process, leading 
to lower failure rates later in the process (87, 122). 
In an ideal world, drugs in Phase 3 of the DDP would only fail due to the 
occurrence of unforeseen and extremely rare adverse events.  However, this is not the case 
and the attrition rate for drugs entering Phase 3 can be as high as 45% (128).  The reasons 
for failure in late-stage Phase 3 studies are numerous, including the underpowering of 
studies or even selecting the wrong dose or dosing regimen (85).  One report suggests that 
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up to 30% of Phase 3 failures can be attributed to lack of efficacy, while safety concerns led 
to another 30% of Phase 3 failures (128).  An even higher failure percentage of 66% due to 
efficacy reasons has been suggested by two separate analyses (130, 131).  In either case, the 
figure is high and signals a problem.  Indeed, the repeating of failed pivotal trials represents 
a significant waste of time, resources, monetary investment, and corporate energy, which is 
why the pharmaceutical industry seeks to avoid this situation (85). 
Many have argued that the generally high attrition rates currently seen are also due 
to an increased stringency in regulatory demands (83, 128).  Indeed, in light of recent 
post-approval withdrawal of high-profile drugs, this precautionary attitude is entirely 
understandable.  Additional reasons for such elevated failure rates may include the attempt 
to treat diseases or conditions that are more complex than in the past (128).  In other words, 
therapies for “easier” disease targets have already been developed.  In addition, standards 
of care have improved considerably over the years, making it even more difficult to prove 
that a drug can provide added benefits compared to what is currently available (128) 
because efficacy trials will be compared to an active, currently marketed treatment instead 
of a placebo. This has led people to discuss the “better than the Beatles” argument, whereby 
regulatory agencies are exceedingly demanding of companies by requiring new medications 
to be better than everything else, instead of allowing drugs to come onto the market when 
they are efficacious even though they would not appear from the Phase III trial to 
necessarily be the best product (132).  The argument is not without merit, as of course if we 
were to prevent music from being marketed unless proven to be better than the Beatles’ 
music, then this would lead to severe attrition of new commercialized music. In addition, 
the true benefit of a drug is often not realized or found during the DDP but later when it is 
marketed, supporting the argument that the regulatory bar for new medicines may currently 
be too high. 
6.3 Room for Improvement 
The constantly increasing costs associated with drug development, as well as the 
high chance of failure, have led to a decrease in the number of new therapies that are 
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marketed yearly.  Since the 1990’s, the top 50 pharmaceutical companies have seen a 
decline in their productivity (defined as the number and quality of new chemical entities 
brought to market) (133).  This trend is reflected in the number of new molecular entities 
(NMEs) that have been submitted to the FDA over a fifteen year period (from 1996 to 
2011), which have been declining steadily.  In 1996, 45 applications were submitted while 
in 2010, only 23 submissions were filed (134). 
The high risks and rising costs associated with drug development may also foster 
other problems, by encouraging drug companies to develop products that are deemed to be 
“higher selling” (to obtain a better return on investment), which are normally drugs that act 
against proven targets.  This means that there will be less impetus to develop drugs with 
novel mechanisms of action or products to treat less common conditions (86).  Despite 
incentives such as the “Orphan drug status”, which offers companies fast-track review and 
in the US a seven-year market exclusivity for targeting diseases that affect less than 200 
000 people, costs remain prohibitively high for these specialized markets (82).  Thus, if 
cutting the cost of drug development can encourage researchers to develop products for all 
unmet needs, without favouring the more lucrative options, then this is certainly something 
that cannot be ignored. 
These disturbing issues and trends have not gone unnoticed and led the FDA to 
publish its oft-cited “Challenge and Opportunity on the Critical Path to New Medical 
Products”, sometimes called the “Critical Path document” (134).  This document has been 
viewed somewhat as a “call to arms” for the pharmaceutical industry, to spur researchers 
into reshaping their ways.  In it, the FDA re-iterates that the DDP is an expensive, time-
consuming process that has a very low success rate and that high clinical failure rates can 
generally be attributed to safety problems and lack of effectiveness.  Throughout the 
document, they highlight the need for a new set of tools (such as assays, standards, 
computer modeling techniques, biomarkers, and clinical trial endpoints) that will help make 
the process more efficient and effective.  Some suggested areas of improvement mentioned 
in this document were the making use of proteomics and toxicogenomics, developing new 
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tools to assess heart rhythm abnormalities, expanding the knowledge base for pediatric 
studies and finding new biomarkers or surrogate endpoints.  
Among the items that they list as opportunities for improvement, the FDA included 
in silico (computer) modeling, which could enhance development knowledge management 
and decision-making with regards to both safety and efficacy.  However, even before the 
publication of the FDA’s infamous “Critical Path Initiative”, others had recognized the 
need for change and the role that modeling and simulations could play in bringing about 
such change.  In his 1997 paper, Carl Peck suggests that modeling and simulations should 
play a more prominent role in the DDP, as they do in other industries such as the aerospace 
or automotive industries.  He also suggests that data should be analyzed to gain insight on 
the dose-response relationship, rather than simply relying on empirical hypothesis testing 
(135).   
The concept of model-based drug development described in the FDA’s white paper 
was also largely inspired by Sheiner’s “learn-confirm” concept first presented in 1997 
(136).  In this new paradigm for drug development, the phases of drug development are 
viewed as successive learn-confirm cycles.  In the learning phases, the goal of study design 
is to glean as much information as possible about exposure-response relationships and 
mechanisms of action.  The confirmatory portions of the cycle serve to provide further 
evidence to support specific claims, for instance regarding risk/benefit ratios or optimal 
doses.  Thus, Phase 1 studies are studies designed to learn about tolerated doses and explore 
dose-response relationships while Phase 2a studies are meant to confirm that selected doses 
are associated with the desired response.  The learn-confirm cycle begins anew with Phase 
2b studies where researchers learn about the drug’s behaviour in the intended patient 
population.  Finally, Phase 3 and 4 studies aim to confirm the dose and dosing regimen 
selected based on the Phase 2b studies as well as provide further supportive evidence on the 
drug’s postulated efficacy. 
It is clear that many opportunities exist for improving the current drug development 
process, and it is the hope that these modifications will allow the pharmaceutical industry to 
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continue to provide new therapies to patients which are safe, reliable and effective.  
Furthermore, the changes brought about should allow the industry to do so in a timely and 
more cost effective manner.  Indeed, cost analyses have shown that improvements in the 
development process can lead to significant savings.  For example, reducing the lengths of 
clinical phases by 25% is associated with a 16% reduction in capitalized costs (roughly 
129$ million year 2000 dollars).  Furthermore, increasing the success rate from 21.5% to 
33.3% would save 221 to 242 million dollars (year 2000 dollars) per NCE, which is not 
negligible (137).  According to one model, decreasing Phase 2 attrition rates from 66% to 
50% would yield a 25% in the cost of bringing a NME to market.  Similarly, a decrease in 
Phase 3 attrition rates from 30% to 20% would be associated with cost savings of 12% (81).  
Thus, there is a clear economic incentive to decrease failure rates. 
If humanity is to continue to benefit from advances in drug therapy, it is imperative 
that old methods be cast off and replaced with different ones.  This thesis will therefore 
focus on approaches that can contribute to the improvement of the drug development 
process. 
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7. Research Hypotheses 
 
In light of the elevated costs and risks that plague the drug development process, 
changes must be made if these are to be decreased.  While it is not always possible to 
shorten the time period devoted to clinical trials (because a minimum amount of data, 
especially pertaining to long-term safety and efficacy, must be collected), and thereby 
reduce costs, it is possible for researchers to use their time more efficiently by employing 
some of the methods described earlier.  Similarly, it is not within our power to change the 
stringent regulatory requirements, nor would it be advisable to reduce safety standards, but 
there are certainly methods that can be devised or processes that can be improved so that 
these demands are met in a more timely and efficient manner. 
As previously described, one tool that could render different aspects of the drug 
development more efficient is modeling and simulations.  More specifically, risks can be 
decreased by using modeling and simulations to answer questions that are a key part of 
decision-making which will ultimately influence how (and if) a drug will make it on the 
market.  Importantly, modeling and simulations can provide quantitative answers that are 
more objective than “gut-feelings” and that do not rely upon a researcher’s underlying 
desire to “see the project through”.  These answers can ultimately ensure that subsequent 
studies are better designed to succeed and that they are conducted in a timely manner. 
In its white paper, the FDA has cited a need for “new tools to get fundamentally 
better answers” (134), and we hypothesize that modeling and simulation is one such tool.  
Thus, this thesis will demonstrate how modeling and simulations, including new tools in 
the form of innovative models, can be used to answer the following key questions that may 
arise during drug development: 
 
1) How to prove that two different intravenous formulations of iron are equivalent 
using a new innovative approach instead of relying on standard approaches that 
contradict iron’s known pharmacology? 
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2) How to determine the factors that may influence the PK of a drug in patients and 
select a more refined dosing regimen accordingly? 
3) How to predict the dose of a drug that could be administered to patients when no 
data is available yet in that population? 
 
The articles presented hereafter will each present the utility of creating innovative 
models within modeling and simulations to answer the above key questions.  In addition, it 
will be shown that the use of such tools to answer these critical questions can significantly 
improve the drug development process by relying on data from smaller trials, eliminating 
the need for additional trials and planning trials that have a higher probability of success. 
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2.1 Preface 
The first research project undertaken for this thesis aimed to demonstrate how 
advanced pharmacokinetic techniques, such as modeling, can be used to improve the 
development of generic products.  Compartmental modeling is not a technique that has 
been entirely embraced in this particular subset of drug development, yet this article will 
show that it can be instrumental in answering important questions related to generic drugs, 
such as “Are two products bioequivalent?”. 
In a society that is already burdened by healthcare costs and an increasingly aging 
population, the savings afforded by generic drug products are an excellent incentive 
towards their continued, and increased, usage.  Indeed, the cost savings associated with the 
use of generic products are substantial.  One study reports that only 12 months after the 
introduction of a generic product to a therapeutic class, overall reductions in daily cost of 
therapy were noticeable.  For lipid regulators and biphosphonates, the cost decreased by 
32%, while it was 42% for selective serotonin reuptake inhibitors and 20% for calcium-
channel blockers (138).      
Accordingly, the use of generic drugs is on the rise, accounting for 51% of 
prescriptions in 2002 and 67% in 2007 (138).  A recent estimate indicates that by the end of 
2010, generic drugs accounted for 78% of all retail prescriptions dispensed in the U.S. 
(139).  Similarly, in Canada, patented drugs have experienced a decline in overall drug 
sales between 2003 and 2012, suggesting that the sale of generic drugs has increased over 
the same time period (140).  With the expiration of more and more patents, and with the 
increased economic pressure faced by third-party payers and patients, these figures can be 
expected to increase steadily. 
Because of this increased use of generic drug products, it is important to consider 
how the manufacturers of such products can continue to provide quality drugs in a timely 
manner.  In truth, the challenges faced by the pharmaceutical industry not only apply to the 
development of innovative new products, but they also affect the development of generic 
drugs.  Although developing a generic drug product entails less risks and costs compared to 
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a brand-name product, generic drug companies must also be cost-efficient because of lower 
profit margins and increased competition with other generic manufacturers (141).  Effective 
use of time is also an issue in generic drug development, and efforts are also made to 
perform the necessary assessments in a timely and effective manner.  Thus, this research 
project aimed to address some of these challenges through the use of modeling and 
simulations.  
In order to address drug development issues specific to the generic drug industry, 
the FDA emitted a document entitled “Critical Path Opportunities for Generic Drugs”, 3 
years following the publication of their original “Critical Path Initiative” (142).  In this 
document, the FDA lists four main areas of opportunity specific to generic drug 
development: 1) improve the science of quality by design for the development and 
manufacture of generic drug products 2) improve the efficiency of current methods for 
assessment of BE of systemically acting drugs (including complex ones or those that 
employ novel methods of drug delivery 3) develop methods for the assessment of 
bioequivalence of locally acting drugs 4) develop methods for characterizing complex drug 
substances and products. 
Some ideas proposed by the FDA to improve the science of quality by design 
include the use of modeling and simulations (such as absorption models or in vitro-in vivo 
correlation models) to better formulate products.  Various methods are also suggested to 
improve the efficiency of current methods for evaluating the BE of systemic compounds, 
including expanding biowaivers based on BCS criteria to include categories II and III.  
Additionally, new approaches could be developed to assess the BE of drugs with novel 
delivery technologies (such as transdermal patches) or highly variables drugs.  
Improvements could also be made to the BE assessments of locally acting and targeted 
delivery drugs, such as inhaled products, nasal sprays, topical dermatological products and 
liposome products.  Finally, complex drug substances could benefit from improved 
analytical methods for identification and from better statistical methods to compare 
profiles.  
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By addressing some of the issues raised by the FDA, it may be possible to develop 
generic products for innovator drugs that are either too complex to mimic, or difficult to 
characterize properly.  It has been estimated that for a drug with no generic counterpart 
earning $500 million dollars per year, the introduction of a generic product could result in 
cost savings equivalent to hundreds of millions of dollars (141).  Therefore, using improved 
tools to develop generic equivalents for products that only exist under innovator form could 
translate to significant savings.  An improved process would not only lead to the creation of 
new generic products, but would also be worthwhile for the generic industry as a whole.  
Indeed, simulation results have also suggested that “sizable cost savings can also be 
attained by increasing generic efficiency rates” (138).   
It is therefore important to examine ways in which the development of generic drugs 
can be improved.  As demonstrated by the results of this first research project, one tool that 
has been used more considerably in the development of innovator products, but that can 
also be applied in the development of generic drugs, is modeling and simulations.  
Although the FDA mentions some of the advantages that this technique could confer at the 
drug formulation stage, modeling and simulations could also be used later on in the 
development process. 
One of the potential utilities of modeling and simulations within the generic context 
is as a tool to assess bioavailability for further assessment of bioequivalence.  This 
approach could be particularly useful when traditional methods of estimating bioavailability 
(based on PK studies and noncompartmental analyses) are not appropriate or robust.  As 
previously mentioned, although they are relatively simple to conduct, noncompartmental 
analyses make certain assumptions which do not always hold true with all compounds.  
Iron complexes are examples of such compounds, as they are not significantly eliminated 
from the body and exhibit non-linear PK behaviour.  Furthermore, it is not possible to 
directly measure iron that is bound to complexes. Therefore, data obtained from iron 
complexes are ideal candidates for compartmental analyses, which, as previously 
explained, can take into consideration all types of elimination (or lack thereof) as well as 
non-linearity.  Compartmental analyses can also be used to describe the disposition of iron 
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associated with complexes in an indirect manner, by modeling the PK of analytes that are 
detectable (such as total iron or transferrin-bound iron). 
Thus, the following article will demonstrate how population PK (compartmental) 
analyses can be used to determine if two formulations of iron complexes are bioequivalent.  
It will also illustrate that properly conducted population PK analyses can replace larger, 
traditional PK studies that rely on noncompartmental methods, thereby resulting in time 
and cost savings. 
2.2 Abstract 
 
Purpose:  Iron-containing products are atypical in terms of their pharmacokinetic 
properties because iron is only removed by plasma sampling and is non-linear. This study 
aims to present a novel way of assessing the relative bioavailability of two sodium ferric 
gluconate complex (SFGC) formulations and compare this approach to a standard 
previously published noncompartmental approach.  
 
Methods: Data were from open-label, randomized, single-dose studies (Study 1 was 
parallel whereas Study 2 was crossover). Subjects with low but normal iron levels were 
infused IV SFGC in sucrose by GeneraMedix Inc. and/or Ferrlecit® Injection (Watson 
Laboratories Inc.). In Study 1 (n=240), 125 mg was infused over 10 minutes. In Study 2 
(n=29), 62.5 mg was infused over 30 minutes. Samples were assayed for total iron (TI) and 
transferrin-bound iron (TBI) over 36 hours (Study 1) or 72 hours (Study 2) post-dose. 
Studies 1 and 2 used standard noncompartmental analysis. Study 2 also used population PK 
(PPK) analyses with ADAPT 5®. The final model predicted SFGC area-under-the-curve 
(AUCpred) and maximal concentration (Cmaxpred). Analyses of variance was conducted on 
ln-transformed PK parameters. Ratios of means and 90% confidence intervals (CIs) were 
estimated. Bioequivalence was demonstrated if values were within 80-125%.   
 
Results: For Study 1, ratios and 90% CIs for TI baseline-corrected Cmax and AUC0-36 
were 100.4 (96.5 – 104.5) and 99.7 (94.2 – 105.5). For TBI, results for TI baseline-
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corrected Cmax and AUC0-36 were 86.8 (82.7 – 91.1) and 92.4 (85.6 – 99.7). For Study 2, a 
multi-compartmental model simultaneously described the PK of TI, TBI and SFGC. Ratios 
and 90% CIs for SFGC Cmaxpred and AUCpred were 89.9 (85.9 - 94.0) and 89.7 (85.7 - 
93.9), while ratios and 90% CI obtained from the noncompartmental analysis of Study 2 
did not meet BE criteria because of low power.   
 
Conclusions:  Both the standard and PPK modeling approach suggested bioequivalence 
between the iron products. However, with the PPK method, less subjects were required to 
meet study objectives compared to the standard noncompartmental approach which 
required considerably more subjects (29 vs 240). 
 
2.3 Introduction 
Iron plays several important roles in the human body, by participating in 
transmembrane transport, electron transfers, DNA synthesis and acting as a co-factor in 
enzymatic reactions (especially those involving heme)  (1,2). In addition to these functions, 
iron plays a vital part in the transport of oxygen via the heme molecule, a porphyrin ring 
structure with a central iron atom (1,2). It is also a component of enzymes such as 
peroxidase, myeloperoxidase, amino acid hydroxylase and 5-lipoxygenase (2). 
Because of its vital importance to so many bodily functions, severe iron deficiency 
is often treated with intravenous administration of iron. Parenteral iron was first 
administered over a century ago, and since then various intravenous formulations of iron 
have been developed (3). Although the different iron nanoparticles (iron dextran, iron 
sucrose, sodium ferric gluconate, ferumoxytol) exhibit various characteristics, once the iron 
is internalized, it is taken up by the reticuloendothelial system (RES) composed of 
monocytes and macrophages in the liver, spleen and bone marrow (2,4,5).  Subsequently, it 
is bound to transferrin, either intracellularly in pools or extracellularly for transport to 
erythrocytes. It should be noted that a small fraction of iron likely binds to extracellular 
transferrin directly from the plasma (4). Only a small amount of iron is excreted daily in the 
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urine and feces (around 1 mg or 0.03% of the average body’s total stores), as there is no 
true excretion pathway for iron, and the loss from desquamation of skin cells and sweat is 
negligible (1,5,6,7). Thus, iron requirements for erythropoiesis are generally met through 
the recycling of iron from senescent erythrocytes (1,5).  An overview of iron metabolism is 
presented in Appendix 1. 
The pharmacokinetics (PK) of iron appears to be non-linear, as demonstrated by the 
saturable plasma clearance of iron dextran, which appears to reach a plateau after doses 
exceeding 500 mg (8). This non-linearity is thought to occur between the distribution of 
iron taken up by the RES that subsequently binds to transferrin.  In addition, it is virtually 
not eliminated from the body, as it is only lost through phenomena such as blood 
donations/sampling or through blood loss and hemorrhagic events (2,9). Because of these 
particular PK characteristics, iron does not lend itself well to noncompartmental PK 
analyses (10). Indeed, it violates certain basic assumptions of noncompartmental analysis 
such as linearity and constant elimination from the sampling compartment (10,11,12). In 
addition, the endogenous baseline concentration of iron is not constant and changes 
significantly after iron dosing simply because iron is not eliminated. All of this can pose 
problems when using the noncompartmental approach to derive baseline adjusted 
parameters such as the maximal observed serum or plasma concentration (Cmax) and the 
area under the plasma/serum concentration time curve (AUC) as this method assumes 
linearity in the PK of iron and in its baseline levels. These PK parameters are often used to 
assess the relative bioavailability (BA) between two formulations, a process that compares 
"the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed 
from a drug product and becomes available at the site of drug action” (13). This comparison 
is central to the bioequivalence (BE) assessment, which aims at determining if 
administration of the same molar dose of the same active ingredient or moiety under 
identical conditions leads to similar BA, or BA that is not significantly different. 
Specific BE guidelines outlining the ideal study design and statistical approaches 
that are preferred have been published by various regulatory (government) agencies 
(14,15,16,17), and for most drug products, BE is generally assessed by comparing the 
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average BA parameters (Cmax and AUC) of two products. Study designs tend to be two-
period, two-treatment, two-sequence crossovers conducted in healthy volunteers, to 
minimize variability by administering the test and reference products to the same subjects. 
Using the ln-transformed PK parameters calculated for each subject, analyses of variance 
(ANOVA) are then performed and least square mean (LSM) ratios of test to reference PK 
parameters and 90% confidence intervals (CIs) associated with the ratios are obtained. Pre-
defined bioequivalence limits, which can be viewed as target goalposts, are then used to 
determine BE by assessing whether or not LSM ratios and CIs fall within the targeted 
range. 
Although such BE guidelines are generally appropriate for most drugs, the BE 
assessment of drugs with particular PK characteristics remains challenging.  For example, 
the presence of endogenous levels for drugs such as iron or levothyroxine can make it 
difficult to distinguish between drug concentrations that come from exogenous sources and 
those already present in systemic circulation, especially if baseline levels account for a 
large portion of the observed concentrations (18,19).  Furthermore, endogenous substances 
are frequently subject to processes not typically associated with non-endogenous products 
(feedback mechanisms (20,21,22), saturable transport or elimination, etc.) (23). 
For iron products, the Office of Generic Drugs (OGD) of the US Food and Drug 
Administration (FDA) has recommended to sponsors of generic submissions that 
bioequivalence be assessed on baseline-adjusted Cmax and AUC0-t of total serum iron and 
of transferrin-bound iron. Considering the relative bioavailability of two iron formulations 
theoretically cannot be determined reliably by noncompartmental methods using total 
serum iron (TI) and transferrin-bound iron (TBI) because of the changing baseline 
following iron administration and its non-linear PK, other approaches for calculating AUC 
and Cmax and subsequently establishing the bioequivalence of iron products should be 
considered. Thus, we postulated that compartmental analyses, rather than 
noncompartmental analyses, could be more powerful (e.g., would present better statistical 
power for the same number of subjects) to use to determine the PK parameters necessary 
for the assessment of the relative bioavailability of two formulations of intravenously-
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administered Sodium Ferric Gluconate Complex in Sucrose (SFGC) simply because the 
non-linear characteristics of iron and its changing baseline could be addressed with that 
method. In other words, the aim of this analysis was to assess the relative bioavailability of 
two IV formulations of iron by using the compartmental approach.  Standard 
noncompartmental analyses were also conducted so that statistical power would be 
compared, including results from a previously published study.    
2.4 Subjects and Methods 
2.4.1 Study Design 
This study was an open label, randomized, single dose, two-treatment, two-period, 
two-sequence, crossover study. A four week washout period was observed between doses. 
Subjects received both the test product (Sodium Ferric Gluconate Complex in Sucrose 
Injection, 62.5 mg/5 mL) and the reference product (Ferrlecit® Injection by Watson 
Laboratories Inc., 62.5 mg/5 mL) at a dose of 62.5 mg as an intravenous infusion over 30 
minutes. Both treatments were diluted in 50 mL of 0.9% NaCl.     
Subjects were advised to fast for at least 10 hours before dosing, and until at least 4 
hours after dosing. Water was permitted ad libitum. Standardized meals (with no specific 
restrictions on iron content) were served at about 4 (breakfast), 10 (lunch) and 14 (dinner) 
hours post-dose on Day 1 and at 24 (breakfast), 28 (lunch) and 33.5 (dinner) hours post-
dose on Day 2.  
Subjects were confined to the clinical facility from at least 10 hours before Day 1 
dosing in each period and were required to stay until 36 hours thereafter. Subjects returned 
to the clinical site for the 48 (± 1) and 72 (± 1) hour post-dose blood sample collection. 
During both periods, twenty one (21) PK samples were collected at the following 
times based on the start of the infusion: -0.5, -0.25 and -0.083 hour (to establish baseline 
values); 0.25 hour (mid-point of infusion), 0.5 hour (immediately at the end of the 
infusion); and 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours after the 
start of the infusion. An additional 12.5 mL of blood was obtained from subjects pre-
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infusion and an additional 8.5 mL of blood was obtained from subjects at 4, 16, 48 and 72 
hours post-infusion start for the measure of hematocrit (only pre-infusion), ferritin, 
transferrin saturation and total iron binding capacity. A total of about 420 mL of blood was 
obtained from each subject over the course of the study for analysis.  
Adverse events and vital signs were monitored throughout the study. Subjects were 
closely supervised and remained within sight of study personnel for four hours after 
receiving their initial dose. In addition, seated blood pressure and heart rate were measured 
prior to dosing and at 12, 24 and 36 hours post-dose.  
2.4.2 Population 
The study population was comprised of healthy male and non-pregnant female 
volunteers between the ages of 18 to 55 years old, inclusively, with low but normal iron 
levels. Ferritin levels had to be between 22 and 100 ng/mL, inclusively, for men, and 
between 10 and 100 ng/mL, inclusively, for women prior to first dosing. All subjects were 
required to have a body mass index of 18-32 kg/m
2
 as well as an acceptable medical 
history, laboratory evaluation and physical examination before study entry. The laboratory 
tests included screens for biochemistry, hematology, urinalysis, cotinine, drugs of abuse, 
hepatitis B and C, and HIV as well as beta-human chorionic gonadotropin (if applicable) 
and follicle-stimulating hormone (if applicable). 
2.4.3 Ethics 
The protocol, protocol amendments and informed consent forms were approved by 
an institutional review board before any study-related procedures were initiated. Written, 
informed consent was obtained from volunteers prior to their participation in this study. 
This study was conducted in accordance with ethical principles outlined in the Declaration 
of Helsinki, and the Tri-Council Policy Statement: Ethical Conduct for Research Involving 
Humans as well as Canadian Regulatory requirements and guidelines. 
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2.4.4 Sample Handling and Bioanalytical Method 
Samples were sequentially collected by direct venipuncture or catheter and 
processed in a timely manner. Samples were allowed to clot at room temperature for a 
minimum of 30 minutes and for a maximum of 45 minutes. The tubes were then 
centrifuged at 3000 RPM and 4 ± 1° C for 10 minutes and then placed at room temperature 
for a maximum of 15 minutes. A minimum of 1 mL of serum was transferred into duplicate 
5 mL polypropylene tubes and maintained in the ice bath or cooling device until frozen. 
Samples were stored at approximately -20°C (between -10 and -35°C) until transfer or 
shipment to the bioanalytical laboratory. The time between sample collection and freezer 
storage did not exceed 1.5 hours.  
A validated analytical colorimetric method was used to assay total iron (TI) and 
transferrin bound iron (TBI). TI and TBI concentrations were measured within the 
validated standard curve range of 50 to 2000 mcg/dL. Assays were performed by Cetero 
Research. 
2.4.5 Population Pharmacokinetic Modeling 
Datasets included subjects who completed the study and who had measurable 
concentrations of TI and TBI. Actual doses, infusion durations and sampling times were 
used to create the datasets, and iron lost through blood sampling was also taken into 
consideration. For each subject, the hematocrit value used to account for iron lost during 
blood sampling was calculated as an average of the hematocrit values taken before dosing 
in either Period 1 or 2. Concentration values that were below the limit of quantitation 
(BLQ) were treated as missing values. 
Compartmental analyses were performed using the software ADAPT 5® (24), first 
using the maximum likelihood method to obtain initial estimates and subsequently using 
the iterative two stage (ITS) approach. This is a fully automated mixed effect modeling 
approach using both maximum likelihood and maximum a posteriori (MAP) modeling 
approaches. Briefly, the first probable population PK parameters and variance estimates 
(e.g., residual variability) were found by using maximum likelihood. Then a population 
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analysis is undertaken where population, individual and residual variability PK parameters 
are calculated and updated with ever more probable values at every new population 
iteration. The mixed modeling approach was eventually stopped when it had converged 
(last iteration preceded by 10 consecutive iterations having a similar objective function 
(within 3%)) and the most probable and stable results were found. 
The base model used for model discrimination was a previously published 
multicompartmental model that simultaneously described the time courses of total iron, 
transferrin-bound iron and iron bound to sodium ferric gluconate complex (SFCG-I) (25). 
The primary PK parameters estimated by this model included: CL1 (the clearance of SFGC-
I to the RES), CL2 (clearance of SFGC-I directly to transferrin), CL3 (clearance of iron 
entering and exiting the marrow and red blood cell compartment), CL4 (clearance of TBI to 
the RES), Km (Iron concentration associated with half of the maximal rate of exchange 
between the RES and TBI compartments), Vss (the apparent steady-state volume of 
distribution of SFGC-I), V_RES (volume of distribution associated with the RES), V_RBC 
(marrow and red blood cell compartment), V_TBI (volume of distribution associated with 
TBI), and Vmax (maximal rate of exchange between the RES and TBI compartments).  
All iron concentrations were fitted using weighting procedures of Wj = 1/j2 where 
the variance j
2
 was calculated for each observation using the equation Sj
2
=(a+bYj)
2
 where 
a and b are the intercept and slope of each variance model. The slope is the residual 
variability proportional to each concentration and the intercept is the additional component 
of the residual variability.  Inter-subject variability was also estimated for each PK 
parameter estimated by the model. 
Secondary PK parameters that were derived from the primary PK parameters 
included the following: CL (total clearance for SFGC-I, calculated as the sum of CL1 + 
CL2), AUCpred (area under the serum-time curve of SFGC-I, from the beginning of the 
infusion to infinity, calculated as dose divided by CL), Cmaxpred (maximum predicted 
serum concentration of serum SFGC-I over the 72-hour sampling period), and T1/2 
(apparent first-order terminal elimination half-life of SFGC-I). 
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In addition to standard metrics used to evaluate goodness of fit, visual predictive 
checks were performed. With the final model estimates for both population PK parameters 
and variability, concentration-time profiles for 1000 subjects were simulated, and median 
concentrations along with 95% confidence intervals were established using the predicted 
concentrations.  Observed concentration values and predicted confidence intervals were 
then overlaid graphically. 
2.4.6 Statistical Analyses for Bioequivalence Assessment 
Analyses of variance (ANOVA) were performed on the natural logarithm of 
Cmaxpred and AUCpred for SFGC-I obtained from the compartmental analysis. The ANOVA 
model included group, sequence, period nested within group and formulation as fixed 
effects and subject nested within group*sequence as a random effect. The 
group*formulation interaction was tested at a 5% level of significance and removed from 
the model if it was not significant. Sequence was tested using subject nested within 
group*sequence as the error term. A 10% level of significance was used to test the 
sequence effect. Each analysis of variance included calculation of least-squares means, the 
difference between adjusted formulation means and the standard error associated with this 
difference. The above statistical analyses were conducted using the appropriate SAS® 
procedure. 
In agreement with the two one-sided test for bioequivalence (26), 90% confidence 
intervals for the difference between drug formulation least-squares means (LSM) were 
calculated for AUCpred and Cmaxpred obtained from the compartmental analysis, using the 
data transformed to their natural logarithm. The confidence intervals were expressed as a 
percentage relative to the LSM of the reference formulation. 
Ratios of means were calculated using the LSM for the above mentioned ln-
transformed AUCpred and Cmaxpred obtained from the compartmental analysis. The 
geometric mean values were reported and  ratios of means were to be expressed as a 
percentage of the LSM for the reference formulation. 
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Bioequivalence was to be declared if the Test/Reference ratios of geometric means 
of Cmaxpred and AUCpred and their complete 90% confidence intervals were to be contained 
within the bioequivalence interval 80.00 to 125.00% for iron bound to the SFGC. 
2.4.7 Noncompartmental Analyses 
Baseline-adjusted PK parameters AUC0-t, AUCinf, Cmax and Tmax were calculated 
for TI and TBI.  Baseline adjustments were performed by subtracting each individual’s 
baseline value (which was the average of all 3 pre-dose values) from each of their post-dose 
concentration value.  ANOVA were conducted on ln-transformed PK parameters AUC0-t, 
AUCinf and Cmax for TI and TBI using the same statistical model as the one employed for 
the parameters obtained from the compartmental analysis.  Similarly, ratios of LSM and 
90% CI were calculated for each parameter. 
Results derived from noncompartmental analyses were also obtained from a 
previously published study (27). This study was an open-label, randomized, single-dose, 
parallel-group study conducted in 240 healthy volunteers under fasting conditions. Subjects 
received 125 mg of the test (Nulecit™, Watson Pharmaceuticals) or reference (Ferrlecit™, 
A. Nattermann & Cie. GmbH.) SFGC formulation infused intravenously over 10 minutes. 
Samples for TI and TBI analysis were collected prior to dosing and at 0.0833, 0.167, 0.25, 
0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, and 36 hours after the start of the infusion. 
Samples were also collected at 24, 18, 12, 6, and 0 hours before dosing to determine 
baseline levels. Validated spectrophotometric assays were used to assay TI and TBI (refer 
to original publication for more details).  
Post-dose concentration values were adjusted using the average of all 5 baseline 
values for each individual, and PK parameters AUC and Cmax were determined by 
standard noncompartmental methods with these baseline-adjusted concentrations assuming 
a stable baseline. ANOVA was conducted to compare ln-transformed PK parameters 
between formulations. Treatment, group and group-by-treatment were used as classification 
variables. The group-by-treatment interaction and group terms were removed if they were 
deemed non-significant at an alpha level of 5%. Geometric mean treatment ratios and the 
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corresponding 90% CIs were determined and BE was declared if the ratios and 90% CIs 
were contained within 80 and 125% (27). 
2.5 Results 
2.5.1 Population Characteristics 
A total of 32 subjects were enrolled in the study, and 29 completed both periods of 
the study. Subjects were dosed in two groups, where Group 1 (Subjects 1 to 16) was dosed 
on February 5, 2008 (Period 1) and March 4, 2008 (Period 2) and Group 2 (Subjects 17 to 
32) was dosed on February 8, 2008 (Period 1) and March 7, 2008 (Period 2).  Table 1 
summarizes the demographic characteristics of the subjects enrolled in the study (both 
groups combined). 
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Table 1. Demographic Traits of Subjects Included in the Population PK Analysis 
Characteristic Number (%) 
Sex  
 Female 24 (75%) 
 Male 8 (25%) 
Race  
 Caucasian 20 (62.5%) 
 African American 7 (21.9%) 
 Asian 4 (12.5%) 
 Native American 1 (3.1%) 
  
Characteristic Mean ± SD (CV%) 
Median (Minimum – Maximum) 
Age (years) 
37.3 ± 9.29 (24.9%) 
37.5 (22 – 51) 
Height (cm) 
164.4 ± 7.20 (4.38%) 
164.5 (149.5 – 180.0) 
Weight (kg) 
67.8 ± 10.3 (15.1%) 
65.5 (47.1 – 89.1) 
Body mass index (kg/m
2
) 
25.0 ± 3.00 (12.0%) 
24.8 (20.4 – 31.8) 
Hemoglobin at screening (g/dL) 
13.4 ± 1.09 (8.13%) 
13.2 (11.2 – 15.4)   
Hematocrit at screening (%) 
40.3 ± 3.35 (8.32%) 
39.9 (33.9 – 46.1) 
 
CV% : Percent coefficient of variation; SD : Standard deviation 
 
Of the 3 subjects who did not complete the clinical phase of the study, 2 withdrew 
before Period 2 because of adverse events deemed unlikely to be related to the 
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investigational product and one subject was withdrawn by the Investigator because of a 
positive drug screen test (amphetamines) at Period 2 check-in. 
Subjects included in the previously published study were predominantly White 
(comprising around 91% of the subjects receiving the generic formulation and 85% of the 
subjects receiving the reference formulation).  Around 7% and 13% of subjects in the 
generic and reference treatment arms, respectively, were Black or African American and 
other races (American Indian/Alaskan, Native Hawaiian/Pacific Islander, multirace 
subjects) accounted for less than 2.5% of subjects in both groups.  In terms of ethnicity, 
over 90% of subjects in each arm were not Hispanic or Latino.  In both treatment arms, 
around 50% of the subjects were male.  Mean (± SD) age, height, weight and body mass 
index in the generic cohort were 30.8 ± 9.6 years, 171 ± 9.5 cm, 75.1 ± 15.0 kg and 25.5 ± 
3.77 kg/m
2
, respectively.  Mean (± SD) values for age, height, weight and body mass index 
were similar in the reference cohort, at 29.9 ± 8.5 years, 172 ± 8.7 cm, 77.5 ± 13.4 kg and 
26.0 ± 3.50 kg/m
2
, respectively. 
2.5.1 Population PK Approach  
A total of 2413 concentrations of TI and TBI were included in the analysis. Two 
basic models were evaluated. In the first model, it was assumed that the test and reference 
product had the same values for CL1, CL2 and Vss but with a different relative 
bioavailability factor (Frel). In other words, CL1, CL2 and Vss between formulations only 
differed by the same factor Frel. In the second model, different values for CL1, CL2 and Vss 
were estimated for the test and reference products. Results from the STS analysis 
performed with these 2 models are presented in Table 2. 
Table 2. PK Model Discrimination 
Model  BIC AIC OF 
R
2
 
Residual 
variability (%) 
TI TBI TI TBI 
Model 1 990.742 945.014 453.507 0.927 0.808 21.0 17.2 
Model 2 998.591 948.050 453.025 0.930 0.829 20.1 16.0 
AIC – Akaike information criterion; BIC – Bayesian information criterion; OF – Objective function; R2 – 
Coefficient of determination; TI – Total iron; TBI – Transferrin-bound iron; 
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Based on the model discrimination criteria, especially as indicated by the Bayesian 
and Akaike information criterion, as well as the graphical indicators of goodness of fit, the 
first model was superior. Two additional parameters were estimated: C_NTBI_P1 and 
C_NTBI_P2. These parameters estimated the concentrations of non-transferrin bound iron 
in Periods 1 and 2, respectively.  Differential equations describing the final model were: 
𝑑𝑋(1)
𝑑𝑡
= 𝑅(1) −
𝐶𝐿1 + 𝐶𝐿2
𝑉𝑠𝑠
∙ 𝑋(1) 
𝑑𝑋(2)
𝑑𝑡
=
𝐶𝐿1
𝑉𝑠𝑠
∙ 𝑋(1) +
𝐶𝐿3
𝑉_𝑅𝐵𝐶
∙ 𝑋(4) +
𝐶𝐿4
𝑉_𝑇𝐵𝐼
∙ 𝑋(3) −
𝑉𝑚𝑎𝑥
𝐾𝑚 ∙ 𝑉_𝑅𝐵𝐶 + 𝑋(2)
∙ 𝑋(2) 
𝑑𝑋(3)
𝑑𝑡
=
𝐶𝐿2
𝑉𝑠𝑠
∙ 𝑋(1) +
𝑉𝑚𝑎𝑥
𝐾𝑚 ∙ 𝑉_𝑅𝐵𝐶 + 𝑋(2)
∙ 𝑋(2) −
𝐶𝐿4
𝑉_𝑇𝐵𝐼
∙ 𝑋(3) −
𝐶𝐿3
𝑉_𝑇𝐵𝐼
∙ 𝑋(3) 
𝑑𝑋(4)
𝑑𝑡
=
𝐶𝐿3
𝑉_𝑇𝐵𝐼
∙ 𝑋(3) −
𝐶𝐿3
𝑉_𝑅𝐵𝐶
∙ 𝑋(4) − 𝐾0 ∙ 𝑅(2) 
 
Where X(1), X(2), X(3) and X(4) represent the amount of iron in the serum, RES, 
TBI and red blood cell (marrow) compartments.  R(1) represents the SFGC infusion rate 
while R(2) is an on/off switch that accounts for the iron loss associated with blood 
sampling.  K0 was the rate of iron loss, which was calculated as the product of the 
hematocrit (for each subject at each period) and the approximate blood volume extracted 
per blood draw (7 mL).  
The parameter Vmax was defined as Vmax = (CL3 + CL4) x (Km + TBIbase), 
where TBIbase represents the observed baseline TBI concentration for each subject before 
dosing in each period.  This equation was determined from the assumption that prior to the 
administration of SFGC, iron levels are at an equilibrium between the RES, TBI and RBC 
(marrow) compartments. 
Observed concentrations for total serum iron and TBI, parameterized as Y(1) and 
Y(2), respectively, were fitted according to the following equations, where C_NTBI was 
different for Periods 1 and 2, as previously described. 
𝑌(1) =
𝑋(1)
𝑉𝑠𝑠
+
𝑋(3)
𝑉_𝑇𝐵𝐼
+ 𝐶_𝑁𝑇𝐵𝐼 
𝑌(2) =
𝑋(3)
𝑉_𝑇𝐵𝐼
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The final model is depicted in Figure 1 and the PK parameter estimates from the 
final model are presented in Table 3. 
Figure 1. Final PK Model 
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Table 3. Population PK Parameter Estimates 
PK Parameter Mean (CV%) Median (Minimum- Maximum) 
CL1 (L/h) 2.25 (32.0%) 2.03 (1.46 – 4.17) 
CL2 (L/h) 0.0458 (11.8%) 0.0455 (0.0357 – 0.0571) 
Vss (L) 4.41 (14.5%) 4.53 (3.32 – 5.50) 
V_RES (L) 1220 (0.175%) 1220 (1214 – 1226) 
V_TBI (L) 0.589 (5.62%) 0.595 (0.522 – 0.637) 
CL3 (L/h) 0.000000213 (59.5%) 0.000000267 (4.01E-11 – 3.48E-07) 
V_RBC (L) 0.000288 (55.0%) 0.000369 (0.00000539 – 0.000451) 
CL4 (L/h) 0.0313 (23.2%) 0.0315 (0.0170 – 0.0439) 
Km (mcg/dL) 36.1 (37.0%) 38.8 (3.61 – 59.7) 
Frel 0.905 (13.9%) 0.926 (0.644 – 1.19) 
C_NTBI_P1 (mcg/dL) 44.3 (52.8%) 45.5 (5.18 – 83.1) 
C_NTBI_P2 (mcg/dL) 75.8 (50.2%) 73.6 (0.00 - 147) 
 
CL1: Clearance of SFGC-I to the reticuloendothelial system (RES) compartment; CL2: Clearance of SFGC-I 
directly to transferrin; Vss: the apparent steady-state volume of distribution of SFGC-I; V_RES: volume of 
distribution associated with the RES; V_TBI: volume of distribution associated with TBI; CL3: clearance of 
iron entering and exiting the marrow and red blood cell compartment; V_RBC: marrow and red blood cell 
compartment; CL4: clearance of TBI to the RES; Km: Iron concentration associated with half of the maximal 
rate of exchange between the RES and TBI compartments; Frel: Relative bioavailability factor; C_NTBI_P1: 
Concentration of non-transferrin-bound iron during Period 1; C_NTBI_P2: Concentration of non-transferrin-
bound iron during Period 2; CV%: Percent coefficient of variation 
   
Plots of goodness of fit are presented in Figure 2 while visual predictive checks are 
presented in Figure 3.  
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Figure 2. Goodness-of-Fit Plots Individual observed versus individual predicted total iron 
concentrations on a log scale (A); Standardized residuals versus individual predicted total iron concentrations 
(B); Standardized residuals versus time for total iron concentrations (C); Individual observed versus 
individual predicted transferrin-bound iron concentrations on a log scale (D); Standardized residuals versus 
individual predicted transferrin-bound iron concentrations (E); Standardized residuals versus time for 
transferrin-bound iron concentrations (F); Legend: Circles = observed concentrations, Dotted line = reference 
line (unity or zero), Solid black line = Loess curve (span = 0.5, degree = 1) 
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Figure 3. Visual Predictive Checks Total Iron Concentration Time Profiles (Linear Scale) (A); Total 
Iron Concentration Time Profiles (Semi-Log Scale) (B); Transferrin Bound Iron Concentration Time Profiles 
(Linear Scale) (C); Transferrin Bound Iron Concentration Time Profiles (Semi-Log Scale) (D); Legend: 
Circles = observed concentrations; Dotted line = 95% confidence intervals; Dashed line = median predicted 
concentration 
 
As demonstrated by the goodness-of-fit plots and visual predictive checks, the 
model adequately describes all observed concentrations of total iron and transferrin-bound 
iron. Predicted versus observed concentrations were randomly scattered around lines of 
identity. No important trends were observed with respect to the standardized weighted 
residuals or with respect to time. In addition, the residual variability, which includes the 
intra-individual variability, variability from the bioanalytical measurement, all experimental 
error and all errors from the modeling itself, was only 23.0% and 17.2% for total iron and 
transferrin-bound iron, respectively. 
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Secondary PK parameters estimated from the final model are presented in Table 4. 
The median estimated terminal elimination half-life for both the test and reference products 
was 1.63 hours (ranging from 0.785 to 5.92 hours).  
 
Table 4. Secondary PK Parameters 
Parameter 
Mean (CV%) 
Median (Range) 
Test Reference 
Vss (L) 
4.96 (19.3%) 
5.20 (3.38 – 6.41) 
4.41 (14.5%) 
4.53 (3.32 – 5.50) 
 
CL (L/h) 
2.60 (34.4%) 
2.30 (1.55 – 4.77) 
2.30 (31.4%) 
2.07 (1.51 – 4.22) 
 
AUCpred (mcg*h/dL) 
2662 (30.8%) 
2714 (1400 – 4033) 
2927 (24.9%) 
3017 (1481 – 4152) 
 
Cmaxpred (mcg/dL) 
1150 (20.5%) 
1100 (854 – 1654) 
1270 (14.7%) 
1227 (946 – 1649) 
 
AUCpred: Area under the serum-time curve of SFGC-I, from the beginning of the infusion to 
infinity, calculated as dose divided by CL; CL: Total clearance for SFGC-I, calculated as the sum 
of CL1 + CL2; Cmaxpred: Maximum predicted serum concentration of serum SFGC-I over the 72-
hour sampling period;  CV%: Percent coefficient of variation; Vss: Apparent steady-state volume 
of distribution of SFGC-I 
 
ANOVA results demonstrated no statistically significant sequence effect at a 10% 
level, although there was a statistically significant group effect for ln-transformed Cmaxpred 
(p=0.0104). Because the sizes of Groups 1 and 2 were similar (n=15 and n=14, 
respectively), the equality of variances test was not performed since ANOVA is robust to 
the violation of the equality of variance assumption when groups are equally sized and 
larger than 5 (28). Statistical analyses on the ln-transformed Cmaxpred and AUCpred 
parameters for SFGC-I are presented in Table 5. 
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Table 5. Summary of the Statistical Analyses for Ln-transformed PK Parameters 
 
Study Analysis Type Analyte 
Cmax (mcg/dL) AUC (mcgh/dL)
d
 Statistical 
Power to  
Prove BE 
Test
a
 Reference
a
 
Ratio
b
 
(90% CI) 
Test
a
 Reference
a
 
Ratio
b
 
(90% CI) 
          
Study 1 
(n=29) 
Compartmental SFGC-I 1127 1256 
89.9 
(85.9 - 94.0) 
2534 2828 
89.7 
(85.7 - 93.9) 
> 80% 
         
Noncompartmental
c
 
TI 1338 1279 
104.6 
(86.3 – 127.0) 
8807 9071 
97.1 
(74.1 – 127.2) 
< 40% 
TBI 171.1 178.4 
95.9 
(83.4 – 110.2) 
3364 2811 
119.7 
(20.5 – 698.6) 
          
Study 2 
(n=240) 
Noncompartmental
c
 
TI 3106 3098 
100.4 
(96.5 – 104.5) 
11101 11033 
99.7 
(94.2 – 105.5) 
> 80% 
TBI NA NA 
86.8 
(82.7 – 91.1) 
NA NA 
92.4 
(85.6 – 99.7) 
 
NA – Information not available in publication 
a
Geometric mean for Study 1 and arithmetic mean for Study 2 (geometric mean not reported for Study 2) 
b
Ratio of geometric means (Test/Reference) 
c
Baseline-adjusted PK parameters 
d
AUCinf for Study 1 and AUC0-36 for Study 2 
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2.5.1 Noncompartmental Approach 
Mean concentration-time profiles for TI and TBI associated with each of the studies 
are presented in Figure 4.  ANOVA results obtained from noncompartmental analyses of 
both studies are summarized in Table 5. 
A. 
 
C. 
 
B. 
 
D. 
 
 
Figure 4. Mean Concentration Versus Time Profiles  (A) Baseline-adjusted total iron 
profiles (linear scale) (B) Baseline-adjusted total iron profiles (semi-log scale) (C) 
Baseline-adjusted transferrin-bound iron profiles (linear scale) (D) Baseline-adjusted 
transferrin-bound iron profiles (semi-log scale); Legend: Dashed lines represent the test 
product while solid lines represent the reference product.  Diamond and triangle symbols 
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represent data associated with Study 1 while squares and circles are associated with Study 
2. 
2.6 Discussion 
Both the standard, noncompartmental approach to BE assessment (only when n = 
240) as well as the innovative population PK approach (n = 29) demonstrated BE between 
the iron formulations that were tested. To our knowledge, this is the first published account 
of compartmental analyses being used to demonstrate BE with pharmacokinetic endpoints 
for iron products. This unconventional approach was favoured over the traditional 
noncompartmental method of calculating Cmax and AUC because of the particularities of 
iron pharmacokinetics. Noncompartmental analyses are robust when certain assumptions 
hold true, and iron violates many of these assumptions. The first assumption is that the drug 
in question displays linear pharmacokinetics (10,12). In other words, exposure increases in 
proportion with increasing dose.  A second important assumption is that the drug is 
eliminated strictly from the body from the pool in which it is being measured, the plasma, 
for example and in a continuous fashion (11,12). Finally, this approach assumes that all 
sources of the drug are direct and unique to the measured pool, and that consequently 
baseline levels remain constant (12). In contrast, the compartmental method employed in 
the current analysis does not require the drug under study to meet such assumptions as the 
model included all of these iron PK characteristics. Similar approaches could be applied to 
analyze other difficult drugs from a PK point of view. Examples may include enzymes or 
metabolites that are metabolized intra-cellularly (29).   
Another challenge for assessing SFGC pharmacokinetics is the inability to assay the 
iron associated with SFGC directly. Although it is possible to assay total serum iron and 
transferrin-bound iron, it is impossible to distinguish endogenous iron from the iron 
provided by SFGC supplementation. One approach that is often used to work around this 
problem involves subtracting transferrin-bound iron levels from total serum iron levels, 
thus assuming that the resulting concentration differences represent iron from the SFGC. In 
contrast, the compartmental model used in the current analysis estimates iron levels coming 
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from both endogenous and exogenous sources without performing this simple subtraction 
and does not assume that total iron is only composed of TBI and SFGC-I. 
In order to apply compartmental analysis in a BE context, the first step was the 
determination of a compartmental model that described the pharmacokinetics of iron in all 
its forms (total, bound to transferrin and associated with SFGC). Based on a previously 
published model (25), a model describing both formulations of iron was established. 
Overall, it explained the data very well. Although twelve parameters were estimated by the 
model, the model was not deemed overparameterized since two analytes were being fitted, 
each demonstrating two visible exponentials in their disposition with known nonlinearity 
(30). In addition, over 80 concentrations were fitted per subject, signifying that 6 samples 
were available per PK parameter, which represents a clear rich sampling scenario for the 
PK model (sparse sampling can be defined when less than 1 sample is available per fitted 
PK parameter).  This PK model accounted for serum iron, iron bound to transferrin, and 
stores in the reticuloendothelial system and bone marrow (red blood cells). The model also 
took into consideration iron lost during each blood sample, as well as iron not bound to 
transferrin.  Although the administration of intravenous iron is not associated with the 
generation of detectable or dialyzable free iron (3,31), there is evidence that points to the 
existence of non-transferrin bound iron (NTBI) that is biologically active and labile 
(9,31,32). This NTBI may even be bound to albumin (32). The levels of NTBI estimated in 
our population were about 46 mcg/dL before any treatment (Period 1) and about 74 mcg/dL 
before Period 2, which are equivalent to roughly 0.001 and 0.002 M and which are well 
under the 1 M levels normally seen in healthy subjects (1).  
The PK parameters for volume of distribution and clearance estimated with our 
model were slightly lower than what has been reported in the literature. The Vss and CL 
estimated for SFGC-I from our analysis were 4.41 L and 2.3 – 2.6 L/h, whereas they were 
5.72 L and 3.87 L/h in the previous study for which a compartmental analysis was used 
(25). Conversely, the average SFGC-I half-life in our study was 1.63 h whereas it was 
closer to 1 h in the other study (25). The differences observed between the PK parameter 
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estimates from our analysis and those in the literature may result from the differences in 
study populations. In the current study, enrolled subjects had ferritin levels between 22 
ng/mL (10 ng/mL for women) and 100 ng/mL, inclusively, whereas levels were less than or 
equal to 20 ng/mL in the other study. This means that the subjects in this analysis had a less 
profound iron deficiency than those studied by Seligman et al., considering ferritin is a 
measure of bodily iron stores (9). Degree of deficiency has been shown to influence iron 
pharmacokinetics, particularly its rate of transfer from RBC to RES (4). Patients who are 
more iron-deficient incorporate iron faster into the RES, which could explain why the 
terminal elimination half-life of SFGC-I determined by others was shorter than in the 
current study. In addition, the proportion of women was different in each study. The study 
population in the current study was composed of 75% women whereas women only made 
up 43% of the other population. As iron storage and loss are different between men and 
women (9), it is possible that the different gender compositions led to slightly different 
pharmacokinetic parameter estimates. 
By using a compartmental approach to assess the BE of two formulations of SFGC, 
problems associated with the noncompartmental method were altogether avoided. Indeed, 
because SFGC-I Cmax and AUC were calculated by model-based methods, iron’s non-
linear behaviour, non- continuous elimination (e.g., only through the specific blood 
samples), unstable baseline, and continual recycling were no longer issues as they were 
directly addressed by the model. All the specificity of iron pharmacokinetics such as non-
transferrin bound iron and iron lost through blood draws were specifically incorporated. 
The absence of a stable baseline for both total iron and TBI also became a non-issue as the 
model fitted all the analytes specifically and allowed for the fact that the iron administration 
in the two periods naturally raised the levels of TBI and total serum iron. The overall result 
is that all of this unaccountable variability in the baseline adjusted concentrations of total 
serum iron and TBI are not present in the population compartmental analysis, therefore 
demonstrating BE with a much lower number of subjects because of this lower 
unaccountable variability.  
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The population PK modeling approach described in this article shows that BE can 
be demonstrated with a relatively small sample size for iron products. Although BE was 
concluded in the study described by Baribeault (27), it was necessary to dose 240 subjects 
in a parallel-group design. Moreover, when noncompartmental analyses were conducted 
with data from our study, only one parameter (Cmax of baseline-adjusted TBI) met 
bioequivalence criteria.  Post-hoc analyses also revealed that the study lacked the power to 
show equivalence at ± 20% with an alpha error of 5% (i.e., power was less than 40%).  
Overall, this suggests that in order to demonstrate BE between SFGC formulations using 
traditional noncompartmental methods, a very large number of subjects must be dosed. In 
contrast, the compartmental approach was adequately powered to show equivalence with a 
sample size of 29 subjects.  This highlights again the strengths of the compartmental 
approach used in this study, as it is able to demonstrate bioequivalence with a significantly 
smaller number of subjects in a crossover design. In other words, this approach is not only 
scientifically sound, but it decreases the number of subjects who are exposed to the study 
drugs, resulting in a more cost-efficient and time-efficient study.  
Other researchers have shown, through the analysis of simulated data or data 
obtained from real clinical trials, that the compartmental approach can be used to assess 
bioequivalence (33,34,35,36,37,38,39,40,41). However, the PK models employed in 
previously published analyses were relatively simple ones (one or two compartment 
models). The population PK model developed in the current analysis is obviously more 
complex, but it allowed us to simultaneously characterize the PK of two different analytes 
(TI, TBI) and present concentration time profiles for what was directly administered 
ferrlecit-bound-iron or SFGC. 
The analysis presented here demonstrates how the compartmental approach can be 
used to perform BE assessments for drugs that do not meet assumptions necessary to 
employ more traditional, noncompartmental approaches.  These drugs may or may not be 
highly variable drugs (i.e., drugs for which within-subject variability of AUC or Cmax are 
greater than 30%).  Thus, for highly variable drugs that do not lend themselves to 
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traditional analyses, the compartmental approach described here can be adopted.  This 
would first entail developing a model that simultaneously describes the PK of both the test 
and reference drugs, which could be based on models already described in the literature.  
Specific model development criteria must be established a priori in the protocol and ideally 
in a population PK analysis plan.  For highly variable drugs that meet the criteria associated 
with standard noncompartmental analyses, use of the compartmental approach can also be 
used but other types of analyses, such as the reference-scaled average bioequivalence 
method (42,43), should also be considered.     
Although there were many advantages to adopting this non-traditional approach to 
evaluating BE, the development of a PK model for iron was more time-consuming and 
labour-intensive than the noncompartmental approach from an analysis perspective. The 
advantages and disadvantages of using a compartmental PK approach for a highly variable 
drug that meets the assumptions associated with standard analyses must be weighed in 
comparison with the reference-scaled average bioequivalence approach. Despite this, 
results show that this compartmental approach to BE assessment should be seriously 
considered for iron and potentially other rare, complicated drugs from a PK point of view 
for which traditional methods are unsuitable. 
2.7 Conclusions 
A compartmental analysis approach was applied successfully to demonstrate the BE 
between two formulations of sodium ferric gluconate complex in sucrose. BE was also 
concluded for the same products in a separate, much larger, parallel-design study 
employing traditional, noncompartmental methods of analysis. The results of this study 
suggest that alternative methods, such as the population compartmental analysis proposed 
here, should also be considered for assessing BE of drugs that are complicated from a PK 
point of view and for which the standard approach becomes artificially variable thereby 
necessitating the enrollment of too many subjects. 
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2.8 Abbreviations 
Term Definition 
AIC Akaike information criterion 
ANOVA Analysis of variance 
AUCpred Area under the serum-time curve of SFGC-I, from the beginning of the 
infusion to infinity, calculated as dose divided by CL 
AUC0-36 Area-under-the-concentration-time-curve from time zero to 36 hours 
BA Bioavailability 
BE Bioequivalence 
BIC Bayesian information criterion 
BLQ Below the limit of quantitation 
CI(s) Confidence interval(s) 
CL1 Clearance of SFGC-I to the RES 
CL2 Clearance of SFGC-I directly to transferrin 
CL3 Clearance of iron entering and exiting the marrow and red blood cell 
compartment 
CL4 Clearance of TBI to the RES 
CL Total clearance for SFGC-I, calculated as the sum of CL1 + CL2 
Cmaxpred Maximum predicted serum concentration of serum SFGC-I over the 72-hour 
sampling period 
C_NTBI_P1 Concentration of non-transferrin-bound iron during Period 1 
C_NTBI_P2 Concentration of non-transferrin-bound iron during Period 2 
CV% Percent coefficient of variation 
FDA Food and Drug Administration 
Frel Relative bioavailability 
ITS Iterative two-stage 
Km Iron concentration associated with half of the maximal rate of exchange 
between the RES and TBI compartments 
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Term Definition 
LSM Least squares mean 
MAP Maximum a posteriori 
NTBI Non-transferrin bound iron 
OGD Office of Generic Drugs 
PK Pharmacokinetics 
PPK Population pharmacokinetics 
RBC Red blood cells 
RES Reticuloendothelial system 
SD Standard deviation 
SFGC Sodium ferric gluconate complex 
SFCG-I Iron bound to sodium ferric gluconate complex 
STS Standard two-stage 
T1/2 Apparent first-order terminal elimination half-life of SFGC-I 
TBI Transferrin-bound iron 
TI Total iron 
Vmax Maximal rate of exchange between the RES and TBI compartments 
V_RBC Marrow and red blood cell compartment 
V_RES Volume of distribution associated with the RES 
Vss Apparent steady-state volume of distribution of SFGC-I 
V_TBI Volume of distribution associated with TBI 
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3.1 Preface 
The previous article demonstrated that the innovative use of modeling and 
simulations in the development of a generic drug could provide a scientifically sound and 
robust approach to bioequivalence assessment when other traditional approaches were 
inappropriate.  In addition, this method was able to answer the study objective without 
relying upon a large and lengthy clinical study, therefore it proved to be a cost-efficient and 
time-efficient approach.  Modeling and simulation can also be applied to develop innovator 
products, as the current article will demonstrate.  Indeed, in the present article, advanced 
pharmacokinetic techniques are used to better understand factors that could influence the 
PK and PD of a first-in-class biological agent that was being developed to treat gout.  The 
drug in question has since been approved by regulatory agencies and is available on the 
market, which is further evidence that these approaches can contribute to a product’s 
success. This article is also the first published population PK/PD analysis for a drug 
belonging to the urate-oxidase drug class conducted on a large cohort of Phase 3 gout 
patients.   
Therapeutic biological agents are essentially proteins or peptides that are derived 
from biotechnology.  In other words, the technology used to produce these agents generally 
involves recombinant DNA and organisms such as bacteria, yeast or mammalian cells (22, 
143).  Some well known examples of biologics include insulin and rituximab.  A 
classification system has been proposed that categorizes biological therapeutics into 
different groups based on their functions (143).  Group 1 includes agents with enzymatic or 
regulatory activity, meaning that these biologics replace absent or dysfunctional enzymes, 
modulate existing pathways or provide novel functions.  This group includes drugs such as 
recombinant erythropoietin and rasburicase.  Group 2 therapeutics target specific activities 
or act as delivery agents for other compounds or proteins, and includes products such as 
infliximab and trastuzumab.  In Group 3 are protein vaccines (for instance the Hepatitis B 
vaccine) and in Group 4 are proteins used for diagnostic purposes (such as the recombinant 
purified protein derivative used to diagnose tuberculosis exposure).   
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Biologics are two to three times larger than most “small molecule” drugs which are 
synthesized chemically (22).  Other differences between biologics and small molecules 
include their route of administration (small molecules can often be administered orally 
while biologics must often be given parenterally), immunogenicity (biologics can be highly 
antigenic compared to small molecules), and pharmacokinetic properties (22, 144).  Some 
particularities regarding the PK of biologics are that they often reach systemic circulation 
via the lymphatic system, they are poorly distributed outside of the vasculature and they are 
not metabolized into active or inactive metabolites (rather, they are catabolized to 
endogenous amino acids). 
Given these fundamental differences between biologics and small molecules, it is 
understandable that there are some drug development issues that are specific to biologics.  
Although the phases of drug development are the same regardless of the source of the drug 
(biological or chemical), some challenges are unique to biologic therapeutics.  Primary 
among them is immunogenicity.  Even for agents that are endogenous or from “natural 
sources”, the possibility that the organism mounts an immune response against the 
therapeutic agent is always an underlying concern.  The consequences of antibody binding 
to the protein can vary, ranging from a complete absence of clinical effect to increased 
activity or elimination (144).  In some cases, immune responses leading to harmful effects 
can even occur (145), which is why special attention is paid to the immunogenicity of these 
compounds.  In addition, due to their heterogeneous nature, developing reliable and 
accurate analytical methods to assay protein therapeutics can prove to be difficult (143, 
144).         
Beyond the goal of developing safe and effective drugs, one concern that is shared 
by developers of both small molecules and biologics is cost effectiveness. DiMasi and 
colleagues have shown that developing biologics is just as expensive as developing a small 
molecule, with similar estimated total capitalized costs between the two ($1241 million 
2005 dollars for biologics and $1318 million 2005 dollars for small molecules) (123).  It 
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must be noted, however, that initial out-of-pocket costs were 24% higher in total for 
biologics, which was offset by shorter clinical development times (123). 
Despite the challenges in bringing a biologic to market, as of 2008, there were at 
least 130 biological therapeutic agents available on the U.S. market (143).  The number of 
biologics submissions have continued to rise since 1982 (146), and they will no doubt 
continue to do so.  Protein therapeutics can provide treatments for diseases that cannot 
always be treated by small molecules, and they can also be complimentary to certain small 
molecule therapies (146).  There is clearly an interest in continuing to develop such 
products and to render the process more efficient. 
Some have suggested that a better understanding of PK and PD during the biologic 
drug development process can lead to many improvements (144).  More specifically, it was 
suggested that the application of an integrated PK/PD database throughout the drug 
development process could save time and money, reduce the number of unnecessary 
studies, generate pivotal information to influence key decisions, and improve the overall 
odds of demonstrating safety and efficacy.  A thorough understanding of PK/PD can also 
be useful in making decisions at the regulatory level, such as those pertaining to product 
labeling.  Because an overwhelming amount of PK/PD information can be gathered during 
the course of preclinical and clinical trials, it is important to find a way to integrate all of 
this information and to build upon previously acquired knowledge.  One way of managing 
all of these PK/PD findings is through model building.  The construction of PK/PD models 
leads to clear dose-response relationships which have the flexibility of incorporating past 
results with more recent ones, in a continual and ongoing basis.   
Thus, the following article demonstrates how the development of a PK/PD model 
for a biological product was able to answer a key question regarding potential factors that 
could influence the PK and PD of the drug.  This product was the first of its class that was 
developed to treat gout, and because of its novelty, clinical studies and specific analyses 
were necessary to better understand the drug and answer this question.  (Additional 
information concerning the drug class can be found in Appendix 1.)  In the end, the PK/PD 
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model that was created answered the question efficiently and contributed to the eventual 
product labeling. 
3.2 Abstract 
Two identical Phase 3 studies were conducted in persistently hyperurecemic 
patients with treatment refractory chronic gout.  Subjects received placebo or 8 mg 
pegloticase intravenously infused over approximately 2 hours every 2 or 4 weeks for 24 
weeks.  Samples for pegloticase, uric acid and antibody assays were collected from baseline 
through 2 weeks after the last dose.  Population pharmacokinetic (PK) and 
pharmacodynamic (PD) analyses were conducted with data from 163 subjects using 
NONMEM VI.  Covariates tested were weight, height, body surface area (BSA), anti-
pegloticase antibody level (Ab), creatinine clearance, age and sex. Pegloticase PK was best-
described by a 1-compartment model with linear elimination with BSA and Ab exhibiting 
covariate effects on Vc and CL.  An indirect model described the PD of pegloticase, where 
the depletion rate of uric acid was influenced by pegloticase and Ab levels.   
Keywords: Urate oxidase, uricase, population pharmacokinetics, population 
pharmacodynamics, uric acid, PEG 
3.3 Introduction 
Gout is the most common inflammatory arthritis in developed countries, occurring 
in 1 to 3% of people in most developed countries and in 3.9% of the US population, 
predominantly men.(1, 2) The hallmark biochemical marker of gout is hyperuricemia, 
although hyperuricemia alone is insufficient to diagnose gout.  When the concentration of 
serum uric acid (SUA) is above the biochemical limit of solubility, 6.8 mg/dL, 
monosodium urate (MSU) crystals precipitate in tissues. (3) It is the biological response to 
MSU crystals in tissues, and not to circulating urate, that causes the signs and symptoms of 
the disease. These include the occurrence of episodic acute inflammation in and around a 
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joint or joints (a gout flare), the formation of gout tophi, gouty arthritis, and uric acid 
nephropathy (including uric acid renal stones). (4, 5)   
Approximately 3 – 5.9 million patients in the US diagnosed with gout receive 
treatment to lower serum uric acid, and > 90% of these patients are treated with allopurinol 
(a xanthine oxidase inhibitor, XOI), making allopurinol the standard conventional urate-
lowering therapy. (3-13)  However, for a subset of chronic gout patients, XOIs either 
cannot control hyperuricemia with the maximum medically appropriate dose or is 
contraindicated. (3, 14)  Compliance can also be an issue.  These treatment refractory 
chronic gout patients tend to have advanced disease characterized by frequent gout flares, 
multiple gout tophi, and chronic painful joints (gouty arthritis), and also may have urate 
nephropathy. (1, 4, 15)  
Almost all mammals, except for humans and great apes, express an enzyme that 
catalyzes the conversion of urate, the by-product of purine metabolism, to allantoin. (4)  
Allantoin, unlike urate, is easily eliminated by renal excretion.  The administration of 
exogenous uricase to control urate levels is therefore an attractive alternative for chronic 
gout patients who cannot benefit from existing therapies.  Pegloticase (a PEGylated 
recombinant modified mammalian urate oxidase), which was developed to provide this 
therapeutic option, was approved by the US FDA in September 2010 and received 
marketing authorization in Europe in January 2013. 
Pegloticase was shown to effectively decrease plasma uric acid (PUA) to well 
below the solubility limit in early clinical development.  Phase 1 and 2 clinical studies 
suggested that 8 mg of pegloticase by intravenous (IV) infusion can maintain PUA levels 
below the clinical target of 6.0 mg/dL. (16, 17) Additionally, these Phase 1 and 2 studies 
revealed a long half-life (17 days), low pegloticase concentration associated with 50% of 
the maximal effect and sustained PUA suppression over dosing intervals, which supported 
the use of a long dose administration interval (two weeks).  Population pharmacokinetic 
(PK) and pharmacodynamic (PD) analysis of Phase 2 data suggested that no dose 
adjustment is required to account for covariates such as age, sex, race, body weight, ideal 
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body weight and antibody levels, since no covariates had a significant effect on the PD of 
the drug. (18) 
The current parallel, randomized multi-center placebo-controlled pivotal Phase 3 
studies were designed to determine the safety and efficacy of pegloticase and to further 
characterize the PK/PD of pegloticase using population PK methodology.  This article 
presents the population PK/PD results from these studies of pegloticase for the treatment of 
patients with chronic gout refractory to conventional therapy. 
3.4 Methods 
3.4.1 Study Design 
These were two Phase 3 multicenter, randomized, double-blind, placebo-controlled, 
three-arm, parallel treatment group studies conducted in patients suffering from gout and 
hyperuricemia.  A total of 212 patients were dosed and 157 subjects completed the study 
per protocol.  Patients were administered placebo or 8 mg pegloticase IV over 
approximately 2 hours, every 2 or 4 weeks for 24 weeks.  Samples for PK/PD analyses 
were collected at various timepoints, as depicted in Table 1.  In the event of an early 
termination, a sample was also collected at that time. 
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Table 1. Sampling Schedule 
Week Dose PK sample PD sample Ab sample 
1 1 X
a,b
 X X 
3 2 X X X 
5 3 X
b
 X X 
7 4 X X  
9 5 X
a,b
 X X 
10 . X   
11 6 X
a
 X  
12 . X   
13 7 X X X 
15 8 X X  
17 9 X X X 
19 10 X X  
21 11 X
a,b
 X X 
22 . X   
23 12 X
a
 X  
24 . X   
25 . X X X 
aIncluding a 2-hour post-dose collection 
bIncluding a 24-hour post-dose collection 
 
Each subject was expected to participate in the study for approximately 27 weeks, 
including a 2-week screening period, the 24 week treatment period and a 1 week post-
treatment follow-up.  Patient safety was monitored throughout the study.  This included the 
monitoring of adverse events (such as infusion reactions and gout flares), vital signs, 
clinical laboratory tests (hematology, serum chemistry, and urinalysis), pegloticase 
   
  100 
 
antibodies, total hemolytic complement function, electrocardiograms, and physical 
examinations. 
3.4.2 Ethics 
Prior to initiation of the study, the protocol, informed consent form and other 
pertinent information were reviewed by a properly constituted Institutional Review 
Board/Independent Ethics Committee.  Written, informed consent was obtained from all 
subjects before they participated in any protocol-related activities. 
3.4.3 Inclusion and Exclusion Criteria 
Subjects included in the study were: outpatients of either sex;  18 years; 
hyperuricemic (screening SUA  8 mg/dL); subjects with symptomatic gout (at least 3 gout 
flares experienced in the 18 months prior to entry, or at least 1 gout tophus, or gouty 
arthritis); subjects in whom conventional therapy was contraindicated or had been 
ineffective (i.e., history of hypersensitivity or of failure to normalize SUA with at least 3 
months treatment with allopurinol, the only marketed XOI when the studies were 
conducted, at a maximum medically appropriate lower dose based on dose-limiting toxicity 
or dose limiting comorbidity). 
3.4.4 Analytical Methods 
Bioanalytical assays were conducted at Charles River Laboratories Preclinical 
Services Montreal Inc.  Pegloticase in serum, anti-PEG antibodies and anti-pegloticase 
antibodies were measured by enzyme-linked immunosorbent assay, with pegloticase as the 
capture antigen and horseradish peroxidase-conjugated as secondary antibody.  PUA was 
measured in trichloroacetic acid-precipitated chilled plasma, using a similar validated 
method.  Analytical methods have been described in detail elsewhere. (18)  
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3.4.5 Population PK/PD Analysis 
Data from the two Phase 3 studies was pooled in these analyses.  Subjects who 
received active treatment and who had at least one detectable post-dose pegloticase 
concentration were included in the PK/PD analyses.  Actual doses, infusion rates, dosing 
times and sampling times were used. 
Using NONMEM VI 2.0, various structural PK models were tested, such as one- 
and two-compartment models with linear and non-linear elimination processes. (30, 33)  
Quality of fit and selection of the final model was determined using objective function 
(OF), Akaike information criterion, residual variability, and by visual inspection of 
pertinent graphs (e.g., fitted and observed concentrations versus time, weighted residuals 
versus fitted values). 
After selecting the final structural PK model, various covariates were tested for 
potential inclusion in the model.  The impact of covariates was assessed graphically and 
using a generalized additive model implemented in Xpose Release 3.104 with S-Plus
®
 8.0 
for Windows. (34)  Covariates suggested by the previous step were entered into the model 
one by one using forward stepwise regression.  The most significant covariate was retained 
at each step, and subsequent covariates were added to this model.  Covariates were added to 
the model based on their reduction of the OF (using the log-likelihood ratio test at  = 
0.05), and based on their physiological and pharmacological plausibility.  Once all 
significant covariates were added to the model, backward stepwise deletion was performed 
to avoid redundancy and to ensure that all covariates remained significant despite the 
presence of all covariates.  In this process, each covariate was removed one by one from the 
complete model.  If its deletion resulted in a decrease in OF that was statistically significant 
( = 0.01), then it was excluded from the final model.   
Covariates investigated for inclusion in the model were: weight, height, body mass 
index, body surface area (BSA), ideal body weight, age, sex, presence of tophi, creatinine 
clearance (calculated using the Cockcroft-Gault equation), (35) baseline SUA level, number 
of gout flare ups, antibody levels (against PEG and pegloticase), the presence of co-
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morbidities (such as hypertension and diabetes) and allergy or gastrointestinal intolerance 
to allopurinol.  Concomitant medications were not investigated as covariates since no drug-
drug interactions were anticipated to affect the PK/PD of pegloticase. 
Antibody response against pegloticase and PEG were treated as categorical 
variables. Subjects were categorized as having no increase or an increase (either low, 
moderate or high).  No increase included subjects who were negative at baseline, Month 3 
and Month 6 (no titer), or who were positive at baseline but with no increase from baseline 
in titer during Months 3 and 6 (no increase in titer); low increase if titer was  0 and  810 
at Month 3 and/or Month 6; moderate increase if titer was  810 and  7,290 at Month 3 
and/or Month 6; high increase if titer  7,290 at Month 3 and/or Month 6.  Antibody 
isotyping data were not included in the covariate analysis since the data were deemed 
incomplete.  No subjects demonstrated antibody neutralization of pegloticase, therefore, 
this covariate was not included in the covariate analysis. 
For the PK analysis, antibody response against pegloticase was treated as a 
dichotomous categorical variable, where subjects either had no increase or an increase 
(either low, moderate or high).  Antibody response was originally categorized as “no 
increase”, “low increase”, “moderate increase” or “high increase”, however covariate 
analysis using these four categories did not produce pharmacologically plausible results.  
For the PD covariate analysis, the anti-pegloticase antibody level was separated into 5 
categories (“no increase”, “low increase”, “moderate increase”, “high increase” or 
“information unavailable”), as it was possible to stratify the effect of pegloticase based on 
the magnitude of the increase in anti-pegloticase antibody level.  Missing results were due 
to analytical reasons or to subject dropout prior to antibody determination in Month 3.  
After selecting the final PK model, a PD model was evaluated using the previously 
described model discrimination criteria and covariate analysis process.  The same 
covariates were tested as in the PK analysis.  To estimate the PD effect, final individual PK 
parameters were used to predict plasma pegloticase concentrations for developing the PD 
model.  Different models were tested, including the direct model (PD effect is related to 
predicted pegloticase concentrations), effect compartment model (PD effect is related to 
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pegloticase concentrations at the site of action) and indirect model (pegloticase 
concentrations exert their PD effect by influencing the rate of formation or elimination of 
PUA).  In the indirect model, the rate of uric acid presentation to plasma was estimated as 
Kin, which was influenced by the production rate of uric acid by the body and/or the release 
of uric acid from crystalline deposits within the body.  The rate of uric acid depletion from 
plasma was estimated as Kout. The elimination of uric acid from plasma was increased 
directly by plasma pegloticase concentrations through a linear relationship.   
All serum pegloticase concentrations were fitted using a weighting procedure where 
the weighting function is inversely proportional to the estimated variance.  Inter-individual 
variability was assumed to be centered around a mean value of zero with a variance of 2.  
Intra-individual variability for pegloticase was modeled as a combination of additive and 
proportional error, while the error model for PUA was additive.  When it was possible, 
inter-occasion variability (assuming normal distribution of error) was also modeled. 
3.5 Results 
In all, 163 subjects were included in the PK/PD analysis.  The demographic 
characteristics of these patients are summarized in Table 2.  Overall, a total of 1,176 serum 
pegloticase concentrations and 3,358 PUA concentrations obtained from this patient 
population were fitted with the PK/PD model. 
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Table 2. Summary Demographics of Subjects 
Trait Mean (CV%) Median (Range) 
Age (years) 55.6 (26.0%) 57 (23 - 89) 
Body Weight (kg) 99.1 (25.1%) 96.2 (48.2 – 191) 
Height (cm) 174 (6.28%) 175 (145 - 193) 
Body mass index (kg/m
2
) 32.8 (22.5%) 31.5 (15.0 - 65.9) 
Body surface area (m
2
) 2.12 (13.3%) 2.12 (1.44 - 2.88) 
Ideal body weight (kg) 68.2 (16.3%) 70.5 (38.6 - 86.8) 
Screening creatinine clearance (mL/min)* 92.4 (55.4%) 84.5 (17 - 264) 
Screening serum uric acid (mg/dL) 10.07 (14.0%) 9.9 (8.0 - 14.9) 
Number of acute gout flare ups in the past 18 
months (n=161) 
9.70 (113%) 6 (0 - 90) 
 Number of 
Patients 
% 
Sex   
Male 131 80.4 
Female 32 19.6 
Presence of tophi 122 74.8 
Diabetes mellitus 41 25.2 
Hypertension 119 73.0 
Allergy or gastrointestinal intolerance to 
allopurinol 
96 58.9 
Overall anti-pegloticase antibody level   
No increase 16 9.8 
Low increase [0 < titer  810] 49 30.1 
Moderate increase [810 < titer  7, 290]   33 20.2 
High increase [7, 290 < titer] 50 30.7 
Unknown change 15 9.2 
*Creatinine clearance was calculated using the Cockcroft-Gault equation. (147) 
   
  105 
 
 
The PK of pegloticase was best described by a one compartment model with a linear 
elimination process.  The model was parameterized in terms of volume of distribution (Vc) 
and clearance (CL), as described by Equation 1, where C represents serum pegloticase 
concentration. 
Equation 1 C
Vc
CL
dt
dC
  
An indirect model was selected to describe the PD of pegloticase. (19)  Steady-state 
PUA levels prior to pegloticase dosing were defined as the ratio of Kin to Kout, as described 
by Equation 2.  The rate of change of PUA and the effect of pegloticase on Kout are 
described by Equation 3 and Equation 4, respectively. 
Equation 2 
out
in
K
K
IC   
Equation 3    PUAStimKK
dt
dPUA
outin  1  
Equation 4 CSlopeStim   
C = serum pegloticase concentration; IC = initial condition (steady-state uric acid level prior to 
pegloticase dosing); PUA = plasma uric acid concentration; Stim = Stimulation factor; Slope = 
variable representing the linear relationship between serum pegloticase and stimulation of Kout 
 
Thus, according to this model, as the serum concentration of pegloticase reaches its 
peak, the stimulation (represented by Stim) also reaches its peak. Conversely, when serum 
pegloticase levels decrease to zero, the stimulation drops to zero and normal physiologic 
urate elimination remains.  
Significant covariates included in the PK model were BSA and anti-pegloticase 
antibody level on Vc and CL.  For each antibody category, a different population value () 
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was estimated with identical inter-subject variability ().  An example of how these 
covariates were coded (for Vc) can be found in Equation 5 and Equation 6. 
Equation 5 Vc
VcBSA
e
BSA
increaseAbnopopulationVcincreaseAbnoindividual


 















_
12.2
_______  
Equation 6 
Vc
VcBSA
e
BSA
increaseAbpopulationVcincreaseAbindividual


 















_
12.2
_____  
The only covariate included on PD parameters was the overall anti-pegloticase 
antibody level on slope, the variable representing the linear relationship between serum 
pegloticase and stimulation of PUA elimination.  For each category, a different  and  
were estimated. 
An inter-occasion variability (IOV) factor was also added to the PK parameters Vc 
and CL to improve the quality of fit. This improved the model in a statistically significant 
manner and enhanced other goodness-of-fit criteria.  The IOV term accounted for intra-
subject variability from one occasion to another, where the first occasion was the first 3 
months of the study period (Weeks 1 to 12), the second occasion was between months 3 
and 6 (Weeks 13 to 24), and the third occasion was after the sixth month (Week 25). 
The final structural PK/PD model is depicted in Figure 1, while typical predicted 
pegloticase and PUA profiles are presented in Figure 2.  Population PK/PD parameters and 
estimated half-life values are presented in Tables 3 and 4, respectively. 
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Figure 1. Final PK/PD Model for Pegloticase 
 
CL = pegloticase clearance, Dashed arrow = stimulatory effect of pegloticase, Kin = 
rate of uric acid presentation to plasma, Kout = rate of uric acid depletion from plasma, Vc = 
pegloticase volume of distribution 
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Figure 2. Example of Predicted Profiles for One Patient 
 
LEGEND: Circles = observed pegloticase concentrations, Triangles = observed uric acid concentrations, 
Solid line = predicted pegloticase concentrations, Dashed line = predicted uric acid concentrations 
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Table 3. Population PK/PD Parameters of Pegloticase 
Parameter Mean 
Coefficient Variation (%) 
Inter-subject Inter-occasion 
Vc if no increase in anti-pegloticase antibodies (L) 4.73 
24.7 18.2 
Vc if increase in anti-pegloticase antibodies (L) 5.93 
Exponent for BSA on Vc 1.73 Not estimated 
CL if no increase in anti-pegloticase antibodies (L/h) 0.0145 
39.6 17.0 
CL if increase in anti-pegloticase antibodies (L/h) 0.0191 
Exponent for BSA on CL  1.12 Not estimated 
Kin (mg/dL/h) 0.727 14.6 Not estimated 
Kout (1/h) 0.079 9.34 Not estimated 
Slope (mL/mcg) if no increase in anti-pegloticase antibodies 3.93 112 Not estimated 
Slope (mL/mcg) if low increase in anti-pegloticase antibodies 1.60 236 Not estimated 
Slope (mL/mcg) if moderate increase in anti-pegloticase antibodies 0.578 163 Not estimated 
Slope (mL/mcg) if high increase in anti-pegloticase antibodies 0.0526 39.8 Not estimated 
Slope (mL/mcg) if information unavailable on increase in anti-pegloticase antibodies 0.380 Not estimated Not estimated 
Residual variability (%) 
Pegloticase 30.8   
Uric acid 64.0   
Table 4. Bayesian Terminal Elimination Half-life Estimates 
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Subgroup 
Half-life (hours) 
Mean Median Range 
All subjects 221 217 123 – 452 
Subjects with no increase in anti-pegloticase antibody levels 234 216 123 – 444  
Subjects with an increase in anti-pegloticase antibody levels 220 217 124 – 452  
 
  111 
  111 
  111 
 
 
3.6 Discussion 
3.6.1 Pharmacokinetics 
The one-compartment model with linear elimination that was chosen as the base PK 
model for this Phase 3 analysis was identical to the structural model determined by analysis 
of Phase 2 data.(18)  The selection of a 1-compartment model suggests that pegloticase is 
mostly confined to the intravascular space, which can be explained by its size of 
approximately 545 kDa.  With hydration of the PEG moieties, the apparent molecular 
weight is even larger.  Other therapeutic biologics also tend to cross blood capillaries 
slowly (20, 21). 
The inclusion of anti-pegloticase antibody response on Vc and CL indicates that the 
presence of antibodies is associated with an increased Vc as well as an increased CL.  
Increased CL is consistent with results published by Sundy and colleagues, who found that 
the presence of antibodies was associated with an increase in the clearance of IV 
pegloticase. (17)  Since antibodies were non-neutralizing, the presence of antibodies likely 
facilitates the clearance of pegloticase, by a mechanism related to the formation of immune-
complexes between the antibodies and pegloticase, which are possibly captured by the 
reticuloendothelial system. (22) Although anti-pegloticase antibody response was initially 
tested as a categorical covariate comprised of 4 categories, the use of 4 categories did not 
produce pharmacologically plausible results.  More specifically, the presence of increased 
quantities of antibodies was associated with an increase in terminal elimination half-life 
rather than a decrease in half-life.  Therefore, antibody response was classified as a 
dichotomous variable.  
The increase in Vc associated with the presence of antibodies could also be 
explained by the formation of immune-complexes.  Anti-pegloticase antibodies could 
increase the uptake of immune-complexes by phagocytes of the reticuloendothelial system, 
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thereby increasing the intracellularly-bound fraction of pegloticase.  With increasing 
cellular uptake of pegloticase, the quantity of pegloticase in serum naturally decreases.  
Since Vc is a variable that relates serum pegloticase concentration with the amount of 
pegloticase in the central compartment, the decrease in pegloticase concentration is 
reflected by an increase in Vc. 
The only demographic covariate that was retained in the final model was BSA, 
suggesting that increasing body size is associated with increasing Vc and CL.  Indeed, it is 
not surprising that a person who is taller and heavier than another individual would have a 
larger Vc since it not only encompasses the intravascular space, but possibly tissue volume.  
Such a person might have a greater hepatic mass, further enhancing the elimination of 
pegloticase via the uptake of antibody-pegloticase complexes. (13)  Although it has been 
suggested that BSA does not correlate strongly with hepatic metabolic capacity, the 
elimination of pegloticase does not involve metabolism, therefore the inclusion of BSA on 
CL in the model is reasonable. (2)   
Although BSA was retained as a covariate in the PK model, this does not suggest 
that pegloticase dosing adjustments are required with respect to BSA.  It simply indicates 
that part of the inter-individual variability in PK parameters can be attributed to BSA (i.e., 
differences in pegloticase concentrations between patients can be partially explained by 
differences in BSA). Moreover, patients had similar PD responses to pegloticase regardless 
of their BSA.  Thus, based upon analysis of the data using the PK/PD model, dosing 
adjustments to correct for BSA are unnecessary.   
Although the population PK approach was ideal to analyze the sparse data collected 
from this study, one of the analysis limitations was the variability of the data.  Significant 
variability in the pegloticase concentrations was observed, which could explain the residual 
variability value of 30.8% (representing the variability that is not explained by the model, 
including intra-individual variability, the experimental “noise” of the analytical method and 
errors arising from the pharmacokinetic modeling itself), as well as the elevated inter-
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individual variability associated with PK parameters.  Such variability of the measured 
pegloticase concentrations is not unexpected, considering that multiple clinical sites were 
involved and that subjects were not confined to a controlled clinical setting, with the 
exception of visits to clinical sites for dose administration. 
3.6.2 Pharmacodynamics 
The use of PUA as a PD marker was deemed appropriate, as it is the direct target of 
pegloticase and it correlates well with clinical outcomes. (23)  Indeed, low levels of urate 
are associated with dissolution of MSU crystals (leading to a decrease in gouty flares and 
tophi) (24, 25) and a decrease in the urate pool. (26, 27)  Furthermore, although pegloticase 
was measured in serum, PUA was selected as a PD marker because it avoided the 
possibility of ex vivo SUA degradation by circulating pegloticase.  In addition, statistical 
analyses demonstrated excellent agreement of PUA and SUA levels. (23) 
Pegloticase was designed to catalyze PUA metabolism, and a model reflecting its 
pharmacologic action with stimulation of the rate of urate elimination was selected as the 
best model.  In this model, pegloticase affects the rate of PUA depletion (elimination) from 
the plasma to produce the observed decreases in PUA levels.  Although several other 
structural models were tested, such as the effect compartment model and direct inhibitory 
Emax models, (28, 29) the indirect PD response model with stimulation of Kout provided the 
best overall fit to the observed data.  Although a direct inhibitory Emax model was 
previously used to describe the PD effect of pegloticase based on Phase 2 data (18), only 
one dose of pegloticase was administered in Phase 3 (compared to Phase 2 where 3 
different doses were administered), which made it more difficult to characterize an Emax 
curve in the current analysis.     
Following covariate analysis, only overall anti-pegloticase antibody level had a 
significant effect on the slope (the variable representing the linear relationship between 
serum pegloticase and stimulation of PUA elimination).  Subjects with large increases in 
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overall anti-pegloticase antibody level had a much smaller slope value than those who had 
little or no increase in overall anti-pegloticase level.  A small slope value suggests that large 
amounts of pegloticase are required to effect a small stimulation in the elimination of uric 
acid. Conversely, large slope values suggest significant stimulation of uric acid elimination 
with small pegloticase levels.  This means that in the presence of anti-pegloticase 
antibodies, more pegloticase is required to stimulate the elimination of urate, as illustrated 
by Figure 3.  This finding is consistent with the known effects of antibodies to reduce 
efficacy of therapeutic agents.(22)  However, even in subjects with high anti-pegloticase 
antibody levels, pegloticase elicits a 10.6% increase in the rate of PUA elimination at 
estimated average therapeutic levels (2 mcg/mL).  In addition, despite the detection of 
antibodies in 89% of patients, 42% of patients receiving biweekly pegloticase were 
persistent responders (patients with PUA less than 6.0 mg/dL for 80% of the time or longer 
during months 3 and 6), for whom PUA levels remained well below the solubility limit 
throughout the inter-dosing period (30). 
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Figure 3. Predicted (Simulated) Uric Acid Profiles by Treatment Group and Anti-
pegloticase Antibody Category 
Figure 3a. Pegloticase Administered Every 2 Weeks 
 
LEGEND: Black line = no increase in anti-pegloticase antibodies; Orange line = low increase in anti-
pegloticase antibodies; Blue line = moderate increase in anti-pegloticase antibodies; Green line = high 
increase in anti-pegloticase antibodies; Pink line = information unavailable on increase in anti-pegloticase 
antibodies (n=1); Dashed, horizontal gray line = Dosing time 
Time (days)
0 50 100 150
U
ri
c
 a
c
id
 (
m
g
/d
L
)
0
2
4
6
8
10
12
Predicted (Simulated) Uric Acid Levels for Each Category of Anti-pegloticase 
Antibody Response Following Administration of 8 mg Every 2 Weeks
   
  116 
 
 
 
Figure 3b. Pegloticase Administered Every 4 Weeks 
 
LEGEND: Black line = no increase in anti-pegloticase antibodies; Orange line = low increase in anti-
pegloticase antibodies; Blue line = moderate increase in anti-pegloticase antibodies; Green line = high 
increase in anti-pegloticase antibodies; Pink line = information unavailable on increase in anti-pegloticase 
antibodies (n=1); Dashed, horizontal gray line = Dosing time 
 
In humans, PUA is normally eliminated from the body via the kidney as urate, while 
pegloticase allows it to be eliminated renally as allantoin.  One might therefore expect the 
Kout parameter (which incorporates the transformation of uric acid into allantoin and the 
subsequent urinary elimination of the latter) to be correlated with renal function and 
creatinine clearance to be retained as a statistically significant covariate.  However, the 
results of this analysis suggest that baseline creatinine clearance was not a significant 
covariate of the effect of pegloticase on PUA levels.  Creatinine clearance reflects mostly 
glomerular filtration while uric acid (urate) undergoes glomerular filtration, tubular 
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reabsorption, secretion and post-secretory reabsorption. (31, 32)  It may be that creatinine 
clearance, as calculated by the Cockcroft-Gault formula, is not a variable that completely 
characterizes the renal processes involved in urate elimination, even though for most drugs 
creatinine clearance represents total tubule activity.  Finally, hyperuricemia often involves 
an under-excretion of PUA, (31, 32) therefore the lack of correlation between baseline renal 
function and baseline PUA elimination may simply be a reflection of the abnormal PUA 
excretion. 
Overall, the PD model appears to describe the PUA concentrations well, despite the 
significant amount of variability in the observed data.  The between-subject variability is 
large, particularly for the slope parameter when anti-pegloticase antibody levels are low, 
suggesting that there are large differences in the responses between subjects.  The residual 
variability (64%) is reasonable for this PK/PD analysis, considering that the PK profiles 
were quite variable, as previously mentioned. 
3.6.3 Antibodies  
The effect of antibodies on PK and PD parameters was assessed in a previously 
published Phase 2 study, but results failed to demonstrate any influence of antibodies on 
pegloticase.  (18)  In contrast, this Phase 3 analysis revealed a significant effect on 
pegloticase PK and PD.  The larger sample size of the current study (n = 163 vs. n = 40) 
and the longer treatment period (6 months vs. 3 months) may have enabled the detection of 
an antibody effect in comparison with the previous study. 
The results of the PD model with respect to the effect of anti-pegloticase antibodies 
concord with the efficacy findings of the Phase 3 studies, as measured by the percentage of 
subjects achieving PUA levels < 6 mg/dL for at least 80% of the time during months 3 and 
6 combined.  Indeed, 100% of subjects initially responded to pegloticase treatment with 
lowering of PUA to below the therapeutic target within 24 hours of receiving the first 
pegloticase infusion.  However, persistent response was observed in 42% and 35% of 
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subjects receiving 8 mg every 2 weeks or 8 mg every 4 weeks, respectively and anti-
pegloticase antibody responses were observed in 89% of subjects. (23) 
While the inclusion of anti-pegloticase antibody titer category helped explain the 
variability in the PK/PD model, the titer itself has limited utility in the clinical setting.  
Indeed, only the highest anti-pegloticase antibody observed for each individual was 
incorporated into the model, as it was not possible to co-model antibody levels as a 
function of time.  Therefore, the PK/PD model cannot be used to monitor loss of effect in a 
clinical setting.   
3.7 Conclusion 
The PK model that best described pegloticase was a 1-compartment model with a 
linear elimination process.  For the first time, the influence of antibodies on the PK/PD of 
pegloticase was quantified.  An increase in anti-pegloticase antibodies was associated with 
an increase in Vc and CL.  BSA was also a significant covariate affecting the PK 
parameters Vc and CL.  In other words, inter-individual variability seen in PK parameters 
could be attributed to differences in BSA as well as the presence of antibodies. 
An indirect model was used to describe the PD of pegloticase, where the depletion 
rate of PUA was directly influenced by pegloticase levels.  The stimulation of PUA 
elimination by pegloticase was influenced by antibody levels, such that in the presence of 
increased anti-pegloticase antibodies, greater pegloticase levels were necessary to stimulate 
uric acid metabolism.  No other covariates (BSA, weight or creatinine clearance) influenced 
the PD parameters of pegloticase.  Therefore, based upon the analysis of the data using the 
PK/PD model, dosing adjustments to correct for BSA are unnecessary. 
Overall, both dosing regimens were able to reduce urate levels to well below the 
targeted 6 mg/dL.  However, there was a substantial effect of anti-pegloticase antibodies on 
the pharmacodynamics of pegloticase in a subset of these patients, as indicated by the 
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modeling results.  This is consistent with clinical laboratory results indicating that subjects 
with no or low anti-pegloticase antibody levels had a sustained urate-lowering response to 
pegloticase treatment while subjects who developed high levels of anti-pegloticase antibody 
titers lost their urate control over the course of the study.  However, caution must be 
exercised with respect to the clinical utility of antibody levels, since a model could not be 
developed to predict loss of effect as a function of time-dependent antibody titers. 
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4.1 Preface 
Modeling and simulations is a tool that can enhance the drug development process 
by answering key questions in a timely and efficient fashion, and this applies as much to 
generic drugs as it does to innovator products.  The first article presented in this thesis 
highlighted the role of PK modeling in the bioequivalence assessment of an iron complex, 
which was a novel approach within the generic drug development context.  It was also an 
approach that was less costly and time-consuming than the traditional approach.  The 
second article dealt with the innovator product environment for a biologic agent, 
pegloticase, which despite being different from the world of generic drug development, also 
benefitted from the use of modeling.  PK/PD modeling was able to answer critical 
questions about potential pegloticase dosage adjustments, and the results of the research 
were even incorporated into the product labeling.  Indeed, modeling made significant 
contributions to the eventual approval and successful marketing of pegloticase.   
In the present article, another utility of modeling and simulations is demonstrated in 
the context of innovator drug development.  The findings in this research project highlight 
the role of modeling and simulations in the  selection of appropriate doses and dosing 
regimens, making use of available information and incorporating new data as it became 
available.   In contrast with the previous article, the compound being studied here is a small 
molecule belonging to the antibiotic drug class, but as it will be shown, modeling and 
simulations can be used to enhance the development of a wide array of products.  
The decline in the overall productivity of the pharmaceutical industry has affected 
many therapeutic areas, and antimicrobials are no exception.  Since the early 1980’s, there 
has been a steady decrease in the number of small molecule anti-infective agents that have 
received FDA approval (146, 148). Indeed, compared to other therapeutic classes (such as 
anesthetics/analgesics, antineoplastics, cardiovascular, endocrine, central nervous system, 
gastrointestinal, immunologic and respiratory) which have seen an increase in the number 
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of approvals over the last 3 decades or a mixture of increased and decreased numbers, the 
number of approved anti-infective agents has been on the decline since the 1980’s (148).  
One of the reasons for this trend may be the slew of anti-infective agents already on the 
market, making it a highly competitive area of development (148).  Moreover, the rising 
presence of generic products adds more pressure to those who wish to develop anti-
infectives, because the drug must possess a truly novel mechanism of action or significant 
added benefit to justify its expense. 
Drug resistance is both a hurdle to the development of antibiotics as well as an 
opportunity to improve current therapies.  Increased resistance of bacteria to antibiotics has 
even led some pundits to warn of a return to a pre-antibiotic era (149). Indeed, antibiotics 
have been used for the last 60 years and their extensive use, and often misuse, has 
contributed to the growing resistance (149).  The mechanisms for resistance are numerous, 
and include the modification of drug targets, the pumping out of the drug from the cell via 
efflux pumps, and the metabolism of drugs via bacterial enzymes (149).  Our understanding 
and appreciation of these mechanisms has greatly improved, which helps drug developers 
chemically modify compounds that can bypass these resistance mechanisms.  However, 
resistance remains inevitable, reminding us that antibiotic use must be well-controlled to 
slow down the onslaught of resistance as much as possible, while researchers continue to 
develop products to overcome this continuing problem. 
Despite the challenges in bringing new anti-infective agents to market, the quest to 
add new anti-infectives to our therapeutic arsenal is still being pursued by some.  One 
molecule currently under development is TP-434, a novel fluorocycline belonging to the 
class of tetracyclines.  (A general overview of this drug class can be found in Appendix 1.)  
This IV product offers the possibility of eradicating bacteria that are resistant to antibiotics 
that are currently on the market.  Some targets of TP-434 include methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium and 
Enterococcus faecalis and penicillin-resistant strains of Streptococcus pneumonia.  
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Although it has become harder and harder to identify promising anti-infective 
agents due to the increasing bacterial resistance, among other factors, modeling and 
simulations can help promising agents, such as TP-434, reach the market in a more 
effective and timely manner.  For instance, modeling and simulation can help design 
optimal dosing regimens and aid in the planification of future trials (150). In one drug 
development example cited by the FDA, a more thorough analysis of the first of three trials 
that were conducted with the drug could have led to better planification of the subsequent 
trials, and may have shortened development time and improved the probability of approval 
(114).  In other words, the subsequent trials (and the entire DDP for this drug) could have 
benefitted from a better understanding of the results obtained in the first trial.  In contrast to 
this example described by the FDA, modeling and simulations was embraced during the 
DDP of TP-434, which made the process more efficient by continuously improving the 
understanding of the drug’s PK and by applying this knowledge to dosing regimen 
selection.   
Because the decisions made during the drug development process can have 
important ramifications, it is important that prior information be leveraged.  For example, 
pre-clinical results can be included in PK/PD models to predict effects in humans.  In the 
case of antimicrobials, PK/PD indices have been established for various classes of drugs.  
The minimum inhibitory concentration (MIC) represents the lowest concentration that 
inhibits visible growth of an organism, and this parameter has been correlated with various 
PK parameters to predict outcomes for different antibiotics.  It has been shown for beta-
lactams that time over MIC (over a 24 hour interval) greater than or equal to 40% correlates 
well with efficacy (151, 152).  For aminoglycosides, ratios of Cmax to MIC ranging from 
10 to 12 are good predictors of efficacy (153), while ratios of AUC to MIC ranging from 87 
to 175 seem to predict the efficacy of fluoroquinolones (154-156).  Modeling and 
simulations provide an excellent framework in which this information can be used, 
therefore it can play an important role in the development of antibiotics. 
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Thus, the current article illustrates how modeling and simulations, in conjunction 
with previously acquired knowledge, served to select appropriate TP-434 dosing regimens 
for further investigation.  Importantly, this approach allows future protocols to be modified 
prior to their initiation to include dosing regimens that may not initially have been 
envisaged.  This builds upon the learn and confirm paradigm advocated by Sheiner (136), 
by permitting learning and confirming to occur within different studies in the same phase of 
the DDP and further demonstrates how modeling and simulation can enhance the drug 
development process.  
4.2 Abstract 
Background: TP-434 is a novel fluorocycline being developed.  A first in human, single 
ascending dose (SAD) study was conducted.  TP-434 was infused IV over 30 minutes at 
doses of 0.1 to 3 mg/kg.  This analysis aimed to describe the pharmacokinetics (PK) of TP-
434 following a single dose and to determine the dosing regimens for a multiple ascending 
dose (MAD) study.  
 
Methods:  Population PK analyses were conducted with ADAPT 5 after the completion of 
each cohort using plasma & urinary data.  The best model was chosen using standard model 
discrimination criteria.  Simulations were performed with the model to predict clinical 
endpoints associated with various dosing regimens, such as AUC/MIC (area under the 
concentration-time curve/ minimal inhibitory concentration). MAD regimens were 
proposed using these endpoints. 
 
Results: Seven cycles of modeling and simulation were conducted with data from 42 
subjects.  The model was improved with each successive analysis.  The final model was a 
4-compartment model with linear elimination.  Mean parameters were Vc = 10.8 L, CLnr = 
11.5 L/h, Vp1 = 16.1 L, CLd1 = 44.3 L/h, Vp2 = 132 L, CLd2 = 6.95 L/h, Vp3 = 103 L, 
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CLd3 = 26.9 L/h and CLr = 2.34 L/h. Inter-individual variability ranged from 8.7 to 41%.  
Based on AUC/MIC, simulations suggested that a minimum of 1.5 mg/kg QD for 10 days 
would be efficacious for organisms with an MIC50 = 0.5 g/mL. 
 
Conclusion: Using model-based simulations, dosing regimens originally proposed for the 
MAD study (1.0 mg/kg) were modified to evaluate more appropriate regimens (≥1.5 mg/kg 
daily). 
4.3 Introduction 
Antibiotic resistance is a phenomenon that continues to challenge clinicians and 
researchers who strive to find new treatments for different infections.  This problem has 
touched many classes of antibiotics, if not most, and the tetracyclines have certainly not 
been spared.  Resistance to tetracyclines, caused by the presence of efflux pumps or 
ribosomal protection, has resulted in the decreased use of these antibiotics (16).  However, 
the relatively recent emergence of a new type of tetracycline which is effective against 
resistant organisms, tigecycline, has renewed interest in the class (2).   
Another new type of tetracycline that belongs to the fluorocycline sub-group is 
TP-434, which is currently being developed by Tetraphase Pharmaceuticals, Inc. (5).  It is a 
novel antibiotic that exhibits in vitro activity against a wide array of gram-positive and 
gram-negative pathogens, such as nosocomial and community-acquired methicillin-
susceptible or -resistant Staphylococcus aureus strains (MRSA), vancomycin-susceptible or 
-resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -
resistant strains of Streptococcus pneumoniae (8, 17-18).  In addition, it is active in animal 
models of infection (11). 
Although in vitro and pre-clinical results were promising, the pharmacokinetics 
(PK) and safety of TP-434 in humans had yet to be determined.  To this effect, a single 
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ascending dose (SAD) study was conducted in healthy volunteers.  In this study, TP-434 
was administered as a single intravenous (IV) infusion over 30 minutes, at a dose of either 
0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, or 3 mg/kg.  In each 
cohort, 6 subjects received active treatment while 2 subjects received placebo.  Serial blood 
and urine samples were collected pre-dose until 96 hours post-dose.    
We hypothesized that the modeling of data from this SAD study, together with our 
knowledge of antimicrobial pharmacokinetic and pharmacodynamic (PD) relationships, 
would allow us to gain more insight into the PK of TP-434 during the conduct of the study 
and help us select more appropriate dosing regimens for a multiple dose study, before the 
initiation of the latter.  Indeed, exposure response relationships for a similar compound, 
tigecycline, demonstrated that the ratio AUCSS/MIC (the area under the concentration-time 
curve over 24 hours at steady state divided by the minimal inhibitory concentration) was a 
good predictor of clinical efficacy (1, 3, 4, 10).  Because data was available after the 
completion of each successive cohort, it would be possible to create a PK model and 
improve upon the model with the inclusion of new results.  Our objective was therefore to 
develop a PK model to describe the disposition of TP-434 after the administration of each 
dose and to select repeated dose regimens using simulations performed with this model. 
4.4 Materials and Methods 
4.4.1 Study Design 
The study was a randomized, double-blind, parallel-group, placebo-controlled 
study.  Healthy men and women, between 18 to 50 years of age inclusively, were included 
in the study.  Good health was assessed by the Principal Investigator based on lack of 
clinically significant abnormalities in health assessments such as vital signs, 
electrocardiograms (ECG), laboratory tests, body mass index.  Women included in the 
   
  131 
 
 
 
study must have been surgically sterile (by tubal ligation, bilateral oophorectomy, or 
hysterectomy) for at least 6 months prior to study initiation.   
Seven dose levels were studied: 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 
mg/kg, 2 mg/kg and 3 mg/kg.  In each cohort, 6 subjects received active treatment while 2 
subjects received placebo.  TP-434 was administered by IV infusion over 30 minutes.  Dose 
escalation only proceeded in the absence of dose-limiting adverse events or clinically 
relevant safety laboratory parameters such as (but not limited to) alanine aminotransferase 
levels and absolute reticulocyte counts.   
Subject safety was monitored throughout the study.  Blood samples for TP-434 
assay were collected prior to dosing and at the following times post-dose: 0.25, 0.5, 0.583, 
0.75, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours.  Urine samples were obtained before 
dosing and between 0 to 8 hours, 8 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 
hours after the start of the infusion.  Subjects were asked to void their bladders completely 
prior to dosing. 
Protocol approval was obtained from the local institutional review board prior to the 
commencement of the study.  In addition, written informed consent was obtained from 
study participants before conducting any study-related procedures. 
4.4.2 Analytical Methods 
Bioanalytical sample analysis for TP-434 was performed by Tandem Labs (Salt 
Lake City, UT, US).  TP-434 in plasma was assayed using a validated liquid 
chromatography/mass spectrometry (LC/MS/MS) method with a quantitation range of 5.00 
ng/mL to 1000 ng/mL. Assay precision (%CV) varied from 2.8% to 6.8% while accuracy 
(% bias) ranged from -0.1% to 3.0%.  Similarly, TP-434 in urine was assayed using a 
validated LC/MS/MS method with a quantitation range of 5.00 ng/mL to 1000 ng/mL.   
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Assay precision (%CV) varied from 4.6% to 8.5% while accuracy (% bias) ranged from -
0.8% to 3.3%. 
4.4.3 Pharmacokinetic Analyses 
Population PK analyses were performed using clinical and analytical data from all 
subjects receiving active treatment.  Actual dose, drug infusion times, PK sampling times 
(for plasma and urine) as well as urinary volume were collected and used.  Both plasma and 
urinary TP-434 concentrations were included in the analysis.  Dataset preparation was 
performed using Microsoft Excel
®
 2003 and S-Plus
®
 8.0 for Windows. 
Two, three and four-compartment models with linear elimination were first tested 
using the standard two-stage (STS) option in ADAPT 5
®
 (6).  The best model was selected 
based on standard discrimination techniques such as the minimization of the Akaike 
information criterion test, the residual variability, the maximization of the coefficient of 
determination, and based on graphical representation of the goodness of fit (e.g. observed 
versus predicted concentrations, weighted residuals versus predicted concentrations). All 
plasma and urinary concentrations were simultaneously fitted and explained by the model. 
Following the determination of the final structural pharmacokinetic model using 
STS, a population pharmacokinetic analysis was performed using the maximum likelihood 
expectation maximization (MLEM) method within ADAPT 5
®
. This is a fully automated 
mixed effect modeling approach using both maximum likelihood and sampling-based 
methods. Briefly, the first probable population PK parameters and variance estimates (e.g., 
residual variability) were found by the STS approach using maximum likelihood. Then a 
population analysis was undertaken where population, individual and residual variability 
PK parameters were calculated and updated with more probable values at every new 
population iteration.  The procedure was stopped when convergence was achieved (PK 
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mean and variance estimates were stabilized after over 1000 iterations were run) and the 
most probable and stable results for the population and individuals were determined.   
All TP-434 concentrations were fitted using weighting procedures of Wj=1/j
2
 
where the variance j
2
 was calculated for each observation using the equation Sj
2
=(a + b x 
Yj)
2
 where a and b are the intercept and slope of each variance model.  The slope is the 
residual variability proportional to each concentration and the intercept is the additional 
component of the residual variability.  These parameters were estimated continuously at 
each population iteration step as noted above using the MLEM approach. 
Using the individual PK parameter estimates from the final model, secondary PK 
parameters were calculated for each subject.  Cmax and Cmin were the maximal and 
minimal predicted concentration values for each subject (Cmin was the trough 
concentration at 24 hours post-dose).  The area-under-the-curve from time zero to infinity 
(AUCinf) was calculated as dose divided by total clearance (CLT), which was the sum of 
renal and non-renal clearances.  Secondary PK parameters were calculated using Microsoft 
Excel
®
 2003 and S-Plus
®
 8.0 for Windows. 
The model’s predictive performance was assessed using the secondary predicted PK 
parameter AUCinf, as the overall predicted exposure would be used for exposure-response 
correlations.  The predicted AUCinf values were visually compared to AUCinf values that 
were determined by noncompartmental methods (linear trapezoidal) using observed 
concentrations (7).  Bias was determined as the percentage difference between the observed 
(noncompartmental) and predicted parameter, relative to the observed value, while 
precision was calculated as the absolute value of the bias (15).  Equations for bias and 
precision are presented below, where AUCinfobs represents the AUCinf determined by 
noncompartmental methods while AUCinfpred is the AUCinf predicted by the model. 
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4.4.4 Simulations 
Monte Carlo simulations (n=1000) were performed using the final model, in order 
to predict PK parameters in a population and associated with various dosing regimens that 
were either included in the MAD protocol or being considered for further investigation.  
The following 10-day dosing regimens were simulated for an average patient weighing 70 
kg: 
 0.5 mg/kg IV administered over 30 minutes QD 
 0.75 mg/kg IV administered over 30 minutes QD 
 1.0 mg/kg IV administered over 30 minutes QD 
 1.0 mg/kg IV administered over 60 minutes QD 
 1.5 mg/kg IV administered over 30 minutes QD 
 1.5 mg/kg IV administered over 60 minutes QD 
 2 mg/kg IV administered over 30 minutes QD 
 1 mg/kg administered over 30 minutes BID 
Using predicted concentrations from the simulated subjects in each of the dosing 
regimens, the PK parameters AUCtau(ss) (AUC over the dosing interval tau at steady-state), 
Cmax(ss) (maximal concentration at steady state) and Cmin(ss) (minimum concentration at 
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steady state) were calculated.  AUCtau(ss) was calculated as dose divided by CLT, while 
Cmax(ss) and Cmin(ss) were the maximal and minimal predicted concentration values for 
each subject over the dosing interval.  The clinical endpoint AUC/MIC associated with 
various dosing regimens was also estimated.  In addition, the percentage of subjects 
achieving a target AUC/MIC value was also determined for each dosing regimen.  These 
target values were calculated from total (bound and unbound) tigecycline concentrations, 
and because TP-434 has a similar percentage of protein binding (40%) (2), no adjustment 
for free fraction was deemed necessary.  For complicated skin and skin-structure infections 
(caused by S. Aureus and Streptococcus sp.), the targeted AUC/MIC value was 17.9 while 
it was 12.96 for complicated intra-abdominal infections (caused by Escherichia coli, 
Klebsiella sp., and Enterobacteriacea) (4, 10).  These endpoints were obtained from studies 
conducted in patients who received tigecycline monotherapy.  The AUC/MIC targets for 
community-acquired pneumonia (S. pneumoniae) and hospital-acquired pneumonia 
(Escherichia coli and MRSA) were 64 and 5.75, respectively (3). 
Predicted PK parameters AUCtau(ss), Cmax(ss), and Cmin(ss) were calculated using 
Microsoft Excel® 2003 and S-Plus® 8.0 for Windows. 
4.5 Results 
A total of 56 subjects were enrolled in the study, with 42 subjects who received 
active treatment.  Fifty-two subjects completed the clinical portion of the study (two 
subjects were withdrawn due to potential influenza infections).  A summary of subject 
demographics is presented in Table 1. 
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Table 1. Subject Demographics   
Characteristic n (%) 
Sex  
 Male 49 (87.5%) 
 Female 7 (12.5)% 
Race  
 Asian 3 (5.4%) 
 Amerindian 1 (1.8%) 
 African-american 5 (8.9%) 
 Caucasian 47 (84%) 
Characteristic Mean ± Standard deviation 
Age 28.1 ± 8.65 
Weight (kg) 80.2 ± 12.5 
Height (cm) 176 ± 7.71 
 
Results associated with 2-, 3-, 4- and 5-compartment structural models that were 
investigated are presented in Table 2.  The model with the lowest AIC value was the 4-
compartment model.       
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Table 2.  Structural Model Determination for TP-434 using Standard Two-Stage Analysis 
Model Description 
Negative Log 
likelihood 
AIC BIC 
R
2
 Residual variability (%) 
Plasma Urine Plasma Urine 
2-compartments, 
linear elimination 
106.25 230.5 239.2 0.924 0.994 33.1 13.9 
3-compartments, 
linear elimination 
82.94 187.9 198.3 0.983 0.996 11.8 11.9 
4-compartments, 
linear elimination 
74.30 174.6 186.9 0.996 0.995 8.9 10.8 
5-compartments, 
linear elimination 
77.65 185.3 200.2 0.996 0.993 8.4 16.1 
AIC: Akaike information criterion,  BIC: Bayesian information criterion, R2: Coefficient of determination 
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The final model selected to describe the plasma PK of TP-434 was a 4-compartment 
model with a linear (first order) elimination process, as depicted in Figure 1.  The model 
was parameterized with a central volume of distribution (Vc), peripheral volumes of 
distribution (Vp1, Vp2 and Vp3), renal clearance (CLr), non-renal clearance (CLnr) and 
distributional clearances (CLd1, CLd2 and CLd3). 
 
Figure 1. Final Pharmacokinetic Model for TP-434 
 
A total of 578 plasma concentrations and 209 urinary concentrations were 
simultaneously fitted by the model.  Residual variability for plasma was 9.42% while it was 
19.2% for urine.  An example of a goodness-of-fit plot is presented in Figure 2.  Plots of 
goodness of fit for weighted residuals (as a function of predicted concentrations or time) 
demonstrated no trends or biases in the quality of fit.  Mean observed and predicted plasma 
concentration-time profiles are presented in Figure 3. 
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Figure 2. Predicted versus Observed TP-434 Concentrations 
 
a) Plasma Concentrations 
 
a) Urinary Concentrations  
 
LEGEND: Dark circles represent concentrations while the dotted line represents the line of identity. 
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Figure 3. Mean Observed versus Predicted Plasma TP-434 Concentrations (Semi-log scale) 
 
Note: Orange dashed line represents the lower limit of quantitation  
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Population PK parameter estimates and their precision are presented in Table 3 and 
a summary of secondary PK parameters by treatment group are presented in Table 4. 
 
Table 3.  Population Pharmacokinetic Parameter Estimates for TP-434 
Parameter 
Mean Inter-subject 
Estimate %RSE Estimate as CV% %RSE 
Vc (L) 10.8 12.1 20.6 41.2 
CLnr (L/h) 11.5 6.74 19.5 29.1 
Vp1 (L) 16.1 16.9 23.8 68.1 
CLd1 (L/h) 44.3 11.1 8.69 181 
Vp2 (L) 132 9.96 20.2 49.1 
CLd2 (L/h) 6.95 20.9 40.8 51.4 
Vp3 (L) 103 13.2 25.1 46.1 
CLd3 (L/h) 26.9 14.2 30.8 49.7 
CLr (L/h) 2.34 6.41 18.4 37.2 
CLd1: distributional clearance between central compartment and first peripheral compartment; CLd2: 
distributional clearance between central compartment and second peripheral compartment; CLd3: 
distributional clearance between central compartment and third peripheral compartment; CLnr: non-renal 
clearance; CLr: renal clearance; %RSE: standard error as a percent of the corresponding maximum likelihood 
estimate; Vc: central volume of distribution; Vp1: first peripheral volume of distribution; Vp2: second 
peripheral volume of distribution; Vp3: third peripheral volume of distribution;  
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Table 4.  Predicted Secondary Pharmacokinetic Parameters for TP-434 
Dose 
(mg/kg) 
Mean  SD (CV%) 
AUCinf (mcg*h/L) Cmax (mcg/L) Cmin (mcg/L) 
0.1 560  122 (21.7%) 212  38.3 (18.1%) 5.16  1.42 (27.6%) 
0.25 1363  203 (14.9%) 503  79.7 (15.9%) 13.4  2.63 (19.7%) 
0.5 2680  660 (24.6%) 1067  207 (19.4%) 25.2  6.84 (27.2%) 
1.0 5546  1085 (19.6%) 2027  450 (22.2%) 53.4  12.3 (23.1%) 
1.5 8896  1563 (17.6%) 3287  656 (20.0%) 84.3  14.1 (16.7%) 
2.0 12376  2010 (16.2%) 4694  787 (16.8%) 110  17.6 (16.0%) 
3.0 23235  4773 (20.5%) 9855  1530 (15.5%) 175  36.5 (20.8%) 
 
The mean half-life of TP-434 in plasma (all cohorts confounded) was 26.2 h, while 
the median value was 23.1 h.  Renal elimination of TP-434 accounted for approximately 
17.1 ± 2.65 % of overall elimination. 
Predictive performance is depicted in Figure 4, which suggests that AUCinf is well 
predicted by the model since all results are closely aligned with the line of identity (dashed 
line).  Additionally, average bias and precision were 0.27% and 2.6% for AUCinf. 
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Figure 4.  Predictive performance of the final model 
 
LEGEND: Dark circles represent AUCinf values while the dotted line represents the line of identity. 
Mean secondary parameters estimated from the simulated profiles are summarized 
in Table 5, while Figure 5 displays the percentage of target attainment for various dosing 
regimens and different values of AUC/MIC.  Target AUC/MIC values were taken from 
published tigecycline results in different patient populations (3, 4, 10).  The arrow along the 
x-axis in each figure indicates the MIC value associated with TP-434 for the organism(s) 
being targeted.  Therefore, this MIC value indicates the TP-434 clinical response associated 
with different TP-434 regimens for each indication. 
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Table 5.  Secondary Simulated Steady-State Pharmacokinetic Parameters for TP-434 
Dosing regimen (mg/kg) 
Mean  SD (CV%) 
AUCtau(ss) 
(mcg*h/L) 
Cmax(ss) (mcg/L) Cmin(ss) (mcg/L) 
0.5 mg/kg QD over 30 minutes 
2575 ± 459 
(17.8%) 
1025 ± 147 
(14.4%) 
42.0 ± 15.5 
(37%) 
0.75 mg/kg QD over 30 minutes 
2611 ± 498 
(19.1%) 
1556 ± 225 
(14.4%) 
64.1 ± 25.3 
(39.5%) 
1 mg/kg QD over 30 minutes 
5163 ± 920 
(17.8%) 
2051 ± 293 
(14.3%) 
84.0 ± 31.0 
(36.9%) 
1 mg/kg QD over 60 minutes 
5167 ± 938 
(18.2%) 
1405 ± 214 
(15.3%) 
84.4 ± 31.7 
(37.6%) 
1.5 mg/kg QD over 30 minutes 
7814 ± 1389 
(17.8%) 
3106 ± 436 
(14.0%) 
127 ± 45.7 
(35.9%) 
1.5 mg/kg QD over 60 minutes 
7725 ± 1393 
(18%) 
2078 ± 293 
(14.1%) 
126 ± 47.5 
(37.8%) 
2 mg/kg QD over 30 minutes 
10386 ± 1967 
(18.9%) 
4120 ± 586 
(14.2%) 
168 ± 65.9 
(39.4%) 
1.0 mg/kg BID over 30 minutes 
5182 ± 989 
(19.1%) 
2218 ± 318 
(14.3%) 
217 ± 69.6 
(32.0%) 
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Figure 5. Percentage of target attainment for different dosing regimens over a range of MIC 
values 
 
 
 
LEGEND: Arrows indicate the MIC value associated with TP-434 for the organism(s) being targeted. 
Simulated dosing regimens are represented as follows: dark circles with a solid line: 0.5 mg/kg QD; dark, 
inverted triangle with large dashes: 0.75 mg/kg QD; square with medium dashes: 1.0 mg/kg QD; diamond 
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with short dashes: 1.5 mg/kg QD; pale triangle with dotted line: 1.0 mg/kg BID; pale circle with dotted and 
dashed line: 2.0 mg/kg BID;  
4.6 Discussion 
This is the first published account describing the pharmacokinetics of TP-434 in 
humans.  Before the study had even dosed, allometric scaling was performed with pre-
clinical data in order to estimate possible PK parameters in humans. The analysis suggested 
that in humans, one could expect a CL of approximately 46 L/h, a Vc of around 20 L, a Vss 
of around 13 L/kg and a terminal elimination half-life close to 13 hours.  Preliminary dose 
estimations suggested that a minimal daily dose of 1.5 mg/kg would be necessary for 
clinical efficacy against complicated skin and skin structure infections and possibly higher 
doses would be necessary for monotherapy against S. Aureus.  
After the first cohort (receiving 0.1 mg/kg TP-434) had completed the clinical phase 
of the study, the plasma and urinary data that was obtained was used to develop an initial 
PK model.  A 3-compartment model was selected at this stage.  Following the completion 
of the next dose group (0.25 mg/kg TP-434) and the availability of their data, the model 
discrimination process was repeated to include data from both cohorts.  The best model was 
also a 3-compartment model, and revised parameter estimates were obtained.  This process 
was repeated following the completion of each treatment group, such that more data was 
being analyzed each time.  By the time that data for the fourth cohort (1 mg/kg) was 
included in the analysis, the best model became a 4-compartment model, and this model 
was retained for all subsequent analyses. 
The model development process that we used exemplifies the “learn and confirm” 
paradigm proposed by Sheiner nearly a decade and a half ago (14).  Our initial attempt to 
learn about the PK of TP-434 in humans was through allometric scaling using preclinical 
data.  This learning stage was further pursued when data from the first SAD cohort was 
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available and a first PK model was created.  The PK parameters estimated in humans were 
different from those predicted by allometric scaling, therefore this analysis contributed 
significantly to our understanding of TP-434 PK.  The PK results gathered at this stage 
were then confirmed with the availability and analysis of data from cohort 2, therefore this 
represented the first step in the “confirming” process.  Subsequent analyses reinforced the 
“learn & confirm” cycle, improving the PK model and parameter estimates with each 
iteration. 
The law of parsimony requires that the simplest model that describes the PK of a 
compound be used preferentially over a more complicated model, if the standard model 
discrimination criteria are similar between both models.  In our case, the best model was a 
4-compartment model according to the model discrimination criteria applied to the two-
stage analysis results.  The 4-compartment model was associated with lower AIC and 
residual variability values compared to the 2- and 3-compartment models, while the 5-
compartment model did not improve these values any further. 
The number of parameters that can be calculated for a given compartmental model 
depends on many factors, notably the number of visible exponentials in plasma disposition, 
the number of excretory pathways measured, the number of tissue spaces analyzed as well 
as the number of visible nonlinear features in the data (9).  In the current analysis, 3 
exponentials were visible and concentrations were measured in both plasma and urine. 
With this in mind, the rich plasma and urinary sampling scheme in this study 
(approximately 16 samples per subject) provided sufficient information to robustly estimate 
the nine PK parameters associated with the 4-compartment model (CLnr, CLr, Vc, CLd1, 
Vp1, CLd2, Vp2, etc.).         
The residual variability associated with the final PK model (9.42% for plasma and 
19.2 % for urine) represents the variability that is not explained by the model, including 
intra-individual variability, the experimental “noise” of the analytical method and errors 
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arising from the pharmacokinetic modeling itself (model misspecification).  The low 
residual variability associated with our model confirms that the 4-compartment model was 
able to properly capture the PK of TP-434.   
The current analysis demonstrates that TP-434 had a population mean CLT of 13.9 
L/h and a Vss of approximately 262 L (around 3.3 L/kg).  The total clearance value is 
slightly lower than what was previously reported for tigecycline.  The PK of tigecycline in 
healthy volunteers was also described by a multi-compartment model (19).  For this drug, a 
3-compartment model with zero-order input and first-order elimination was chosen to 
describe its PK.  A population mean CL of 16.3 L/h was estimated, with a Vss of 749 L or 
approximately 10 L/kg.   
Total clearance of TP-434 did not change with increasing doses, thus results of the 
current analysis indicate that TP-434 exhibits dose-proportional pharmacokinetics over the 
dose range studied.  In addition, renal clearance estimated by the model (17.1% of total 
clearance) confirms that the elimination of TP-434 is mainly through non-renal pathways.  
This is similar to what was observed in chimpanzees, where urinary excretion was roughly 
20% of total elimination (12). 
Simulations revealed that for most target organisms, all regimens were associated 
with a probability of meeting the target AUC/MIC that exceeded 80%.  However, for 
treating complicated intra-abdominal infections caused by E. Coli and Klebsiella sp., doses 
inferior to 1.5 mg/kg TP-434 per day were not associated with much success.  Indeed, for 
these dosing regimens, less than 10% of subjects achieved the desired AUC/MIC.  Thus, 
prior to initiation of the MAD study, the protocol was modified in order to include a 
treatment regimen of 1.5 mg/kg administered once daily.  Initially, the second dosing group 
of the MAD study was scheduled to receive 1.0 mg/kg QD, but the protocol was amended 
such that the 1.0 mg/kg QD was replaced by the 1.5 mg/kg dose group.  In addition, single 
doses of 1.5 mg/kg appeared to be well tolerated by the subjects in the SAD study, and 
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simulations did not suggest significant accumulation following repeated administration.  
Finally, a twice-daily (BID) dosing regimen was added to the MAD study (1.0 mg/kg BID), 
in light of the simulation results and the tolerability of a single dose of 2.0 mg/kg in the 
SAD study. 
4.7 Conclusion 
The final model was not only used to describe the PK of TP 434 following single 
dose administration, but was also used to predict plasma TP-434 concentrations associated 
with various multiple dose regimens.  These predictions were used to further refine the 
regimens tested in a multiple dose setting, prior to study initiation, and demonstrated the 
utility of modeling and simulations in early stages of drug development. 
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5.1 Preface 
The research that was presented in the first three manuscripts demonstrated how 
modeling and simulations can be used to answer key questions that are frequently 
encountered during the drug development process.  In the first article, modeling and 
simulations played a critical part in an innovative approach to bioequivalence assessment, 
while in the second article, population modeling was used to better understand the PK and 
PD of a biologic drug and enhance the product labeling.  The third article illustrated how 
PK/PD concepts used in conjunction with a population PK model could be useful as early 
as in Phase 1 of clinical development, in a single ascending dose study, and that such a 
model could lead to more rational dose and dosing regimen selections for subsequent 
studies.  The current (fourth) article demonstrates how pharmacokinetic models can be 
continually refined as more information becomes available, such that it incorporates all 
current knowledge to allow for more informed decision-making. 
As described in the third manuscript, the antibiotic TP-434 is being developed to 
treat various types of infections caused by highly resistant organisms.  A first-in-man, 
single ascending dose study was conducted in healthy volunteers and the data collected 
from this study was incorporated into a population PK model that was used to select dosing 
regimens for investigation of repeated dosing.  The current study describes the first repeat-
dose study of TP-434 in man, which benefitted from previous population PK analyses 
(described in Article #3) with the addition of dosing regimens that were not originally 
envisaged.  More specifically, a twice daily dosing regimen was evaluated instead of a once 
daily dosing regimen.  Population PK analyses were also undertaken with data obtained 
from this multiple ascending dose study of TP-434 and they served to broaden our 
understanding of the PK of TP-434, as well as confirm the previously defined model.  
Thus, the research presented in this manuscript was conducted in the spirit of “learn and 
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confirm” advocated by Sheiner (136) and demonstrates how it can be applied to data 
obtained within the same phase of drug development.  It shows how the continual use of 
modeling and simulation throughout the drug development process can increase confidence 
levels when important decisions must be made, thereby decreasing some of the risk 
inherent to bringing a drug to market.  Dosing regimens that were administered in this 
multiple ascending dose study, and that had been tested purely based on the results of 
Article #3, were ultimately selected for administration to patients in Phase 2.  Thus, this 
approach ensured that dosing regimens for the target population were assessed following 
repeated administration in healthy patients, prior to the initiation of Phase 2, which would 
not have occurred without the use of modeling and simulations.  
5.2 Abstract 
 
Background: A multiple ascending dose study was completed for TP-434.  Placebo or TP-
434 (either 0.5 or 1.5 mg/kg QD over 30 minutes, or 1.5 mg/kg QD or 1 mg/kg BID over 1 
hour) was administered for 10 days.  Plasma and urine samples were collected throughout.  
This analysis aimed to describe the pharmacokinetics (PK) of TP-434, confirm previously 
determined PK & confirm dosing regimens for further investigation. 
 
Methods:  Population PK analyses were done with ADAPT 5
®
 using plasma and urinary 
data.  Two-, three- and four-compartment models were tested and standard model 
discrimination criteria were used to select the best model.  Results were compared to those 
obtained from single dose (SD) data. 
 
Results: TP-434 was well described by a 4-compartment model with linear elimination.  
Mean parameters were Vc = 12.2 L, CLnr = 11.5 L/h, Vp1 = 16.6 L, CLd1 = 29.9 L/h, Vp2 
= 188 L, CLd2 = 4.90 L/h, Vp3 = 103 L, CLd3 = 21.2 L/h & CLr = 2.05 L/h.  Inter-
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individual variability ranged from 2.3 to 47%.  Steady-state volume of distribution was 320 
L and mean half-life was  48 hours.  Results were similar to those of SD and confirm 
predictions made from SD data.  Exposure associated with daily doses  1.5 mg/kg was 
expected to be efficacious against organisms with minimum inhibitory concentrations 
(MIC) ≤ 2 µg/ml.        
 
Conclusion: Multiple dose PK of TP-434 was described by a 4-compartment model, with 
results similar to those following SD.  Observed and predicted exposure confirmed the 
doses predicted to be efficacious in Phase 2. 
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5.3 Introduction 
A novel antimicrobial agent belonging to the fluorocycline class, TP-434, is being 
developed by Tetraphase Pharmaceuticals, Inc (4, 7).  Although this antibiotic is a member 
of the tetracycline family, in vitro tests have demonstrated activity against organisms that 
are generally resistant to tetracyclines, including methicillin-resistant Staphylococcus 
aureus, vancomycin-resistant Enterococcus faecium and penicillin-resistant Streptococcus 
pneumoniae (12, 13).  Thus, this molecule could be an excellent addition to a therapeutic 
arsenal that is becoming more and more limited by bacterial resistance. 
A first-in-man, single ascending dose (SAD) study was undertaken with TP-434 to 
evaluate its safety and pharmacokinetics (PK) in humans.  The drug was administered at 
doses ranging from 0.1 mg/kg to 3.0 mg/kg.  Based on the results of the SAD study, a 4-
compartment model was developed to describe the PK of the drug.  Simulations performed 
with the final model were used to determine which dosing regimens should be tested in a 
multiple ascending dose (MAD) study, prior to study initiation (C. Seng Yue, J. A. 
Sutcliffe, P. Colucci, C. R. Sprenger, and M. P. Ducharme, submitted for publication).  A 
key principle underlying this analysis was the relationship between clinical efficacy and the 
parameter AUC/MIC (the area under the concentration-time curve over 24 hours at steady 
state divided by the minimal inhibitory concentration) (1-3, 8).  Thus, according to the 
simulation results, a minimum daily dose of a least 1.5 mg/kg would be necessary in order 
to achieve target AUC/MIC values for more resistant pathogens, such as Escherichia coli 
and Klebsiella sp. 
The MAD study was designed to evaluate the safety, tolerability and PK of TP-434 
following multiple dose administration.  In this study, multiple ascending doses of TP 434 
were administered to 4 separate cohorts.  Subjects received TP-434 for a ten day period, at 
a dose of either 0.5 mg/kg infused over 30 minutes QD, 1.5 mg/kg infused over 30 minutes 
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QD, 1.5 mg/kg infused over 60 minutes QD or 1.0 mg/kg infused over 60 minutes BID.  In 
each cohort, 6 subjects received active treatment while 2 subjects received placebo. 
The objectives of this analysis were to describe the PK of TP 434 following 
repeated administration and to validate dosing regimens to be administered in Phase 2 
studies.  In addition, this analysis sought to confirm the PK of TP-434 previously predicted 
using SAD data. 
5.4 Materials and Methods 
5.4.1 Study Design 
The study was a randomized, double-blind, parallel-group, placebo-controlled 
study.  Healthy men and women, between 18 to 50 years of age inclusively, were included 
in the study.  Good health was assessed by the Principal Investigator based on lack of 
clinically significant abnormalities in health assessments such as vital signs, 
electrocardiograms (ECG), laboratory tests, body mass index.  Women included in the 
study must have been surgically sterile (by tubal ligation, bilateral oophorectomy, or 
hysterectomy) for at least 6 months prior to study initiation. 
Four (4) ten-day dosing regimens were studied: 0.5 mg/kg IV infused over 30 
minutes QD, 1.5 mg/kg IV infused over 30 minutes QD, 1.5 mg/kg IV infused over 60 
minutes QD, and 1.0 mg/kg IV infused over 60 minutes BID.  In each cohort, 6 subjects 
received active treatment while 2 subjects received placebo.  Dose escalation only 
proceeded in the absence of dose-limiting adverse events or clinically relevant safety 
laboratory parameters.   
Subject safety (laboratory results, electrocardiograms, vital signs, adverse events) 
was monitored throughout the study.  Blood samples for TP-434 assay were collected on 
Days 1 and 10 prior to dosing and at the following times post-dose: 0.25, 0.5, 0.583, 0.75, 
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1, 2, 4, 6, 8, and 12 hours.  In addition, pre-dose samples were collected on Days 2 to 9, and 
on Days 11-14, samples were collected 24, 36, 48, 72, and 96 hours after the start of the 
infusion on Day 10.  Urine samples were obtained on Days 1 and 10 before dosing and 
between 0 to 8 hours, 8 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours after 
the start of the infusion of each of these days. 
Protocol approval was obtained from the local institutional review board prior to the 
commencement of the study.  In addition, written informed consent was obtained from 
study participants before conducting any study-related procedures. 
5.4.2 Analytical Methods 
Bioanalytical sample analysis for TP 434 was performed by Tandem Labs (Salt 
Lake City, UT, US).  TP-434 in plasma was assayed using a validated liquid 
chromatography/mass spectrometry (LC/MS/MS) method with a quantitation range of 5.00 
ng/mL to 1000 ng/mL.   Assay precision (%CV) varied from 2.8% to 6.8% while accuracy 
(% bias) ranged from -0.1% to 3.0%.  Similarly, TP-434 in urine was assayed using a 
validated LC/MS/MS method with a quantitation range of 5.00 ng/mL to 1000 ng/mL.   
Assay precision (%CV) varied from 4.6% to 8.5% while accuracy (% bias) ranged from -
0.8% to 3.3%. 
5.4.3 Pharmacokinetic Analyses 
Population PK analyses were performed using clinical and analytical data from all 
subjects receiving active treatment.  Actual dose, drug infusion times, PK sampling times 
(for plasma and urine) as well as urinary volume were used.  Both plasma and urinary TP-
434 concentrations were included in the analysis.  
Two, three and four-compartment models with linear elimination were first tested 
using the standard two-stage (STS) option in ADAPT 5
®
 (5).  The best model was selected 
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based on standard discrimination techniques such as the minimization of the Akaike 
information criterion test, the residual variability, the maximization of the coefficient of 
determination, and based on graphical representation of the goodness of fit (e.g. observed 
versus predicted concentrations, weighted residuals versus predicted values). 
Following the determination of the final structural pharmacokinetic model using 
STS, a population pharmacokinetic analysis was performed using the maximum likelihood 
expectation maximization (MLEM) method within ADAPT 5
®
. This is a fully automated 
mixed effect modeling approach using both maximum likelihood and sampling-based 
methods. Briefly, the first probable population PK parameters and variance estimates (e.g., 
residual variability) were found by the STS approach using maximum likelihood. Then a 
population analysis was undertaken where population, individual and residual variability 
PK parameters were calculated and updated with more probable values at every new 
population iteration.  The procedure was stopped when convergence was achieved (PK 
mean and variance estimates were stabilized after over 1000 iterations were run) and the 
most probable and stable results for the population and individuals were determined.   
All TP-434 concentrations were fitted using weighting procedures of Wj=1/j
2
 
where the variance j
2
 was calculated for each observation using the equation Sj
2
=(a + b x 
Yj)
2
 where a and b are the intercept and slope of each variance model.  The slope is the 
residual variability proportional to each concentration and the intercept is the additional 
component of the residual variability.  These parameters were estimated continuously at 
each population iteration step as noted above using the MLEM approach. 
Using the individual PK parameter estimates from the final model, secondary PK 
parameters were calculated.  These included Vss, terminal elimination half-life and total 
clearance.  Peak and trough concentrations were also determined using predicted 
concentrations on Day 1 and Day 10.  On Day 1, Cmax and Cmin were the maximal and 
minimal predicted concentration values for each subject over the dosing interval.  For 
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subjects dosed twice daily, these parameters were calculated for the morning dose.  On Day 
10, the maximal and minimal predicted concentrations over the dosing interval were 
labeled Cmax(ss) and Cmin(ss). In addition, the area-under-the-curve over the dosing interval 
at steady-state (AUCtau(ss)) was calculated as dose divided by total clearance (CLT) while 
AUC0-24 for Day 1 was calculated with the linear trapezoidal method using all predicted 
concentrations during the dosing interval (6). 
Predictive performance was assessed using the secondary predicted PK parameter 
AUCtau(ss), as the overall predicted exposure was critical for exposure-response correlations.  
The predicted AUCtau(ss) values were visually compared to AUCtau(ss) values that were 
determined by noncompartmental methods using observed concentrations (6).  Bias was 
determined as the percentage difference between the observed (noncompartmental) and 
predicted parameter, relative to the observed value, while precision was calculated the 
absolute value of the bias (11).  Equations for bias and precision are presented below, 
where AUCinfobs represents the AUCinf determined by noncompartmental methods while 
AUCinfpred is the AUCinf predicted by the model. 
100
inf
infinf







 

obs
predobs
AUC
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Bias  
100
inf
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Pr 


obs
predobs
AUC
AUCAUC
ecision
 
Dataset preparation and secondary PK parameter calculations were performed using 
Microsoft Excel® 2003 and S-Plus® 8.0 for Windows. 
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5.5 Results 
A total of 32 subjects were enrolled in the study, with 24 subjects who received 
active treatment.  All 32 subjects completed the clinical portion of the study.  A summary 
of subject demographics is presented in Table 1. 
Table 1. Subject Demographics   
Characteristic n (%) 
Sex  
 Male 31 (96.9%) 
 Female 1 (3.1)% 
Race  
 Asian 1 (3.13%) 
 Amerindian 1 (3.13%) 
 African-american 1 (3.13%) 
 Caucasian 29 (90.6%) 
  
Characteristic Mean ± Standard deviation 
Age 30.8 ± 9.66 
Weight (kg) 79.4 ± 13.1 
Height (cm) 175 ± 8.05 
 
Results associated with 2-, 3-, 4- and 5-compartment structural models that were 
investigated are presented in Table 2.  The model with the lowest AIC value was the 4-
compartment model. 
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Table 2.  Structural Model Determination for TP-434 using Standard Two-Stage Analysis 
Model Description 
Negative Log 
likelihood 
AIC BIC 
R
2
 Residual variability (%) 
Plasma Urine Plasma Urine 
2-compartments, 
linear elimination 
275.97 569.9 586.2 0.891 0.951 43.4 17.0 
3-compartments, 
linear elimination 
244.36 510.7 530.6 0.975 0.948 13.3 20.3 
4-compartments, 
linear elimination 
234.50 495.0 518.5 0.984 0.949 12.3 21.6 
5-compartments, 
linear elimination 
234.55 499.1 526.2 0.984 0.948 12.3 21.1 
AIC: Akaike information criterion,  BIC: Bayesian information criterion, R2: Coefficient of determination 
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The final model selected to describe the plasma PK of TP-434 was a 4-compartment 
model with a linear (first order) elimination process, as depicted in Figure 1.  The model 
was parameterized with a central volume of distribution (Vc), peripheral volumes of 
distribution (Vp1, Vp2 and Vp3), renal clearance (CLr), non-renal clearance (CLnr) and 
distributional clearances (CLd1, CLd2 and CLd3). 
A total of 812 plasma concentrations and 237 urinary concentrations were 
simultaneously fitted by the model.  Residual variability for plasma was 14.0% while it was 
21.5% for urine. An example of a goodness-of-fit plot is presented in Figure 2.  Plots of 
goodness of fit for weighted residuals (as a function of predicted concentrations or time) 
demonstrated no trends or biases in the quality of fit.  Mean observed and predicted plasma 
concentration-time profiles are presented in Figure 3. 
 
Figure 1. Final Pharmacokinetic Model for TP-434 
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Figure 2. Predicted versus Observed TP-434 Concentrations 
a) Plasma Concentrations 
 
b) Urinary Concentrations 
 
Legend: Dark circles represent concentrations while the dotted line represents the line of identity. 
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Figure 3. Mean Observed versus Predicted Plasma TP-434 Concentrations (Semi-log scale) 
Day 1 Day 10 
  
LEGEND: Dark circle = observed concentrations for Cohort 1 (0.5 mg/kg), white circle = observed concentrations for Cohort 2 (1.5 mg/kg over 30 minutes), Dark 
triangle = observed concentrations for Cohort 3 (1.5 mg/kg over 1 hour), White triangle = observed concentrations for Cohort 4 (1.0 mg/kg over 1 hour BID), Solid line 
= predicted concentrations for Cohort 1 (0.5 mg/kg), Dotted line = predicted concentrations for Cohort 2 (1.5 mg/kg over 30 minutes), Dashed line = predicted 
concentrations for Cohort 3 (1.5 mg/kg over 1 hour), Dashed and dotted line = predicted concentrations for Cohort 4 (1.5 mg/kg over 1 hour BID), Orange dashed line = 
lower limit of quantitation 
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Population PK parameter estimates and their precision are presented in Table 3 and 
a summary of secondary PK parameters by treatment group are presented in Table 4. 
Volume of distribution at steady-state was approximately 320 L.  The mean half-life 
of TP-434 in plasma (all cohorts confounded) was 47.7 h, while the median value was 35.3 
h.  Renal elimination of TP-434 accounted for approximately 15.5 ± 2.37 % of overall 
elimination. 
Predictive performance is depicted in Figure 4, which suggests that AUCtau(ss) is 
well predicted by the model since all results are well aligned with the line of identity 
(dashed line).  Additionally, average bias and precision were -5.8% and 7.1% for AUCtau(ss). 
Table 3.  Population Pharmacokinetic Parameter Estimates for TP-434 Following 
Repeated Administration 
Parameter 
Mean Inter-subject 
Estimate %RSE Estimate as CV% %RSE 
Vc (L) 12.2 19.4 10.9 186 
CLnr (L/h) 11.5 12.4 23.0 52.2 
Vp1 (L) 16.6 36.8 2.28 902 
CLd1 (L/h) 29.9 69.0 21.2 300 
Vp2 (L) 188 10.2 15.4 81.4 
CLd2 (L/h) 4.90 49.2 46.7 61.1 
Vp3 (L) 103 17.1 9.56 356 
CLd3 (L/h) 21.2 39.0 29.4 81.8 
CLr (L/h) 2.05 10.9 15.7 62.6 
CLd1: distributional clearance between central compartment and first peripheral compartment; CLd2: 
distributional clearance between central compartment and second peripheral compartment; CLd3: 
distributional clearance between central compartment and third peripheral compartment; CLnr: non-renal 
clearance; CLr: renal clearance; %RSE: standard error as a percent of the corresponding maximum likelihood 
estimate Vc: central volume of distribution; Vp1: first peripheral volume of distribution; Vp2: second 
peripheral volume of distribution; Vp3: third peripheral volume of distribution; 
  
  167 
 
 
Table 4.  Secondary Pharmacokinetic Parameters for TP-434 
Dosing 
Regimen 
(mg/kg) 
Mean  SD (CV%) 
Day 1 Day 10 
AUC0-tau 
(mcg*h/L) 
Cmax 
(mcg/L) 
Cmin 
(mcg/L) 
AUC0-tau(ss) 
(mcg*h/L) 
Cmax(ss) 
(mcg/L) 
Cmin(ss) 
(mcg/L) 
0.5 mg/kg QD 
over 30 minutes 
1991 ± 405 
(20.3%) 
1020 ± 132 
(13.0%) 
26.1 ± 9.46 
(36.2%) 
2992 ± 838 
(28.0%) 
1075 ± 149 
(13.9%) 
55.9 ± 23.5 
(42.1%) 
1.5 mg/kg QD 
over 30 minutes 
5903 ± 553 
(9.4%) 
3582 ± 316 
(8.8%) 
57.8 ± 10.5 
(18.2%) 
7803 ± 928 
(11.9%) 
3596 ± 295 
(8.2%)
a
 
121 ± 32.2 
(26.7%)
a
 
1.5 mg/kg QD 
over 60 minutes 
6449 ± 898 
(13.9%) 
2486 ± 354 
(14.2%) 
68.0 ± 11.2 
(16.5%) 
8671 ± 1391 
(16.0%) 
2605 ± 376 
(14.4%) 
129 ± 28.6 
(22.1%) 
1.0 mg/kg BID 
over 60 minutes 
3937 ± 462 
(11.7%) 
1815 ± 180 
(9.9%) 
104 ± 19.1 
(18.3%) 
6667 ± 668 
(10.0%) 
2142 ± 200 
(9.3%)
b
 
280 ± 48.2 
(17.2%)
b
 
a
n=3; 
b
n=4 
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Figure 4.  Predictive performance of the final model 
  
Legend: Dark circles represent AUCtau(ss) values while the dotted line represents the line of identity. 
5.6 Discussion 
The analysis presented here embodies Sheiner’s “learn and confirm” cycle (10).  
Previous modeling work shed light upon the PK of TP-434 following single dose 
administration, but before this study had been completed, no information was available 
about disposition of multiple-dose TP-434.  Therefore, this study allowed us to gather 
additional information and learn more about TP-434.  At the same time, the PK analysis 
confirmed the selection of the 4-compartment model that was applied to single-dose data.  
Indeed, the pharmacokinetics of TP-434 following repeated administration was best 
described by a 4-compartment model with linear elimination, which was the same model 
used to describe its disposition after single dose administration.  Consequently, this analysis 
served both “learning” and “confirming” roles. 
Although certain residual figures suggested the presence of outlier concentration 
data, all concentration data was retained for the final analysis.  When outlier concentrations 
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were removed from the analysis (C. Seng Yue, J. A. Sutcliffe, P. Colucci, C. R. Sprenger, 
and M. P. Ducharme, unpublished data), mean population values did not change 
significantly and there was only a minimal improvement in inter-subject variability, 
therefore they were kept in the analysis.  
The residual variability associated with the final PK model (14.0% for plasma and 
21.5 % for urine) represents the variability that is not explained by the model, including 
intra-individual variability, the experimental “noise” of the analytical method and errors 
arising from the pharmacokinetic modeling itself (model misspecification).  The low 
residual variability associated with our model was similar to the residual variability in the 
SAD study, and further confirms that the 4-compartment model was able to properly 
capture the PK of TP-434.   
The current analysis demonstrated that TP-434 had a population mean CLT of 13.5 
L/h and a Vss of approximately 320 L (around 4.2 L/kg).  These values are similar to what 
was obtained in the SAD study (13.9 L/h and 262 L).  Renal clearance values were also 
similar in the SAD and MAD population PK analyses (2.34 L/h and 2.05 L/h, respectively).  
In addition, the total clearance value is similar to what was previously reported for 
tigecycline.  The PK of tigecycline was also described by a multi-compartment model (14).  
For this drug, a 3-compartment model with zero-order input and first-order elimination was 
chosen to describe its PK.  A population mean CLT of 16.3 L/h was estimated, with a Vss 
of 749 L or approximately 10 L/kg. 
The mean terminal elimination half-life value estimated from the MAD data was 
approximately 48 hours (median 35.3 hours) and individual values ranged from 27.6 to 
108.9 hours.  No relationship was observed between individual half-life values and 
administered doses, further confirming the linear PK of TP-434.  The mean half-life value 
estimated in the MAD study was longer than the one estimated using the SAD data (mean 
of 26.2 hours, median of 23.1 hours).  This could be attributed to greater inter-individual 
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variability in the volume of distribution estimates (Vc, Vp1, Vp2 and Vp3) in the SAD 
study.  It is also possible that the longer sampling schedule and the greater number of 
samples per subject associated with the MAD study allowed a better characterization of the 
terminal elimination half-life, since the collection period spanned over 300 hours (at least 6 
times the half-life).  Another possibility is that with repeated dosing, the rate of TP-434 
penetration into certain compartments is increased, thereby increasing its half-life.  Indeed, 
the ratio of the rate constants K12 and K21 (describing transfer between the central and 
second peripheral compartment) increased by approximately 26% following multiple 
dosing, in comparison with single dose administration.  This suggests that the net transfer 
from the central compartment into the second peripheral compartment increases with 
repeated administration.  Despite the differences between the terminal elimination half-life 
estimated separately with SAD and MAD data, both population PK analyses indicated that 
TP-434 has a long half-life. 
Results of the current analysis indicated that TP-434 exhibits dose-proportional 
pharmacokinetics over the dose range studied, similar to what was found with the SAD 
analysis.  Total clearance of TP-434 did not change with increasing doses or with the 
administration of multiple doses.  In addition, renal clearance estimated by the model 
(15.5% of total clearance) confirms that the elimination of TP-434 is mainly through non-
renal pathways.  This is similar to what was observed in the SAD study, as well as in 
chimpanzees, where urinary excretion was roughly 20% of total elimination (9). 
Finally, secondary PK parameters AUCtau(ss), Cmax(ss) and Cmin(ss) from the MAD 
study were similar to the values that were predicted using the model based on the SAD 
study.  This provides further confirmation that the 4-compartment model used to describe 
the PK of TP-434 after both single and multiple dosing is adequate.  Thus, simulation 
results that were previously obtained, suggesting that a minimal daily dose of 1.5 mg/kg of 
TP-434 would be efficacious against multidrug-resistant gram-negative aerobic and 
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facultative bacilli and gram-positive pathogens, remained accurate (C. Seng Yue, J. A. 
Sutcliffe, P. Colucci, C. R. Sprenger, and M. P. Ducharme, submitted for publication).  
Consequently, dosing regimens selected for further investigation in Phase 2 studies 
included 1.5 mg/kg administered once daily and 1.0 mg/kg given twice daily. 
5.7 Conclusion 
The same model describes the PK of TP-434 regardless of the number of doses that 
are administered, and this model can predict the PK of TP-434 under varying dosing 
conditions.  Results from this multiple ascending dose study confirmed the dosing regimens 
that had been previously selected for administration to patients in Phase 2 studies. 
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Chapter 6 – General Discussion 
The four research projects presented within the context of this thesis all demonstrate 
how advanced pharmacokinetic techniques, such as modeling and simulations and the 
development of innovative new models, can be used to enhance decision-making within the 
drug development process.  These articles highlight the versatility and flexibility of such 
techniques, since each article presents a different, critical question that is efficiently 
answered by modeling and simulations.  Thus, the findings from each article fully support 
the hypothesis that this tool can be a significant asset in drug development.   
As previously described, the drug development process is in drastic need of an 
overhaul, as evidenced by soaring costs which do not necessarily translate into an increased 
number of drugs submitted to regulatory agencies, let alone the number of drugs that 
eventually reach the market.  Furthermore, those who wish to bring a drug to market 
undertake important risks, because the success rate is so low.  The repercussions associated 
with a suboptimal drug development process can be felt on many levels.  On a more direct 
level, the failure to successfully bring a product to market can mean that significant money 
is wasted, especially if attrition occurs during later phases of the process and expensive 
clinical trials have already been completed.  Another important resource that is spent on the 
failed endeavour includes manpower, or the time and efforts of a diverse array of people 
who are involved in drug development.  The energy that was invested in the failed product 
could conceivably have been invested elsewhere with a potentially greater return, such as in 
the development of another product that might have been successfully marketed.   
The difficulties encountered in bringing a drug to market make new therapies even 
less accessible for the patients who use them in the end.  This manifests itself in two ways.  
Firstly, so much time and money have been invested in bringing a drug to market that once 
regulatory approval has been received and market access is attained, new drugs are often 
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extremely costly, and prohibitively so for some patients.  Secondly, due to the multiple 
challenges faced by drug developers, there are simply less new drugs being marketed, as 
demonstrated by the declining submission rate over the years (134).  
Many aspects of the drug development process could benefit from some form of 
improvement.  For example, better tools could be developed to predict toxicity, which 
currently relies on animal models that are not always highly predictive of toxicity in 
humans.  The manufacturing aspect of drug development could also be enhanced by 
adopting state-of-the-art technology into its processes, and by creating software that could 
predict the effect of formulation or manufacturing process changes on drug performance in 
humans (134).  While these aspects of drug development must not be neglected, the focus 
of the research presented within this thesis has been on the utility of modeling and 
simulations at later stages of the drug development process.  The four articles have shown 
that advanced pharmacokinetic techniques, such as modeling and simulations, can be used 
to answer key questions frequently encountered during Phase 1 and Phase 3 of drug 
development. 
The first research article presents an innovative approach to proving whether or not 
two different intravenous formulations of iron are equivalent.  This question is normally 
answered by analyzing study data using a noncompartmental approach, but our research 
proposes a flexible and innovative model developed using a compartmental population 
approach that does not necessitate the enrollment of a large group of subjects.  Furthermore, 
this method makes no assumptions about linearity, nor does it require the drug under study 
to meet any assumptions regarding elimination.   
Despite the advantages that the compartmental method has to offer, it is rarely used 
in the context of bioequivalence assessments.  In the area of BE, in silico modeling is most 
often associated with biowaivers of drugs belonging to certain BCS classes (157-163), 
however some researchers have studied its applications in proving BE from in vivo studies.  
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In 2005, Panhard and Mentré compared traditional noncompartmental bioequivalence 
assessments to a population compartment approach using data from simulated theophylline 
studies with varying designs (164).  They evaluated two global tests and two tests based on 
empirical Bayes’ estimates (EBEs).  Compared to standard tests based on 
noncompartmental methods, the global tests were associated with inflated Type I error 
while the tests based on EBEs produced results that were similar to standard tests.  Dubois 
and colleagues performed a similar comparison using simulated theophylline data, however 
they used the stochastic approximation expectation maximisation (SAEM) algorithm rather 
than the FOCE algorithm, and they also used a different statistical approach (linear mixed 
effects model to determine treatment effect rather than paired t-tests) (165).  Their findings 
showed that sample means estimated by the noncompartmental approach were generally 
more biased than with the compartmental approach, but for both methods, root mean square 
error increased as the number of samples per subject decreased.  With sparse sampling, type 
I error was greater with the compartmental approach, because of shrinkage which caused 
EBEs to tend towards the mean, making it easier to declare bioequivalence even when it is 
not the case.  However, when small sample sizes or elevated residual error were present, 
both approaches were flawed.  Another study performed by the same group also analyzed 
simulated theophylline data using SAEM with Wald tests to evaluate bioequivalence (166).  
They showed that in the case of rich sampling with the compartmental approach, type I 
errors were close to the nominal value of 5%.  They also applied their proposed approach to 
the comparison of two formulations of somatropin, and showed that bioequivalence Wald 
tests performed using ln-transformed PK parameters obtained from both methods yielded 
similar results.  Their overall conclusion was similar to the earlier study, in that 
compartmental analysis could be an alternative to traditional BE approaches except when 
sample size was small or when the drug was highly variable.     
While some researchers performed their analyses with simulated data, others have 
used compartmental analyses to analyze real data from bioequivalence trials.  Due to the 
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small sample size (difficult patient recruitment because of the low disease prevalence) and 
limited blood sampling, Keizer and collaborators opted to use compartmental analyses to 
compare two drug formulations that differed in manufacturing processes (167).  Their 
analyses showed that this approach was superior to the standard one.  Kaniwa et al. 
performed bioequivalence assessments for various drugs (phenytoin, flufenamic acid, 
indomethacin, nalidixic acid, metronidazole and griseofulvin) using both standard and 
compartment approaches (with NONMEM) and demonstrated that similar ratios and 
confidence intervals were obtained with both methods (168).  Combrink and collaborators 
determined relative bioequivalence using noncompartmental and compartmental methods 
for two formulations of ibuprofen that were administered in a single dose, open-label, 
crossover study in healthy volunteers (169).  They found that relative bioavailability 
estimates obtained with the compartmental analysis were not biased by outlier data, 
contrary to the noncompartmental approach.  In addition, confidence intervals associated 
with the compartmental approach, which were determined using two different methods (one 
which used the standard error of the estimate taken directly from NONMEM and the other 
which relied on a log-likelihood procedure), were similar in width to the one obtained with 
the standard method.  However, these results were obtained with data that was not very 
variable, therefore the authors could not extrapolate these conclusions to more variable 
data.  Fradette and colleagues also compared both methodologies (standard 
noncompartmental versus population compartmental) in the bioequivalence assessment of 
two formulations of cyclosporine administered to a group of patients (170).  They 
demonstrated that both approaches led to similar conclusions of bioequivalence.  Other 
researchers have also reached similar conclusions for the bioequivalence assessment of 
chlorthalidone (171), tiludronate (172), somatropin and epoetin- (173). 
In light of the paucity of published BE studies that employ non-traditional 
compartmental methods to meet their objectives, the first article presented in this thesis 
makes a significant contribution to the analysis of BE trials and to furthering our 
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knowledge about the use of advanced PK techniques within the field of generic drug 
development.  Contrary to previously published articles (164, 165, 167-172, 174, 175), this 
article relies on an innovative, complex and sophisticated PK model that fits multiple 
analytes simultaneously and also includes a non-linear component.  Although one other 
model incorporated non-linearity (PK model for epoetin-) (173), the other published 
models are simpler (one- and two-compartment models with linear elimination), therefore 
this article provides additional insight into the use of more elaborate PK models in the 
world of BE evaluation.  Furthermore, our analyses were conducted with highly variable 
data, thereby demonstrating that this approach is not only limited to homogeneous data, but 
that it can be used to better understand more variable data as well.  This article is also the 
first published account which uses the software ADAPT 5
®
 to conduct a bioequivalence 
assessment. 
Importantly, the first article demonstrates that the population PK approach can 
result in considerable savings, from both a monetary and time perspective.  Findings 
demonstrated that conclusions derived from this novel approach were comparable to those 
obtained from a traditional method applied to a sample size that was more than 8-fold 
greater (n=29 vs n=240).  This suggests that less subjects need to be dosed if a non-
traditional approach is favoured, which means that less money and time are invested in the 
clinical trial and less subjects are needlessly exposed to an investigational drug.  This has 
important ramifications for the drug development process of generic products, which is 
subject to important time constraints and financial concerns.     
The research presented in the first article in this thesis contributes significantly to 
the progress of bioequivalence assessments, which have greatly evolved since the last 
century (176).  From a historical perspective, the concepts related to bioavailability were 
introduced in the mid 1940’s, but interest in bioequivalence and its assessments only date 
back to the early 1960’s, when there was rising concern on the bioavailability of generic 
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products with respect to innovator products (177).  People were worried that generics might 
not provide equivalent exposure to innovators and that patients would suffer from these 
differences.  Ideas and approaches evolved over the subsequent decades in what can be 
viewed as four phases.  In the first phase, from the 1970’s to the early 1980’s, regulatory 
agencies such as the FDA began demanding proof of bioavailability in drug submission 
applications, and statistical discussions regarding bioequivalence assessments began to take 
place. In 1984, the “Drug Price Competition and Patent Term Restoration Act” was passed 
by the U.S. Congress, which allowed the FDA to approve generic drug products based on 
bioavailability and bioequivalence data. During the second phase, from 1984 to 1992, 
issues relating to the statistical aspect of bioequivalence testing were examined, 
culminating in the publication of the FDA guidance entitled “Statistical Procedures for 
Bioequivalence Studies Using a Standard Two-Treatment Crossover Design”. This 
approach is commonly referred to as the “Average Bioequivalence” (ABE) approach.  In 
the third phase, from 1992 to the beginning of the new millennium, discussions arose on 
many topics such as post-approval changes, racemate products, locally acting products, and 
BCS, leading to new guidances such as the skin blanching assay for topical corticosteroids 
(117), the BCS biowaiver option (99), as well as the scale-up and post-approval changes 
(SUPAC) recommendations (178-180).  In addition, the individual bioequivalence 
approach was proposed as a replacement for ABE, but it was eventually abandoned (181, 
182). The start of the fourth phase was marked by the FDA’s publication of their guidance 
document “Statistical Approaches to Establishing Bioequivalence” (183), which was 
followed by guidance documents published in Canada, Japan and European nations (44, 92, 
94, 184). During this phase, concerns arose with evaluating the bioequivalence of highly 
variable drugs (those possessing a within-subject coefficient of variability of at least 30%), 
as proving BE between two highly variable drugs using traditional ABE criteria 
necessitated the enrollment of many subjects, and this seemed unwarranted for drugs that 
generally had a large therapeutic index (185, 186). The scaled average bioequivalence 
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approach emerged from the discussions that ensued as being the most promising approach, 
because it allowed BE limits to be scaled according to the within-subject variability of the 
reference product (obtained through a replicate design study).  Furthermore, with this 
approach, the mean difference between the test and reference product was still required to 
fall between the traditional limits of 80 to 125% (186).  Our research, which supports the 
use of advanced pharmacokinetic modeling for certain bioequivalence assessments, will 
help usher in the newest phase in the evolution of bioequivalence approaches.  
While our research has shown that compartmental analyses can be a valuable tool 
for assessing the relative BE between two products, it is an approach that also has its limits 
and challenges.  Developing a pharmacokinetic model can be a difficult and time-
consuming process, and very often more than one model can be used to describe the same 
set of data.  This makes the results obtained by compartmental modeling more difficult to 
reproduce than the results obtained by traditional noncompartmental methods.  The creation 
of a pharmacokinetic model also requires the skills of an experienced pharmacometrician, 
whereas noncompartmental analyses are easily performed.  Therefore, for most drugs 
which exhibit linear pharmacokinetics, are detectable and are eliminated from the body, 
noncompartmental analyses should be more than sufficient to evaluate relative 
bioequivalence.  However, compartmental analyses should be considered as an alternative 
for drugs which do not meet these criteria. 
In addition to their use in evaluating BE between two drug products, the 
compartmental approach advocated by the results of the first research project could also be 
used to perform meta-analyses of bioequivalence trials to assess the switchability of 
different generic formulations of the same drug.  Although generic drugs are approved 
based on bioequivalence with the established reference product, little research is done to 
compare generic products to one another.  In other words, if a patient is currently being 
treated with an innovator product, bioequivalence trials have shown that it is acceptable to 
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replace the innovator product with an approved generic formulation, but it is unclear 
whether or not this generic formulation can be substituted with another.  This may not be an 
issue for drugs with a wide therapeutic index and large safety margin, but it could pose a 
problem for certain drugs.  Chow and colleagues have described methods for performing 
such meta-analyses (187, 188), but this is an area of research that could also benefit from 
compartmental modeling.  Indeed, compartmental analysis can easily accommodate data 
derived from different studies (with different study designs).  Furthermore, population PK 
models developed to compare multiple generic formulations can estimate different inter- 
and intra-subject variability for each study or formulation, in contrast to previously 
published methods which assume that they are similar across studies (187).  In addition, the 
use of compartmental analysis could also be useful in the development of biosimilars, or 
large molecule therapeutic proteins that are similar but not identical to innovator proteins.  
Our research has shown that advanced techniques such as modeling and simulation 
can improve the development of generic compounds, such as SFGC, and that this approach 
also has wider applications, such as studying the interchangeability of different generic 
formulations.  However, such methods can also be used to develop innovator products.  
Recently, we used a modeling and simulation approach to better understand the 
pharmacokinetics of a novel oncology drug being developed for acute myeloid lymphoma, 
elacytarabine.  The use of advanced PK methods, including the creation of an innovative 
model, allowed us to test certain hypotheses with respect to the pathways involved in the 
formation of an active metabolite and this improved understanding could not have been 
achieved through traditional techniques (189).  Additional applications of modeling and 
simulations for the development of innovator drugs are also demonstrated by the remaining 
articles presented in this thesis.   
There is a clear need to bring to market more innovator products, as there are fewer 
and fewer first-in-class products being developed.  In 2008, of the 21 new drugs approved 
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by the FDA, only 29% were first-in-class while this number decreased the following year.  
In 2009, the FDA approved 24 new drugs, 17% of which were first-in-class (81).  As 
shown in the second article of this thesis (“Population pharmacokinetic and 
pharmacodynamic analysis of pegloticase administered by intravenous infusion in two dose 
regimens to subjects with chronic gout”), modeling can help to develop first-in-class 
medicine for the treatment of refractory gout, by helping to better understand the PK and 
PD of new products (since we cannot rely on previous knowledge).     
Pegloticase is a PEGylated recombinant modified mammalian urate oxidase that 
currently is the only member of the uricase class that is indicated for the treatment of 
chronic refractory gout (190).  It acts by converting uric acid into the more easily excreted 
allantoin, while other treatments for gout exert their urate-lowering effect by reducing its 
production or its renal tubular re-absorption (191).  Although another recombinant uricase 
enzyme is available on the market (rasburicase, commercialized as Fasturtec
 
and Elitek

), 
it is not indicated for the treatment of refractory gout.  Rather, it is indicated for the 
treatment and prophylaxis of hyperuricemia caused by tumour lysis syndrome in pediatric 
and adult cancer patients (192).  Although rasburicase is effective in decreasing uric acid 
levels in cancer patients (193-197), it is associated with a shorter terminal elimination half-
life and persistent immunogenicity (191, 198).  Therefore, despite some publications that 
have described its efficacy in treating refractory tophaceous gout patients (199-204), this 
remains an off-label indication for rasburicase.  
  The second article presented in this thesis represents the first population PK/PD 
analysis for a drug belonging to the urate-oxidase drug class conducted on a large cohort of 
Phase 3 patients.  The only other published population PK/PD analysis for a urate-oxidase 
also involved pegloticase data, but subjects included in the analysis were from a smaller 
cohort (n = 40) of a Phase 2 study (205).  Furthermore, the PD model developed with the 
Phase 2 data (direct inhibitory Emax model) was different from the model developed using 
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the Phase 3 data (indirect model), since the range of doses administered in both studies was 
very different. Fewer dosing regimens and doses were administered in Phase 3, which is 
why it was not possible to apply an Emax model to the data.  Many articles have been 
published on population PK and/or PD analyses conducted on other biological agents, such 
as darbepoetin alfa (206-209), recombinant human erythropoietin (210, 211), alpha 
interferon (212), filgrastim (213, 214), PEGylated thrombopoietin (215), desonumab (216), 
abatacept (217), bevacizumab (218), cetuximab (219), infliximab (220, 221), rituximab 
(222), and trastuzumab (223).  However, to our knowledge, this is the first large-scale 
population PK/PD analysis conducted on a urate-oxidase therapeutic protein.  Thus, the 
findings from our research make important contributions to our knowledge about this drug 
class, by not only describing the PK and PD of pegloticase, but by quantifying its inter-
subject variability and identifying factors (demographic and other) which could be 
influential.  Among the important factors that affected PK parameters were BSA and anti-
pegloticase antibody levels (for Vc and CL), while the PD of pegloticase was only 
influenced by anti-pegloticase antibody levels. 
The results of the research presented in the second article not only improved our 
understanding of pegloticase disposition and effect, but they also played a critical role in 
determining whether or not dosage adjustments would be necessary.  Indeed, they showed 
that body surface area and anti-pegloticase antibody levels influenced both the volume of 
distribution and clearance of pegloticase.  Anti-pegloticase antibody levels also appeared to 
diminish the effect of pegloticase on the elimination of uric acid.  Although anti-pegloticase 
antibody categories helped to explain the variability in pegloticase PK and PD responses, it 
was not necessary to perform any dosage adjustments to take this into account since 
pegloticase managed to elicit therapeutic responses even in patients with high levels of 
antibodies.  Furthermore, the analysis revealed that no dosing adjustments were necessary 
for renal insufficiency, as estimated creatinine clearance (which ranged from 17 mL/min to 
264 mL/min in the cohort) was tested as a potential covariate in the model and was not 
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retained as a significant covariate.  Importantly, the population PK and PD analyses 
conducted on pegloticase contributed to the product labeling (monograph) (190) and 
ultimately enhanced the drug’s development process.  
The advanced pharmacokinetic techniques employed to better understand 
pegloticase were the ideal tool to help meet the analysis objectives, as compartmental 
analyses do not require rich sampling as is the case for noncompartmental analyses.  
Indeed, in Phase 3 trials such as the ones that were analyzed for the second article, it is 
often impractical or unfeasible to collect many blood samples from patients, who are 
already burdened by their disease and often multiple co-morbidities.  Compartmental 
analyses also have the flexibility of incorporating data from different sources, such as trials 
with different study designs or sampling schedules.  Moreover, by performing 
compartmental analyses on the data collected from these two pivotal Phase 3 studies to 
answer specific questions pertaining to pegloticase PK and PD, it was possible to avoid the 
conduct of additional clinical trials designed specifically to study such questions.  For 
example, it was not necessary to conduct a clinical trial with renally-impaired patients, 
since the results of this analysis demonstrated that creatinine clearance was not a factor that 
influenced pegloticase pharmacokinetics or pharmacodynamics.  Thus, advanced modeling 
allowed us to incorporate prior knowledge about pegloticase, gained from modeling of 
Phase 2 data, with data obtained from larger Phase 3 studies in order to extract the 
maximum amount of information from the available data and answer critical drug 
development questions, such as “Do dosing regimens need to be adjusted to account for 
demographic traits such as weight or body surface area?”. 
Modeling and simulations could also prove to be useful in further broadening our 
understanding of pegloticase, more particularly with respect to its immunogenicity.  
Although pegloticase was designed to be less immunogenic than rasburicase and non-
recombinant uricase, by virtue of its PEG conjugates (224-227), immunogenicity remains 
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an important concern.  Infusion reactions (systemic, localized or acute hypersensitivity) are 
an immune-response manifestation (228, 229), and in the Phase 3 studies from which data 
was obtained to conduct the population PK/PD analyses (230), infusion-related reactions 
were the second most common adverse event (the first one being gout flare).  Serious 
infusion reactions occurred in 5 to 8% of patients, but all of them resolved completely.  
These types of immune responses do not only occur with pegloticase, but they can occur 
with any type of therapeutic protein or biological agent (228, 231, 232).  Significant 
immune responses that affected clinical efficacy were reported for drugs such as salmon 
calcitonin (233), gonadotropin-releasing hormone (234), and granulocyte macrophage 
colony stimulating factor (235).   
In light of the concerns surrounding biological agents and their immunogenicity, 
using the pegloticase PK/PD model that was developed as part of this thesis, it would be 
possible to build a model (or extend the current one) to predict the onset of immunogenic 
reactions.  In the Phase 2 studies included in the PK/PD model, it was observed that over 
90% of infusion reactions in the 8 mg biweekly cohort were preceded by uric acid levels 
exceeding 6 mg/dL, while this was the case for approximately 71% of infusion reactions in 
the 8 mg monthly cohort (230, 236).  Indeed, there may be a link between loss of 
pegloticase effect (as reflected by rising uric acid levels) and the occurrence of infusion 
reactions and it has been suggested that discontinuing pegloticase treatment when uric acid 
levels are  6 mg/dL can avoid most infusion reactions (230, 236).  The mechanism behind 
this potential relationship is unknown and although this was not a question that arose at the 
time when the pegloticase PK/PD was being developed, with modeling and simulations it 
would have been possible to confirm the validity of such a threshold uric acid level and its 
relationship with infusion reactions.  Covariate analysis, such as the one conducted in the 
second article, could also help identify other factors related to the patient or the disease 
itself that could contribute to the occurrence of such adverse events.  Factors such as a 
patient’s genetic background, the type of disease, and the manufacturing process are some 
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of the factors known to influence the immunogenicity of therapeutic proteins (228), and 
population PK/PD analyses could help identify the specific factors which affect 
pegloticase’s immunogenicity.  Ultimately, developing such a model could help patients 
benefit from pegloticase treatment while minimizing the risk of unwanted effects. 
Another potential application of modeling and simulations stems from both its 
utility in the characterization of biological agents, as illustrated by the second article of the 
thesis, as well as its use in bioequivalence assessments, as demonstrated in the first article 
of the thesis.  As is the case with small-molecule innovator products, once the period of 
market exclusivity and patent protection have expired for biological agents, there is the 
possibility of developing similar biological agents.  Unlike small molecule drugs, where 
generic drugs are considered identical copies of their innovator counterparts, biological 
agents cannot be copied strictly speaking, due to their inherently heterogeneous nature and 
complex, unique manufacturing process (237-241).  These “similar” biological agents 
(sometimes labeled biosimilars, follow-on biologics or subsequent entry biologics) cannot 
simply rely on pharmaceutical equivalence and bioequivalence to demonstrate their 
comparability to the innovator product, unlike small molecule generics (237, 242, 243).  
Often, biosimilars must show that they are comparable to their innovator counterpart 
through in vitro and in vivo tests that provide evidence of similar quality (purity and 
potency), efficacy and safety, including immunogenicity (238, 240, 241, 243-245).  
Therefore, those who wish to develop biosimilar products are faced with challenges that are 
unique to these types of molecules. 
Biological agents inherently possess traits that do not always make them candidates 
for noncompartmental analyses, making compartmental analyses an attractive alternative to 
demonstrate comparability.  As previously mentioned, some underlying assumptions for 
noncompartmental analysis include linearity and elimination from the sampling 
compartment, and these do not always hold true for all drugs, as shown for iron in the first 
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article.  Like iron, the PK of biological agents can often be non-linear, because therapeutic 
proteins can undergo target-mediated drug disposition, such that the drug’s PK is 
influenced by its PD (specifically by its binding to target receptors).  In such instances, PK 
is often non-linear because of this saturable process (246).  Non-linearity can also be 
caused by immune-mediated clearance or receptor-mediated uptake into hepatocytes for 
subsequent elimination (232).  Furthermore, numerous biological agents are also eliminated 
in peripheral compartments via proteolysis, which violates the assumption that elimination 
occurs solely from the central compartment (231).  The accurate characterization of the PK 
and PD of therapeutic proteins using traditional methods can also be complicated by 
feedback mechanisms or loops that actively modify drug levels, or simply by the presence 
of endogenous counterparts (232).  Although the use of population compartmental 
modeling to compare biological agents has been described in a handful of publications 
(166, 167, 247, 248) and even advocated by the FDA (241), this remains an area that could 
benefit greatly from the application of advanced pharmacokinetic techniques such as the 
ones described in this thesis, including the development of innovative new models.  
Key questions arising during drug development, such as “Are two formulations of 
the same drug are bioequivalent?” or “What factors influence a drug’s PK and PD?”, can be 
efficiently answered by advanced pharmacokinetic techniques such as modeling and 
simulations, as shown in the first two articles presented within this thesis.  Others have 
shown that such methods can also be used to halt drug development, as was the case for a 
cholesterol absorption inhibitor (107) and PEG-modified interferon alfa-2a (249), thus 
preventing more unnecessary time and money from being invested in a product that was 
unlikely to be successful.  Although these examples show how modeling and simulations 
can answer “go or no-go” questions, it is often just as important to be able to answer 
questions that pertain to subsequent steps in the drug development process.  Accordingly, 
the third and fourth articles presented in this thesis illustrate the applicability of advanced 
pharmacokinetic techniques in the planning of future studies.  While the analyses of SFGC 
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and pegloticase demonstrated that modeling and simulations can be used to answer key 
drug development questions, the analyses of TP-434 take this one step further by answering 
critical questions that influence the design of subsequent studies.   
The third article presented in this thesis demonstrates how the careful and timely use 
of modeling and simulations based on data obtained from a single, ascending-dose Phase 1 
study was pivotal in the selection of dosing regimens for Phase 2 patient studies.  
Timeliness is an important consideration with the use of such a tool to answer these 
questions, because decision-making must occur prior to the initiation of subsequent studies.  
Indeed, as noted by Peck, “tardy analysis of a trial guarantees that the results cannot 
influence subsequent trials” (135).  Thus, the findings from the third article show that 
modeling and simulations can not only answer important questions that arise during drug 
development, but they can do so in an efficient manner and within a reasonable timespan to 
modify, if necessary, the course of ongoing or future studies.  
The more quantitative approach to selecting doses for a Phase 2 study, based on 
modeling and simulations, can help lower attrition rate in Phase 2, which remains 
problematic despite our technological achievements and increasing knowledge.  Indeed, 
Phase 2 and 3 attrition are key determinants in research and development productivity and 
efficiency (81), therefore a decrease in Phase 2 attrition rates will directly impact 
productivity and efficiency.  Additionally, the selection of an optimal dose or dosing 
regimen as early as possible during the drug development process can lead to considerable 
savings, in terms of both time and money.  This is illustrated by the drug development path 
taken for nesiritide, a drug indicated for the acute treatment of decompensated congestive 
heart failure whose NDA was submitted to the FDA in April 1998.  From a clinical 
perspective, the FDA did not agree with the proposed dosing regimen, and sent the 
company a nonapprovable letter one year after the submission date.  Based on some 
exposure-response analyses conducted by the FDA, the sponsor conducted an additional 
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study to confirm the selection of the new dosing regimen.  Eventually, the product was 
approved in May 2001, three years after the initial submission.  Clearly, if the exposure-
response relationship had been well-defined prior to the submission, at early stages in the 
development process, the optimal dose could have been selected prior to submission, and 
the ensuing time delays and additional study could have been avoided (115). 
Modeling and simulations are excellent tools for making Phase 2 dosing 
recommendations based on Phase 1 data, because they can make use of prior knowledge.  
Fortunately, in the field of antimicrobials, there is a considerable body of knowledge 
pertaining to PK/PD relationships that can be incorporated into models.  The first insights 
into the PK/PD of antimicrobials were described by Eagle in the 1940’s and 1950’s, who 
noticed that penicillin efficacy was related to its concentration and time above a threshold 
concentration (250-253).  Research in this subject area was pursued in subsequent decades 
and continues to this day.  Thus, for many classes of antimicrobials, such as 
fluoroquinolones (154-156, 254-256), beta lactams (151, 257-260) and aminoglycosides 
(153, 261-263), relationships between PK/PD indices and clinical outcomes are well 
defined and recognized by the scientific community.  In the case of TP-434, when only PK 
results in healthy volunteers were available, previously established PK-PD relationships for 
another tetracycline, tigecycline, were used in conjunction with this information to select 
dosing regimens for further study in a patient population (264-266).  This illustrates one of 
the most appealing features of modeling and simulations, which is its capacity to 
incorporate information from different sources and make use of all available data.      
In the context of drug development, simulations such as those performed for TP-434 
dosing regimen selection can answer questions without relying on the conduct of expensive 
clinical trials.  For instance, using the final PK model developed for TP-434, it was possible 
to conduct many simulations of different dosing regimens in order to determine the 
probable outcome associated with each of these regimens.  This allowed the pharmaceutical 
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company that was developing TP-434 to be more selective of their dosing regimens and 
avoid testing regimens that were unlikely to provide the desired clinical outcomes.  Rather 
than test many dosing regimens, of which only maybe one or two would be promising, this 
allowed the company to test only the most optimal regimens.  Similarly, if only one or two 
regimens were to be tested, this approach ensured that the most promising ones would be 
tested, thereby avoiding the situation that occurred for nesiritide.   
The choice of dosing regimens has important ramifications throughout drug 
development, as an improper selection can result in an inefficacious exposure or 
undesirable side effects, which could force companies to conduct additional studies or even 
worse, halt clinical development.  In the world of antimicrobial drug development, another 
reason for optimizing dosing regimens is the unrelenting development of antimicrobial 
resistance.  Although resistance genes have existed for many millennia (267), unchecked 
clinical antibiotic use has contributed to increased resistance (149).  Thus, one of the ways 
in which resistance can be reduced is by exerting a better control over the use of such drugs 
(149).  By carefully selecting dosing regimens during the course of drug development, we 
can therefore ensure that people are not unnecessarily exposed to antibiotics (which is the 
case when sub-optimal dosing regimens are tested) and that they are being administered the 
minimally effective dose.  In other words, they are not being given more antibiotics than 
what is required to eradicate the infection.  Therefore, the use of modeling and simulations 
to choose optimal dosing regimens for antibiotics under development also fosters a more 
rational and controlled use of these drugs, to thwart potential resistance. 
In anti-infective research, population modeling and simulations have been used to 
better understand a drug’s PK and/or PD in patient populations (268, 269), including 
special groups such as burn patients (270, 271), cancer patients (272, 273), cystic fibrosis 
patients (274, 275), neonates (276, 277), children (278, 279), and pregnant women (280, 
281).  It has also been used to optimize dosing regimens for special populations (such as 
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critically ill patients (282-290), cancer patients (291), neonates (292-300), children (301-
304), the elderly (305, 306), dialysis patients (307-310), and burn patients (311)), compare 
drug dosing regimens or potency of anti-viral drugs given as combination therapy (312, 
313) and determine PK/PD breakpoints for clinical outcome assessments based on patient 
data (154, 156, 265, 266, 314-317).  Moreover, modeling and simulations were used to 
guide Phase 3 dose regimen selection during the drug development of doripenem (318) and 
fusidic acid (319).  However, to our knowledge, the results presented in the third article of 
the thesis are the first report of this approach being used to select Phase 2 dosing regimens 
based solely on in vitro and Phase 1 data.  This illustrates an important role for such 
advanced pharmacokinetic techniques within the drug development context, in that their 
use can extend to the planning of future studies. 
The dose optimization analyses described in articles 3 and 4 are the first published 
population PK analyses for TP-434.  Importantly, they are also the first published accounts 
of the use modeling and simulations for early-stage dose determination of an antibiotic 
under development.  In other words, in previously published reports where modeling and 
simulation was performed to refine dosing regimens for an antibiotic (282-311), patient 
data was always available and included in the analysis, whereas our dose projections were 
only based on healthy volunteer data.  Moreover, although this type of early-phase dose-
defining analysis based on results from healthy subjects has been described for other drugs, 
such as the monoclonal antibody HAE1 (320) and selective factor IXa inhibitor 
pegnivacogin (321), the research presented within this thesis represents the first of its kind 
for antibiotics.  The impact of our Phase 1 modeling and simulations on the TP-434 dosing 
regimens selected for Phase 2 investigations was also definitive and significant, whereas in 
other publications that suggest dosing regimens issuing from compartmental analyses, it is 
unclear whether or not these recommendations were actually put into place (322-324).   
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The last article presented within the context of this thesis, also pertaining to TP-434, 
further highlights one of the strengths of population compartmental analyses within the 
drug development process.  Prior to the conduct of the multiple, ascending dose study in 
healthy volunteers, only single-dose data was available for TP-434, but once the repeated 
administration results became available, it was possible to easily incorporate these results 
into the previously determined population PK model.  Thus, the PK model developed for 
TP-434 could be continuously updated with new information, in order to extract the 
maximum amount of knowledge from available data.  The results obtained from the 
multiple ascending dose study not only allowed us to learn more about TP-434, but they 
also served to confirm the PK model that was chosen based on single dose data.  This 
embodies the “learn and confirm” approach to drug development first proposed by Sheiner 
(136) and advocated by many.  In contrast with the view that drug development is a 
succession of independent steps that ultimately lead to a product’s entry on the market, the 
“learn and confirm” paradigm makes use of advanced pharmacokinetic techniques such as 
modeling and simulations to integrate data throughout the course of drug development.  In 
the latter, there is always the possibility of learning from studies, even those whose 
outcomes are unexpected. 
The successful application of the learn and confirm paradigm in the development of 
a novel antibiotic agent was demonstrated in the last two articles of this thesis.  Although in 
this example, advanced pharmacokinetic techniques were employed in the development of 
a drug belonging to the antibiotic class, the approaches defined by this research can be 
applied to any type of compound within any therapeutic area.  However, some insight into 
the PK and PD relationship of the investigational drug is necessary to take full advantage of 
this tool.  Nonetheless, these articles serve as an example for other researchers wishing to 
develop a new drug, and will hopefully encourage others to adopt a model-based, rational 
approach to dose regimen selection.  
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The articles presented within the context of this thesis demonstrated the utility of 
advanced pharmacokinetic techniques such as modeling and simulations, and the creation 
of innovative models, within the drug development process.  The research presented here 
provides researchers with tools that can be applied not only to drugs with particular PK 
characteristics (such as iron), innovative biological agents (like pegloticase) or novel 
antimicrobial agents (such as TP-434), but to drugs in all therapeutic areas.  Questions that 
can arise at different stages of the drug development process (Phase 1 for TP-434 and Phase 
3 for pegloticase) can be effectively answered using modeling and simulations, which 
makes this an invaluable tool.  However, to make the most of this approach, data should be 
collected and analyzed at the earliest stages of the DDP, and this analysis must be reiterated 
throughout.  Although it can be a time-consuming and arduous task, the research presented 
herein has demonstrated that no matter what the question or phase of drug development, 
modeling and simulations are well worth the effort.  
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Chapter 7 - Conclusion 
 
We are reminded time and time again that drug development is a risky, expensive 
and lengthy process.  Nevertheless, although they often defy quantification, the benefits of 
drug therapy on quality of life and lifespan are undeniable. 
In 1993, the Office of Technology Assessment in the U.S. declared that the most 
important components of pharmaceutical research and development investment were 
money, time and risk (83).  Almost two decades have elapsed since then, but these tenets 
hold true even today. However, more is being done to improve the drug development 
process.  The research conducted within the context of this thesis have important 
ramifications on different aspects of the drug development process and provide concrete 
examples of how advanced pharmacokinetic techniques, such as modeling and simulations, 
can render the process more efficient. 
The first research article demonstrated that compartmental analyses can be used to 
answer questions pertaining to bioequivalence, and that this approach offers many 
advantages over the traditional methods normally espoused.  It not only forgoes the need to 
meet specific assumptions about a drug pertaining to its linearity and elimination, but it 
allows study objectives to be attained without enrolling hundreds of subjects.  From a drug 
development perspective, this translates into significant financial savings and an economy 
of time.  In addition, the research presented in this article makes significant contributions to 
the relatively unexplored domain of compartmental modeling within bioequivalence 
assessments.  Indeed, few publications exist on this topic and this research explores the use 
of more elaborate and complex models that have not been previously described within this 
context.  The approach described in this article not only broadens our appreciation of 
modeling and simulations within the field of generic drug development, but it can also be 
applied to innovator or biosimilar drug development. 
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The second research article describes how advanced pharmacokinetic techniques 
such as population PK/PD modeling improved our understanding of pegloticase.  Not only 
did the research conducted on pegloticase identify covariates that influenced its PK and PD, 
but it quantified the influence of these covariates.  By establishing relationships between 
patient demographics, laboratory parameters and PK/PD parameters, it was possible to 
determine that no dosing adjustments were necessary for pegloticase.  Thus, the research 
described in the article contributed directly to product labeling by answering key questions 
that could otherwise not have been answered from the Phase 3 trials.  Due to the sparse 
sampling collected from patients during these trials, it would not have been possible to 
perform robust noncompartmental analyses, therefore the approach that was adopted was 
ideal for meeting study objectives.  In other words, the population PK/PD analysis 
maximized the information that was extracted from the available data, thereby obviating the 
need to conduct of additional studies or collect many blood samples from patients.  Thus, 
this approach proved to be an economical and efficient tool in the development of a 
biological therapeutic agent.  Furthermore, this tool could be used to gain an improved 
understanding of pegloticase’s immunogenicity, just as it could be used to develop other 
biological therapeutic agents. 
The third and fourth research articles illustrate the use of modeling and simulations 
in determining optimal antibiotic dosing regimens to be studied in subsequent clinical trials.  
Although the methods described in these articles can be applied to drugs in diverse 
therapeutic areas, these articles represent the first account of the use of modeling and 
simulations to select Phase 2 dosing regimens for an anti-infective drug.  The rational dose 
regimen selection that resulted from the use of modeling and simulations improved the 
overall drug development process of TP-434 by avoiding the exposure of subjects to dosing 
regimens that would ultimately prove to be ineffective, and by ensuring that proof-of-
concept would likely be established in the Phase 2 study.  Consequently, this thwarted the 
need for re-dosing additional cohorts or conducting another clinical trial, which would both 
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have been expensive and have added more time to the already lengthy development 
process.  In addition to reducing the cost and time associated with the development of 
TP-434, the modeling and simulation approach employed in this research provided a 
flexible and adaptable framework with which the PK TP-434 could be better understood.  
The PK model developed for TP-434 could be refined as more information became 
available, thereby demonstrating that the learn and confirm paradigm could be applied to 
the development of an antibiotic drug.  Furthermore, the methods described in these articles 
could have broader applications, and could be used to develop new drugs in various 
therapeutic areas.   
In conclusion, the projects described in this thesis have shown that advanced 
pharmacokinetic techniques such as modeling and simulations are able to minimize drug 
development costs through the use of smaller studies, by avoiding the conduct of additional 
studies and by ensuring that future studies are designed for a high probability of success.  
Modeling and simulations, including the development of innovative models, are therefore a 
tool that can result in a significant economy of time and money, which are two components 
that contribute to the challenges present during the drug development process.  By using 
such approaches to answer key questions that arise during drug development, the risk 
involved in the process is decreased, and generic and innovator drugs can be brought to 
market in a faster and more efficient manner.  Ultimately, this will provide clinicians and 
caregivers with even more therapeutic options to treat or cure diseases, and more 
importantly, improve the lives of their patients.   
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Appendix 1 
General Pharmacology of Therapeutic Agents or Classes 
Studied within this Thesis 
